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Summary
Summary
The human gut microbiota is considered to be a highly specialized organ providing 
nourishment, regulating epithelial cell development, modulating innate immune 
responses and colonization resistances, and it significantly impacts human health and 
disease. Dispite of being extensively studied for several decades, the functionality of 
the microbiota colonization in the human gastrointestinal tract and the mechanisms 
of the interactions between the host and bacteria are still poorly understood.
This research follows a novel and unique approach, which combines the 
complementary strengths of in vitro experiment, in vivo study and mathematical 
modelling. The work undertaken has three emphases: 1) probiotic strains and their 
impact on human health; 2) the development of gut microbiota in infants; 3) 
quantification of human gut microbial ecosystem at both the species level and the 
system level. In the first part of this research, a versatile anaerobic continuous culture 
platform was implemented following a novel and unique design, which allows easy 
and continuous sampling and monitoring of microbial growth. A number of carefully 
planned in vitro experiments have been conducted to investigate the growth and 
competition of probiotic strains under different culture conditions. These in vitro 
experiments improve the understanding for the growth behaviour of the specific 
probiotic strains. The second part of this project analyzed 50 faecal samples collected 
from 9 healthy infants with administration of probiotic strains and placebo. The 
analysis is based on the 454-pyrosequencing technology, which reveals the complete 
profiles of gut microbiota in these infants and confirmed the modulation effect of the 
specific probiotic strains. The last part of this research focused on the development 
of mathematical and computational models of human gut microbial ecosystem. The 
outcome from this part of the research includes: a) a new bacterial growth model that 
overcomes the parodox of competitative exclusion caused by previous models; b) a 
versatile computational framework to simulate in vitro fermentation experiments; 
and c) a comprehensive mathematical model for human gut and gut microbiota that is 
the first model for its nature.
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Chapter 1 Introduction
Chapter 1 Introduction
Abstract
This Chapter is prepared to give an overview of the global picture for this 
multidisciplinary PhD work. The aim and objectives of this PhD research are firstly 
clarified, after which the research background and its importance are briefly 
addressed. Then, the main research challenges are identified, for which a novel 
multidisciplinary research strategy is proposed. The layout of the thesis is outlined in 
the last section.
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1.1 Aim and objectives
This research focuses on the microbial ecosystem in the gastrointestinal (GI) tract of 
humans. The research scope covers both the profile of gut microbiota (i.e. what are 
present in the human gut) and the metabolic function of gut microorganisms (i.e. 
what do they do in our gut). Under this umbrella, there are three special emphases in 
this research project: 1) probiotic strains and their impact on human health; 2) the 
development of gut microbiota in infants; 3) quantification of gut microorganisms' 
activity at both the species level and the system level.
1.2 Research background
The large bowel consisting of the proximal colon, the transverse colon and the distal 
colon forms the last part of the human GI tract, as shown in Figure 1.1. For a long 
time, the main function of the large bowel was thought to be water and ion 
absorption. However, it is now clear that the large intestine plays far more important 
roles than just absorbing water and ions. It contributes significantly to carbohydrate 
and protein metabolism, provides essential protection against pathogen invasion, and 
stimulates and modulates the immune system. These critical physiological functions 
are not so much associated with the anatomical structure of the large intestine, and 
instead they are accomplished by the microorganisms living in the large bowel. The 
large intestine of a healthy adult houses hundreds of microbial species (most of them 
are beneficial to man), and they form a stable and active microbial ecosystem with 
over 1014 microbial cells, which is ten times larger than the total somatic and germ 
cells of human. The metabolic activity of gut microorganisms has also been found 
associated with obesity, malnutrition, neurological disorders, inflammatory bowel 
disease and cancer (large bowel is the third largest cancer killer in the UK) etc. The 
gut microbiota could be considered as a "new organ" inside the human body.
The human colon is one of the most complex ecosystems on the planet, whose 
normal microbial community is determined by a number of factors, including host
1
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genomics, diet, age, bacterial succession, immune function and health status etc. 
There have been marked progresses in our understanding o f the micro ecology o f the 
GI tract in recent years. However, we are still at the very beginning o f understanding 
the functional relationships between the microbiota and the host, in health and 
disease. Many fundamental questions remain outstanding: what is a healthy intestinal 
microbiota composition, which microbial groups and activities are involved in health 
and disease, what are the benefits o f specific probiotic and prebiotic, is it possible 
and if  so how to favourably manipulate the gut microbiota to improve human health 
and prevent and treat disease etc.
Figure 1.1 Illustration o f the gastrointestinal tract o f  human
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1.3 Main challenges in this research
The main challenges of researching gut microbial ecosystem arise from two aspects.
• The intrinsic complexity of the system. It is estimated that the gut 
microbiota of a healthy individual comprises around 400-1000 bacteria 
species, whose total cell count outnumbers the somatic and germ cells of 
man by ten times. A great variation also exists between individuals such that 
the profile of gut microbiota has been recognized as a microbial 
"fingerprint" of humans. Compared with the great diversity of the gut 
microbiota, their metabolic and immune functions and interaction 
mechanisms with the host are even more complex.
• The lack of direct measuring or monitoring approaches. Due to technical and 
ethical restrictions, it is very difficult to obtain accurate in vivo data of gut 
microbiota from human, and the limited data are often fragmented and 
corrupted with errors. Animal trials can help to some extent, but it is well 
known that the gut microbiota in animals have very different physiological 
functions and totally different population structures compared with human. 
In vitro studies have therefore become a very popular approach for studying 
the gut microbiota. But its complexity is highly limited. It is very difficult, if 
not impossible, to simulate in vitro even a small portion of the whole gut 
microbial community because a large number of microbial species in the 
human colon are not cultivatable with known culture media.
1.4 A novel research methodology
To cope with the great technical challenges reviewed above this PhD work has 
adopted a novel and unique research methodology, by joining together the 
complementary strengths of in vitro experiments, in vivo trials and mathematical 
modelling. In vitro experiments were conducted to gain knowledge on activities of 
individual gut microbial species in a simplified gut-like environment. By using DNA
3
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sequencing technology, the in vivo trials provided information of the complete 
profile of gut microbiota in selected infants. Mathematical modelling eliminated 
some of the difficulties faced by in vitro and in vivo testing, and helped to gain 
quantitative information of gut microbial ecosystem, including its activity, function 
and interaction with the host.
This research strategy has led to a truly multidisciplinary research adventure, which 
required knowledge and skills in microbiology, engineering and mathematics. To the 
best of our knowledge, this work is the first research attempt that combines in vitro 
experiments, in vivo trials and mathematical modelling in the investigation of human 
gut microbiota. The research group led by Prof DRJ Owen at Swansea has extensive 
experience and world-leading expertise in mathematical modelling and engineering 
computations. However, this PhD research project is the group's first step in the 
direction of gut microbiology, and the associated challenges should not be 
underestimated.
1.5 Layout of thesis
The layout of the main body of the thesis is summarized below:
Chapter 2 provides an up-to-date and comprehensive review on the research of gut 
microbial ecosystem and its relation to human health and disease. The review divides 
previous research works into three groups according to their research methodologies: 
in vivo trials, in vitro experiments and mathematical modelling. The advantages and 
disadvantages of all three research approaches are discussed and compared.
Chapter 3 briefly recaps the knowledge of the human colon, including the 
physiology and anatomy of the large intestine, the microbiota composition, metabolic 
activities and functions of the gut microbiota. The concepts of probiotic, prebiotic 
and synbiotics are also introduced in this Chapter. This Chapter is prepared to make 
the thesis self-contained and more accessible to the engineering and mathematical
4
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readership. Efforts have been made to accurately summarize the information in the 
most efficient manner.
Chapter 4 describes a series of in vitro batch fermentation experiments. These 
experiments were performed to study the growth of several probiotic strains in 
different culture media and different pH conditions. Experience gained from these 
experiments helped the design of a continuous fermentation platform used in later 
experimental study. The data obtained was also used in a later stage to validate the 
new bacteria growth model proposed in this work.
Chapter 5 proposes a unique design of a continuous fermentation platform and 
describes a series of fermentation experiments involving multiple gut 
microorganisms and probiotic strains. The continuous fermentation platform served 
as a prototype in vitro gut simulator while the associated fermentation experiments 
simulated microbial competition in a gut-like environment. These experiments 
provided insights on how the specific probiotic strains react in the simulated gut 
environment. The resulting data were also used in the validation of the new 
mathematical model.
Chapter 6 describes an in vivo study involving 9 healthy infants with administration 
of probiotic strains during the first 6 months after birth. The DNA sequencing 
technique (454-pyrosequencing) was used to analyze the infants' faecal samples 
collected at different stages, and complete gut microbiota profiles were obtained. 
These in vivo testing results show that the specific probiotic strains did have a 
positive impact on the development of gut microbiota in the selected infants.
Chapter 7 proposes a versatile computational model that can accurately simulate 
various in vitro fermentation experiments. The computational model is based on a 
new bacterial growth model, which extends the classic Monod model and overcomes 
the paradox of competitive exclusion. The new simulation platform was validated
5
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against the in vitro experiments described in Chapter 4 and Chapter 5, and good 
achievement has been achieved in all cases.
Chapter 8 proposes an integrated mathematical model of human gut and the gut 
microbial ecosystem. The new mathematical model takes into account the 
deformation and volume change of human gut, and models the large bowel as an 
elastic tube. Also for the first time, the nature of low Reynolds' number flow is 
recognized for the gut media. To capture the different movement of food particles, 
biomass, water and gas in the large intestine, a multiphase flow model is introduced. 
Finally, based on the new bacteria growth model validated in Chapter 7, a 
comprehensive fermentation model has been developed and built into the gut model. 
To the best of our knowledge, this new mathematical gut model is the first theory of 
this nature.
Chapter 9 summarizes the main achievement and research outcome from this PhD 
research, and also provides insight to future research.
6
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Abstract
The human gut microbiota is considered to be a highly specialized organ providing 
nourishment, regulating epithelial cell development, modulating innate immune 
responses and colonization resistance, and therefore significantly impacts human 
health and disease. However, to understand the functionality of the microbiota 
colonization in the human GI tract and to unravel the mechanisms which control 
interactions between the host and bacteria, researchers must deal with the 
individuality and complexity of the microbial ecosystem in a largely inaccessible 
habitat. In order to provide a functional view of the microbial ecosystem, continuous 
efforts have been made in the past few decades and a number of useful tools and 
strategies have been developed, which includes in vivo, in vitro, in silico and 
mathematical models. To lay this research work in the right research context, this 
Chapter reviews the related research over the past few decades that have contributed 
to a better understanding of the human gut microbial ecosystem.
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2.1 A short overview
The human gastrointestinal (GI) tract has a complex, dynamic and spatially 
diversified microbial ecosystem which is established and maintained throughout a 
human’s whole life. This complex microbial ecosystem in the human gut harbours 
about 200 grams living cells, with peak numbers in the colon (about 1014 
microorganisms), in total numbers which are estimated to outnumber human somatic 
and germ cells by a factor of ten (Tumbaugh et al., 2007). Despite such high 
numbers, the microbial diversity is relatively low and the human gut microbiota is 
dominated by only two bacterial phyla, Firmicutes and Bacteroidetes that make up 
over 90% of the intestinal microbiota (Eckburg et al., 2005). The intestinal habitat of 
an individual contains 500 to 1,000 different species of bacteria (Eckburg et al., 
2005). A recent analysis involving a larger number of subjects has suggested that the 
collective human gut microbiota is composed of over 35,000 bacterial species (Frank 
et al., 2007). The intestinal microbiota is not homogeneous and colonization of the 
human gut with microbiota starts immediately at birth (Fouhy et al. (2012a); Cheng 
et al. (2013)). The microbiota composition is unstable from host birth until the age of 
2-4 years, but adult hosts carry a stable host-specific microbial community which 
then becomes unstable with increasing age (Mackie et al. (1999); Zoetendal et al.
(1998); Blaut et al. (2002); dos Santos et al. (2010); Biagi et al. (2012); Duncan et al. 
(2013)). Factors that shape the human microbiota ecosystem can be roughly 
classified into two categories: host factors (e.g. acid, bile, pancreatic secretion, 
peristalsis and food transit times, and host genotype) and environmental factors (e.g. 
food components, ingestion of microbiota and drugs) (Egert et al. (2006); Shanahan 
et al. (2013)).
The gut microbiota is a highly specialized organ providing nourishment, regulating 
epithelial cell development, modulating innate immune responses and colonization 
resistance, and therefore significantly impacts human health and disease (Xu et al.
(2012); Matamoros et al. (2013)). Perturbations of gut microbial community 
structure and functionality are associated with chronic health conditions and
8
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intestinal diseases such as allergies and asthma, obesity, diabetes, inflammatory 
bowel disease and colon cancer (Sekirov et al. (2010); Ballal et al. (2011)). The 
Human Microbiome Project (HMP) launched in 2008 by the United States National 
Institutes of Health was developed to systematically gain insight into the features of 
the microbiome including the stability and resiliency of the microbiome, similarities 
between the microbiomes of people within families/communities, the existence of an 
identifiable core biome, and the effects of the genetic diversity of the biome 
(Tumbaugh et al., 2007). These features would allow for better understanding that 
how the microbiome affects human health and disease and how this can be used to 
better improve the health and well-being of the host.
The human gut microbiota, particularly its composition, metabolic activities and 
products that may influence the host, have been intensively studied in the past few 
decades. However, some considerable methodological problems have been raised to 
study the composition and metabolism of the gut microbiota. Whether or not it is 
feasible to study the microbial ecology of the intestine (Corpet, 1989)? Whether or 
not there is a prospect of unravelling the mechanisms which control interactions 
between the hundreds of species which make up a flora, and host-bacteria 
relationships (Corpet, 1989)? Does it present considerable methodological problems 
to study the composition and metabolism of the colonic flora (Boureau et al., 2000)?
At first sight it would be impossible to study millions of microbiota which are 
difficult to collect from the human gut because of the special physic-chemical 
conditions and also the fact that many of these microbes have not been cultured or 
classified. However, a number of in vivo and in vitro experimental models to 
simulate the human colon and its microbial population have been developed to 
enable metabolism or mechanisms to be studied. An understanding of interactions 
within the intestine can sometimes be achieved by mathematical modelling which are 
normally considered as an alternative to the in vivo and in vitro studies (Corpet, 
1989). Yet, there is no single ideal method that has intrinsic advantages or 
disadvantages over the other methods for studying the ecology and metabolic
9
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activities of the gut microbiota. All the methods must be combined together 
according to their complexity, convenience and suitability to provide a more accurate 
view of the ecosystem (Boureau et al., 2000).
2.2 In vivo studies
In vivo studies for the exploration of the human gut microbiota encompass various 
species of laboratory, animals, gnobiotic animals or human volunteers. During the 
past several decades, a number of animal models have been used to study the 
dynamic, ecologically diverse community of microorganisms that inhabit the GI tract 
and provide a better understanding of the biological complexities of the processes 
that govern host-microbiota symbiosis. These simplified models could provide us 
with insights about how the colonization of the host affects vital host processes. They 
are also a powerful tool to study the individual microorganism so that unique roles 
for different gut microbiota can be established and put in the context of different 
health and disease perspectives (Sekirov et al., 2010).
2.2.1 Conventional animals
Conventional animal species have been widely used for studying human gut 
microbiota stabilization, colonization and colonization resistance, treatment of 
antimicrobial agents and selected drugs’ administration (Burr et al. (1982); Gorbach 
et al. (1988); Van der Waaij et al. (1990); Nielsen et al. (1992); Mysore et al. (1994); 
Pazzaglia et al. (1994); Berends et al. (1996))). The mouse is the most common 
model compared with other species (even its large intestine differs substantially from 
human), followed by guinea pig, pig, chicken, Japanese monkey, Mongolian gerbil, 
ferret and quail (Boureau et al., 2000). Heidt et al. (1990) established colonization 
resistance in specific pathogen free rats using a rat-derived microflora. Fleming et al.
(1991) used rat models to study the short chain fatty acid (SCFA) absorption in the 
cecum. Caplan et al. (1994) developed a neonatal rat model of necrotizing 
enterocolitis (NEC), a common gastrointestinal disorder affecting premature infants. 
Bovee-Oudenhoven et al. (1996) studied the effects of calcium and fermentation by
10
Chapter 2 Literature Review
yoghurt bacteria on the resistance of rats to Salmonella infection. Whitman et al. 
(1996) developed a model of gastrointestinal colonization with vancomycin-resistant 
Enterococucs faecium in CF1 mice to study factors promoting colonization and the 
efficacy of decontamination therapy with antimicrobial agents. Lan et al. (2007) 
studied the survival and metabolic activity of propionibacteria on the gastrointestinal 
tract of human-associated rats. Sato et al. (2008) studied the fermentation pattern of 
administration of lactate-utilizing bacteria with ingestion of galacto-oligosaccarides 
(GOS) in a rat model. Kondo et al. (2010) used a mouse model with obesity induced 
by high-fat diet to evaluate the antiobesity activity of a bifidobacterial strain and the 
result showed that the specific probiotic strain was effective in reducing the risk of 
obesity. Shi et al. (2013) investigated the potential health-promoting effect of a 
specific Lactobacillus gasseri strain on the metabolic characteristics of metabolic 
syndrome rats.
Conventional animals have many advantages: (i) full realism in the case of farm 
animals; (ii) much fewer ethical restrictions than the human model; (iii) good control 
over environment (diet, stress etc.); (iv) good control over genetics of subject 
population; (v) accessibility of their intestinal contents, tissues and organs at autopsy; 
(vi) irreplaceable control of gnotobiotic and genetically engineered animal models 
(Boureau et al., 2000). However, conventional animals still have many limitations 
such as complexity of the model makes interpretation of results difficult and ethical 
restrictions still apply etc.
2.2.2 Gnotobiotic and germfree animals
A novel approach to the study of the cross-talk that occurs between microorganisms 
and their hosts is based on the use of gnotobiotic and germfree animal models (Xu et 
al. (2003); Phillips (2009)). These animal models provide useful information about 
how bacteria affect normal development, establishment and maintenance of the 
immune system and epithelial cell functions. Gnotobiotic animals demonstrate the 
importance of the indigenous microbiota in protecting against intestinal colonization 
by exogenous bacteria. Bacteria are difficult to colonize in the intestinal tracts of
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conventional animals, whereas the same microorganisms are able to colonize in the 
germfree animals (Moberg et al., 1978). Yi et al. (2012) reviewed that the germfree 
murine is a powerful model to study the relationship between gut microbiota and the 
host. The advantages of gnotobiotic and germfree animals are (i) good control over 
flora parameters; (ii) reduced complexity of flora facilitates interpretation of the data. 
However, it still has a few disadvantages: (i) reduced realism (fewer interspecies and 
host microflora interactions); (ii) the complexity of host makes interpretation of 
results complex (Boureau et al., 2000).
Studies with gnotobiotic animals include colonization, colonization resistance, 
interspecies interaction and host responses etc. For example, Hazenberg et al. (1981) 
who inoculated germfree mice with suspensions of human faeces demonstrated that 
the total bacterial composition in the model was similar to that of man and was distinct 
from the indigenous murine flora. These animal models are also very useful to 
investigate the administration of probiotics in animals when challenged with 
pathogens. De Macias et al. (1992) studied the protective effect of Lactobacillus casei 
and Lactobacillus acidophilus against Shigella sonnei infection. Kabir et al. (1997) 
investigated the antagonistic activity exerted by L. casei against S. enterica serovar 
Typhimurium. Rodrigues et al. (1996) showed lactobacilli protection against 
Salmonella typhimurium and Shigella flexneri colonization in the mice model. Becker 
et al. (2011) introduced a simplified human intestinal microbiota (SIHUMI) to the 
gnotobiotic rats to investigate the effect of dietary interventions on the composition of 
the faecal samples. Faith et al. (2011) studied the interrelationships between four 
different diets and the changes of human gut microbial community which was 
introduced into gnotobiotic mice. Tlaskalova-Hogenova et al. (2011) reviewed the role 
of gut microbiota in the human diseases using germfree and gnotobiotic animal 
models.
2.2.3 Human clinical trials
The gut microbiota has also be studied in vivo using healthy human volunteers, 
hospital patients, ileostomists and sudden death victims. Obviously, when possible, a
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human volunteer trial with placebo control and blind coded samples are the best 
models for studying the gut microbiota ecosystem. Plummer et al. (2005) 
investigated the effects of probiotics on the composition of the intestinal microbiota 
following antibiotic therapy. This double-blind placebo-controlled study showed that 
daily supplementation with viable probiotic bacteria during and post antibiotic 
therapy reduces the extent of disruption to the intestinal microbiota. It also reduces 
the incidence and total number of antibiotic-resistant strains in the re-growth 
population. Allen et al. (2010) evaluated the safety of probiotic for the prevention of 
atopy in a neonatal clinical trial. Bartosch et al. (2005) showed symbiotic (a 
combination of probiotic and prebiotic) consumption containing bifidobacteria and 
oligoffuctose protect the faecal bifidobacterial populations, which are often 
dramatically reduced in older people. Fraher et al. (2012) reviewed a few techniques 
that can be used to characterize the complexity of gut microbiota and to provide a 
guideline for the clinician. Weichert et al. (2012) focused on the evidence of 
prebiotic and probiotic in prevention and treatment of pediatric infectious diseases. 
Hell et al. (2013) reviewed the possible role of multistrain probiotic in Clostridium 
difficile infection.
However, there are still some limitations for the human clinical trial. It is difficult to 
collect samples from gut contents and tissues because of technical and ethical 
restrictions. The types of foods or drugs that can be administered to human 
volunteers are restricted. Many of these clinical trials suffer from low compliance 
and high drop-out rates.
2.3 In vitro models
Both human clinical trials and animal experimental works are expensive and require 
specialist facilities compared with in vitro models (Smith et al., 2007). In vitro 
models complement animal and human studies and are an alternative choice to 
simulate the conditions in the human GI tract. In vitro models offer further 
simplification and a further level of control to investigate both the existence of gut
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microbial species and their related functionalities, although they suffer from the 
absence of a complete physiological and host response environment. In vitro model 
could help researchers uncover the role of gut microbiota in everything from 
digestion and nutrient absorption to disorder conditions such as inflammatory bowel 
disease. In vitro model can be used sequentially to simulate the upper GI tract 
(stomach, duodenum, jejunum, ileum) and the colon (proximal, transverse and distal 
colon).
The use of an in vitro model to study the human gut microbiota offers various 
advantages: (i) low cost to operate; (ii) easy to set-up; (iii) good control over species 
in model flora; (iv) rapid turnaround and throughput of samples; (v) good access to 
flora in all parts of the model system; (vi) allow precise manipulation of environment 
variables; (vii) possible use of toxic substances; (vii) ethical restrictions are absent. 
However, the disadvantages of in vitro models are: (i) it will reduce realism without 
host immune or neuroendocrine system functionality; (ii) mucosal and luminal 
models have not yet been integrated; (iii) other biotic factors are usually not 
incorporated into the models (e.g. gut absorptive processes and digestive tract 
secretions) (Boureau et al., 2000). In vitro model can be divided into in vitro 
fermentation model and in vitro mucosal-associated model. In vitro fermentation 
models can be further distinguished as batch cultures, continuous cultures and 
artificial digestive models. All models are anaerobic to simulate the environment that 
supports the growth of microbiota obtained from a human’s faecal sample.
2.3.1 In vitro fermentation model
The simplest and most widespread in vitro fermentation model has broadened from 
batch culture to single- or multistage continuous flow models for investigating 
microbial processes such as carbohydrate and protein fermentation, metabolism 
production using different faecal inoculation techniques (Cinquin et al. (2006a); 
Macfarlane et al. (2007); Van den Abbeele et al. (2010)). Each type of model has its 
own advantages and limitations. In order to set up an appropriate model, the study 
objectives should be carefully evaluated.
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2.3.1.1 Batch fermentation models
Batch fermentation models (Figure 2.1) are the simplest and most common method 
to study the effect of different added ingredients in the batch fermentor with 
intestinal fluid or fecal slurry. These models are usually closed systems with sealed 
vessels or reactors containing suspensions of pure or mixed bacteria in a carefully 
selected medium without further addition of nutrients. The run-times in batch 
fermentation models are relatively short ranging from 2 to 24 hours (Rumney et al.
(1992); Barry et al. (1995); Oufir et al. (2000)). The potential use of prebiotic such as 
fructans or resistant starch or other complex carbohydrates have been studied in 
batch fermentation models (Pompei et al. (2008); Lesmes et al. (2008)). Noack et al. 
(2013) investigated the fermentation and microbiota profiles of three fibers in an in 
vitro batch fermentation model. Beards et al. (2010) investigated the bacterial, SCFA 
and gas profiles in batch fermentation with human colonic microbiota. Arboleya et 
al. (2013) studied the modulation ability of 16 different bifidobacteria strains and 
fructooligosaccharides (FOS) in an in vitro faecal batch cultures. Knudsen et al.
(2013) investigated the effect of 3 different insoluble carbohydrates on the microbial 
community and fermentation products in an in vitro batch fermentation model 
inoculated with human fresh faecal samples. A large number of substrates and fecal 
samples were tested using the batch fermentation model to investigate the metabolic 
profiles of short chain fatty acids (SCFAs) (Macfarlane et al. (2007); Gumienna et al. 
(2011); Arboleya et al. (2013)).
Short-term batch fermentation models allow a rapid screening and a flexible design 
to assess the inter-individual variability. However, the control of changing conditions 
is not possible because most batch fermentations proceed without pH control and the 
accumulation of fermentation products (e.g. SCFAs) results in continuous changes to 
pH and redox potential. Moreover, only short term experiments can be conducted to 
avoid selection of non-representative microbial populations and accumulation of 
toxic products.
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Figure 2.1: In vitro fermentation models simulating proximal (R l), transverse (R2) and distal 
(R3) colons, operated at physiological section-specific constant pH, temperature (37°C) and 
under strictly anaerobic conditions (e.g. through continuous C 0 2 or N 2 flushing o f the 
headspace), (a) Picture detail o f a proximal colon reactor containing polysaccharide beads 
with immobilized fecal microbiota, (b) Electron microscope image o f microbes embedded 
and attached to the surface o f an intestinal bead (Payne et al., 2012a).
2.3.1.2 Continuous fermentation models
More complex fermentation models with several vessels and continuous substrate 
replenishments can be used to evaluate the microbial community and microbial 
metabolic modulation to avoid this accumulation o f metabolites and depletion of
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nutrients (Payne et al., 2012a). Since the first in vitro colon simulator was introduced 
in 1981 (Miller et al., 1981), the function of all models today have a lot in common 
with this model. Runmey et al. 1992 reviewed the first decade of in vitro gut 
fermentation models. The Reading model developed by Gibson and his colleagues in 
1988 (Gibson et al., 1988a), revised by Macfarlane and co-workers in 1998 
(Macfarlane et al., 1998), is still actively used today.
Single-stage continuous fermentation models
Single-stage continuous fermentation models use a single chemostat for fermentation 
and are often adopted to elucidate proximal colon function and metabolic activities. 
For example, a single-stage continuous fermentation model for Salmonella 
colonization in the proximal colon was developed and used to compare the effects of 
antibiotic therapy and Bifidobacterium thermophilum RBL67 on salmonellosis in 
child gut environments (Le Blay et al., 2009). The single-stage continuous 
fermentation model has been used to investigate bacterial population and SCFA 
ratios within microbial communities from the human colon in various pH and peptide 
supply (Walker et al. 2005). Studies on alternative dietary substrates, competition 
between human colonic bacteria and the role of pH in determining the composition 
of the human colonic bacteria were carried out in single-stage fermentation models 
(Duncan et al. (2003); Duncan et al. (2009)). It is a useful model for specific regions 
of the GI tract under physicochemical controlled conditions. Nevertheless, stability 
of the gut microbial community under long term studies is not always possible.
Multi-stage continuous fermentation models (e.g. the Reading model)
An extension of the single-stage continuous flow chamber is the use of multiple 
stages which enable the simulation of horizontal colon processes to perform long 
time study of the gut microbiota ecosystem (Figure 2.1).
The Reading simulator (Gibson et al. 1988a) simulates the colon using a three-stage 
continuous culture with three vessels (220 ml, 320 ml, and 320 ml) and different pH
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in each vessel (5.8, 6.2 and 6.8) to mimic the human ascending, transverse and 
descending colon, respectively. Macfarlane et al., 1998 revised and validated this 
model using measurements made on colonic contents taken from sudden death 
victims. The system is usually inoculated with human faecal slurry in a batch 
overnight, after which the continuous overflow from vessel to vessel begins and the 
system is run for at least 14 days in order to achieve a steady-state condition in the 
vessels (Macfarlane et al., 1998). Then a specific compound will be tested for 3 
weeks and finally, to determine how long the changes induced by the test substrate 
can still be measured during a washout period (2 weeks) in the absence of the 
substrate itself (Macfarlane et al., 1998).
Considerable work has been carried out in recent years to investigate the 
carbohydrate utilization, fermentation product formation and interspecies interactions 
(cross feeding) using the various multistage fermentation models (Cinquine, et al. 
(2006b); Belenguer et al. (2006); Chassard et al. (2006); Falony et al. (2006); 
Macfarlane, et al. (2007); Zihler, et al. (2010); Van den Abbeele, et al. (2010)). As 
probiotic, prebiotic and synbiotic modulation on fermentation pattern and microbiota 
composition is very important to promote human health, a lot of studies have been 
performed using in vitro multistage fermentation models (Langlands et al. (2004); 
Amaretti et al. (2007); Stewart et al. (2008); Falony et al. (2009)). For example, a 
comparative study on carbohydrate fermentation showed FOS and polydextrose were 
bifidogenic in all three culture vessels of the gut model system (Probert et al., 
2004a). Non-digestible carbohydrates were investigated to stimulate the growth of 
specific groups of beneficial bacteria (predominately bifidobacteria and lactobacilli) 
in the large bowel (Rastall et al., 2005). Effects of antibiotics on the microbiota 
composition and metabolic activities were studied in a three-stage continuous 
fermentation model which mimics a highly simplified gut ecosystem with 14 defined 
populations of human gut microorganisms (Newton et al., 2013).
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Immobilized continuous fermentation models
The traditional continuous fermentation models inoculated with diluted fecal slurry 
present several limitations due to the free-cell state of their microbial populations 
(Cinquin et al., 2004). They may not be fully representative for both planktonic 
(free-cell) and sessile (biofilm-associated) states of bacterial populations in the colon 
(Macfarlane et al., 2007). Moreover, both the lower cell density inoculation (< 
109-1010 CFU mL'1) (Probert et al., 2004a) compared with colonic contents 
(10IO-10-n CFU mL'1) and the rapid washout of less competitive bacteria limit the 
operational time to less than 4 weeks (Sghir et al. (1998); De Boever et al. (2001)). 
To address problems associated with inoculums washout, Doleyres et al. (2002a, 
2002b) and Cinquin et al. (2004) developed a single-cultured chemostat where 
bacteria were immobilized on a porous polysaccharide gel beads either in suspension 
or biofilm-associated. The fecal microbiota could be successfully immobilized and 
stabilized for 54 days, and also high density cells could release from beads and 
eventually enable growth of free cells in the simulator (Cinquin et al., 2004).
However, the single-cultured chemostat developed by Cinquin et al. (2004) can only 
simulate the ascending colon. A three-stage chemostat model was then developed by 
incorporating two additional chemostats to represent the three physiological regions 
of the human colon (Cinquin et al., 2006b). After faecal microbiota are suspended 
within the gel beads to form fecal beads, the beads are transferred to the growth 
medium in the first reactor. Cells release from the beads once a high-cell density 
peripheral layer is formed because of the limitations on substrate and toxic product 
diffusion within beads. The released cells are transported to the second and the third 
reactors, resulting in a relatively high-cell density in all three reactors. More recently, 
Zihler et al. (2011) studied the protective effect of probiotics on Salmonella 
infectivity using an in vitro three-stage fermentation model with immobilized child 
microbiota. Payne et al. (2012b) assessed the impact of different dietary on 
microbiota composition and metabolism using a three-stage continuous fermentation 
model inoculated with immobilized child faecal sample. The immobilized continuous
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fermentation models enable prolonged operation time depending on the objective of 
the study: 29 days as reported by Cinquin et al. (2004), 54 days by Cinquin et al 
(2006b) and 71 days by Le Blay et al. (2010).
2.3.1.3 Artificial digestive systems
Besides the aforementioned batch and continuous fermentation models, 
microbiologists and engineers also designed more sophisticated dynamic in vitro 
simulators to mimic all physic-chemical conditions in the GI tract to better 
understand the gastrointestinal microbial community and its metabolic activity 
(Molly et al. (1993); Minekus et al. (1995); Macfarlane et al. (2007)). These systems 
aim to recreate in vzvo-like conditions such as gastric juice, pancreatic juice and bile 
salts secretion, peristaltic motility, absorption capacities, high shear forces and 
finally, host-microbiota interaction.
Several research groups have developed artificial digestive systems to simulate the 
GI tract both on a structural and a functional level. The SHIME® model (ProDigest 
and Ghent University, Gent, Belgium) (Figure 2.2) and the TIM model (TNO, Delft, 
The Netherlands) (Figure 2.3) are widely received by the research community due to 
their comprehensiveness. Several other research groups also developed their own GI 
tract models for specific scientific focuses. EnteroMix® colon simulator was 
introduced by Makivuokko and co-workers at Danisco Innovation in 2005 (Figure 
2.4) (Makivuokko et al. 2005). A computer controlled dynamic GI tract model used 
for studies on the administration of biotherapeutics has been developed by Satya 
Prakash et al. in McGill University, Canada (Prakash et al. 2011) (Figure 2.5). A 
‘Robogut’ which contains six steel and glass vessels to mimic gut conditions in 
people who suffer from inflammatory bowel disease (IBD) was set up by Emma 
Allen-Vercoe et al. at Guelph University, Canada in 2009 (Figure 2.6).
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SHIME® model (simulator o f the human intestinal microbial ecosystem)
The SHIME model (simulator o f the human intestinal microbial ecosystem) was 
originally developed by Molly et al. (1993). The conventional SHIME is a dynamic 
model o f the human gut comprising 5 reactors respectively simulating the stomach, 
small intestine and ascending, transverse and descending colons. The first two 
reactors mimic the enzymatic and physicochemical environment by controlling pH, 
residence time, and the dosing o f a proper nutritional medium, enzymes and bile salts 
(Molly et al., 1993). These two reactors are the fill and draw system with a dialysis 
filter which is used to simulate the absorptive processes occurring in the stomach and 
the small intestine (Vermeiren et al., 2011). The last three-stage reactors to simulate 
the large intestine are continuously stirred vessels with fresh faecal sample 
inoculation which corresponds to that o f the in vivo situation in terms o f metabolic 
activity and community composition. However, there is no absorption simulated in 
the last three-stage model. In this model a typical stabilization period o f three weeks 
and a basal period o f two weeks are followed by treatment and wash-out periods.
Figure 2.2: TW INSHIME System: two SHIME systems are run in parallel (Source from 
http://www.prodigest.eu).
Since the SHIME model was developed on 1993, it has been used by different 
researchers for different research targets. For example, the SHIME model has been 
employed to study the impact o f various chemical compounds such as polycyclic
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aromatic hydrocarbons (PAH), arsenic, insecticide and isoxanthohumol on the 
composition o f the gut microbiota (Van de Weile et al. (2003); Laird et al. (2007); 
Laird et al. (2013); Possemiers et al. (2006); Joly et al., 2013). The SHIME model 
has also been used to study the effect o f various probiotics and prebiotics on the gut 
microbiota ecosystem (Kontula et al. (1998); Alander et al. (1999); Ganzle et al.
(1999); Van de Wiele et al. (2004); Van de Wiele et al. (2007)). The TWINSHIME® 
model (Figure 2.2) was developed to investigate two different treatments under 
identical parameter settings (Grootaert et al., 2009). Two further extensions o f the 
SHIME model have been recently conducted to improve the simulation power o f the 
GI tract model. A more detailed description o f this is given in Section 2.3.2.
TIM model (TNO intestinal model)
Figure 2.3: TNO-Intestinal Models: TIM1 (left) and TIM2 (right) (Source from 
http://www.tno.nl).
Another well known artificial digestive system is TNO's gastrointestinal model 
(TIM). This model comprises two complementary parts, TIM1 and TIM2 introduced 
by Minekus and co-workers in 1995 and 1999. The TIM 1 system (Figure 2.3 left) 
contains eight glass modules mimicking the stomach, duodenum, jejunum  and ileum 
including bile secretion, motility, pH controlled and absorption capacities (Minekus 
et al., 1995). The TIM 2 (Figure 2.3 right) system consists o f four glass modules in a
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loop mimicking the proximal colon with peristaltic mixing, water and metabolite 
absorption using a hollow fiber membrane (Minekus et al., 1999). The TIM model 
differs from other models in two main aspects: (i) fluid transportation from vessel to 
vessel happens via peristaltic valve-pumps; (ii) there is a constant absorption of 
water and fermentation products through dialysis membranes. TIM1 has two 
integrated 5 kDa dialysis membranes, next to the jejuna and ileal modules and TIM2 
has one hollow-fiber membrane which has molecular mass cut-off of 50 kDa 
(Minekus et al., (1995); Minekus et al. (1999)).
TIM1 can simulate the real-time digestive process from stomach to ileum. TIM2 only 
simulates the proximal colon. TIM2 is inoculated with fecal slurry and its microbiota 
is allowed to adapt to the fermentation conditions for 16 hours. However there is no 
long-term stabilization of the microbial community and the volumes in the different 
chambers are small when compared with in vivo situations. Since Minekus et al. 
(1995) validated the computer-controlled multi-compartment model (TIM1) to 
simulate the stomach and small intestine, considerable work have been done using 
the TIM model. Marteau et al. (1997) used the TIM1 model to investigate the 
survival of lactic acid bacteria, particularly the effect of bile salt in stomach and 
small intestine. In recent years, the combination of both TIM1 and TIM2 models has 
been applied to pharmaceutical investigations of drug delivery, molecule 
bioconversion and nutrient compound bioavailability (Blanquet-Diot et al. (2003); 
Souliman et al. (2006); Souliman et al. (2007); Blanquet-Diot et al. (2009); Anson et 
al. (2009); David et al. (2010); Dickinson et al. (2012)).
EnteroMix® colon simulator
The EnteroMix model is based on semi-continuous culture and it has four parallel 
units each comprising four glass vessels (V1-V4) to mimic caecum & ascending, 
transverse, descending and sigmoid colons, allowing four simulations to be run 
simultaneously using the same fecal inoculum (Figure 2.4) (Makivuokko et al. (2005, 
2006, 2007, 2010)). The pH levels of V1-V4 are controlled at 5.0, 6.0, 6.5 and 7.0, 
respectively. The model reaches steady state 3 hours after incubation of a fecal
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sample, and the initial working volumes of VI-V4 are 3, 5, 7 and 9 ml respectively. 
Three ml of fresh medium, with (three channels) or without (one channel) test 
substance, is pumped to VI. After 3 hours fermentation, the fermented media are 
transferred to V2 and simultaneously 3 ml of fresh medium is pumped to VI. After 3 
hours fermentation in V2, the fermented media will be transferred to V3. Similarly, 
after 3 hours fermentation in V3, the fermented media will be transferred to V4. The 
culture is allowed to ferment in V4 for 3 hours before discharging. The whole 
procedure of transferring liquids from VI to V4 is 15 hours. Finally, the working 
volume is 6 , 8 , 10 and 12 ml, respectively. The fermentation lasts for 48 hours, after 
which samples are collected from each vessel and the simulation is terminated. The 
EnteroMix model has been used to study carbohydrate fermentation as well as 
synbiotic effects of lactitol and specific L. acidophilus strain.
Fresh
medium
V2 V3 V4 +4°C
Effluent
3ml 5 ml 7 ml 9 ml
pH 5.5 pH 6.0 pH 6.5 pH 7.0
Proximal   » Distal
Figure 2.4: EnteroMix colon simulators (Makivuokko et al., 2006).
The EnteroMix model allows four parallel simulations to be run at the same time 
with the same fecal inoculums and same substrates. This model has the smallest 
working volumes, enabling the simulation of small concentrations of the tested 
substrate. However, the operational volumes are small when compared with the in 
vivo situation. As a result, there is no stabilization of the microbial community and 
only short-term experiments can be performed.
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Other artificial digestive models
Figure 2.5: A computer-controlled dynamic human gastrointestinal model (Prakash et al., 
2011).
Shown in Figure 2.5 is a computer-controlled dynamic human gastrointestinal model 
developed in McGill University, Canada (Prakash et al. 2011). Similar to the 
SHIME, it consists o f a succession o f five vessels mimicking the stomach, the small 
intestine, and the ascending, transverse and descending colons. The system is 
computer automated whose temperature, pH and anaerobic parameters are all 
controlled using the Labview® software (Martoni et al. (2007); Martoni et al. (2008); 
Prakash et al. (2011)). This model has been mainly used to study the biotherapeutics 
modulation (prebiotics, probiotics and antibiotics) and delivery formations (e.g. 
microencapsulated probiotics). For example, Martoni et al. (2007) investigated the 
performance o f microencapsulated Lactobacillus plantarum  80 cells for oral delivery 
applications in the simulated GI tract. Encapsulated lactobacilli (Bile salt hydrolase 
over producing strains) are suggested to lower cholesterol levels in the human gut. 
The results showed the microencapsulated process could protect the lactobacilli in 
the simulated stomach prior to intestinal release, and also maintain the higher cell 
viability in the whole simulator.
Shown in Figure 2.6 is the ‘Roboguf simulator developed by Allen-Vercoe at 
Guelph University, Canada. The $300,000 system was set up in 2009, and it contains 
six steel and glass vessels to mimic the human distal gut. The system has been used
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to culture fecal samples from healthy adults, and the cultured artificial fecal is then 
filtered to select a set o f beneficial bacteria for successful treatment in diarrhoea 
(Petrof et al., 2013). The researchers reported that the treatment with synthetic poop 
successfully cured the infections o f two patients by planting the selected beneficial 
bacteria into their intestines during colonoscopies. The new bacteria slowly grew in 
the patients' guts and pushed out the toxic C. difficile, eliminating the cause o f 
infection.
Figure 2.6: Robogut developed Emma Allen-Vercoe in Guelph University. (Source from: 
http://www.uoguelph.ca)
2.3.2 In vitro mucosal-associated models
All the models presented until now do not take into account an important aspect in 
the GI tract: adhesion o f microorganisms to the mucus layer, biofilm formation and 
its potential role on the host physiology, structuring o f the microbial community and 
cross-talk (Marzorati et al., (2010, 2011). It is therefore desirable to simulate in vitro 
the host response through a mucosal-associated model. Several studies have been 
made mostly based on enterocytes, enterocyte-like cells or mucosal explants to 
mimic the bacterial adhesion in the gut wall mucus layer (Ouwehand et al., (1999, 
2002); Probert et al. (2004b); Macfarlane et al. (2005); Van den Abbeele et al. 
(2009); Bahrami et al. (2011)).
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For example, the influence o f normal faecal flora on the adhesion o f a probiotic to 
the mucosa was studied by using an immobilized mucus in vitro model (Ouwehand 
et al., 1999). The same author also studied the adhering potency o f candidate 
probiotic in the new model with colonic tissue (Ouwehand et al., 2002). Probert et al. 
(2004b) developed a fermentation model o f the proximal colon that includes mucin 
beads to mimic mucus gel layer microhabitat with dialysis membrane. The system is 
inoculated with fecal samples, and water and metabolites are removed by osmosis 
using a solution o f polyethylene glycol. Macfarlane et al. (2005) used sterile porcine 
mucin gels in small glass tubes to determine how intestinal bacteria colonize and 
degrade mucus in a two-stage continuous culture system. These tubes can be placed 
in a fermentor simulating a specific area o f the GI tract and removed over a period o f 
48h for further analyses o f the biofilm. Van den Abbeele et al. (2009) studied the 
adhesion assay o f the mucin colonization o f bacteria from the SHIME. Bahrami et al. 
(2011) studied the adherence and cytokine induction in Caco-2 cells by bacterial 
populations from a three-stage continuous fermentation model.
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Figure 2.7: M-SHIME (The design was based on the SHIME. The first ascending colon unit 
consists o f the conventional set-up that only harbors luminal microbes (= luminal SHIME or 
L-SHIME), whereas the second unit is modified by incorporating a mucosal compartment (= 
mucosal SHIME or M-SHIME), which contains 100 mucin-covered microcosms per 500 ml 
suspension. Both units run in parallel in order to attain identical environmental conditions
27
Chapter 2 Literature Review
and identical microbial composition and activities for both units (Van den Abbeele et al., 
2012).
However, none o f the aforementioned models simulating the GI tract has an adequate 
device to study the mechanisms o f bacterial adhesion in response to the host signals 
and the reciprocal cross-talk (Marzorati et al., 2010). Two further developments have 
been recently conducted by the research group who developed the SHIME. One is 
M-SHIME (M ucus-SHIME) and the other is the HMI (Host-M icrobiota Interaction) 
model (Vermeiren et al. (2011); Marzorati et al. (2012)).
In the M-SHIME, a mucosal compartment (mucin-covered microcosms coated with 
mucin type Il-agar) is introduced in the ascending colon vessel to reproduce the 
bacterial adhesion to the gut wall mucus layer (Figure 2.7) (Van den Abbeele et al., 
2012). This improvement aims to provide more in vivo-like communities in 
long-term dynamic in vitro simulations and allow evaluating the colonization of 
unique mucosal microbiota in health and disease (Van den Abbeele et al., 2012). 
Vermeiren et al. (2012) compared the colonization o f microbiota in the mucin layer 
and luminal compartment between health volunteers and ulcerative colitis patients in 
the M-SHIME. Van den Abbeele et al. (2013) also studied that mucosal butyrate 
producers specifically colonize in the mucin layer in the M-SHIME.
]
]
Microbial biofilm
Sem iperm eable
membrane
Enterocyte layer
Figure 2.8: The host-microbiota interaction (HMI) module (M arzorati et al., 2010).
Gut lumen
Mucus layer
Cell compartment
Sampling compartment for bioavailability studies
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The HMI model consists of two compartments separated by a functional double-layer 
composed of an upper mucus layer and a lower semi-permeable membrane. The 
mucus layer on the luminal side is coated with an artificial mucus layer to adhere the 
microorganisms in the luminal compartment. The use of artificial mucus layers is 
advantageous compared to the use of mucus layers formed by epithelial cells, since 
direct interaction and cytotoxicity between the microorganisms and the epithelial 
cells is prevented. The epithelial cells and/or other cell types can be grown in the 
basal compartment of the module and the semi-permeable membrane allows the 
secretion products of these cells to diffuse through the membrane and the artificial 
mucus layer. Furthermore, the use of two separate compartments allows the 
establishment of different oxygen pressures on both sides of the membrane to 
establish the optimal conditions for the aerobic epithelial cells in the basal 
compartment and the anaerobic microorganism in the luminal compartment. The 
combination of these features provides a novel tool to investigate the role of 
microbial metabolism on the biotransformation of active compounds and facilitate 
studies related to new drug development (Vermeiren et al., 2011). This model can be 
combined with SHIME to evaluate the effect of microbial processes on the host cells 
and the effect of host cells on microbial processes (Figure 2.8) (Marzorati et al., 
2010).
2.3.3 Comparison of in vitro models
The in vitro models mentioned above have structural and functional difference 
(Table 2.1). However, the solutions used to reproduce the conditions in the GI tract 
are similar in each model. Firstly, nearly all models use the medium inoculated with 
fecal samples to represent the microbiota population in the human colon, because it 
is very difficult, both ethically and technically, to obtain the realistic samples from 
the ileum or cecum of humans. Secondly, similar growth media are used in these in 
vitro models which originate from the media published by Macfarlane et al. in 1998 
mimicking the ileal fluids obtained from sudden death victims (Macfarlane et al.,
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1998). Thirdly, all models simulate the basic environment of the GI tract such as 
anaerobic conditions, similar pH set-point and similar retention time.
Batch fermentation models have a simple and flexible design to assess the 
inter-individual variability. But they are commonly limited to short-term simulation 
to avoid selection of non-representative microbial populations and accumulation of 
toxic products. The Reading model is the most popular continuous fermentation 
model to simulate the human colon and many researchers today also use similarly 
designed models to investigate the gut microbiota ecosystem. With respect to more 
sophisticated in vitro GI tract models, SHIME and TIM are the most widely 
recognized models, which provide control of the concentrations of gastric, small 
intestinal and pancreatic enzymes, bile, pH, temperature, feed composition, transit 
time in the GI tract and the anaerobic environment with physiological relevance. The 
EnteroMix model is the colon simulator with the smallest working volumes, enabling 
simulation of small concentrations of testing substrates.
The TIM model is specially designed for pharmaceutical investigations of drug 
delivery and performing bioavailability studies in the upper GI tract, while the 
SHIME model is mainly designed to simulate metabolism in the whole human gut. 
The EnteroMix model is the only model allowing four parallel simulations to be run 
at the same time with the same faecal inoculum and same substrate. These systems 
simulate the gut controlled by physicochemical conditions but do not offer the 
opportunity of studying the microorganism adhesion, the gut biofilm formation and 
the host-microbial interaction etc. M-SHIME is an in vitro mucus-associated model 
to enable the bacterial adhesion to the gut wall mucus layer. This improvement 
enables evaluation of the colonization of unique mucosal microbiota related to 
human health and disease. HMI is another recently developed in vitro adhesion 
model. It allows growth, stabilization and study of microbial communities that 
adhere to and colonize host-related surfaces, and also mimics transport of chemical 
compounds across epithelial surfaces to simulate host-microorganism interactions 
and adaptation. A comparison of all major gut models is given in Table 2.1.
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2.4 Mathematical and computational models
In theory, in vivo trials on humans are the preferred ultimate research strategy for the 
most reliable investigation of the human GI microbial ecosystem. But in practice, 
due to ethical and technical constraints, it is rarely possible to conduct the required 
testing on sufficient number of healthy individuals and/or targeted patient groups. In 
vivo experiments using animals provides an alternative route. But it has long been 
well known that animals' GI systems have very different microbial population 
structures with very different physiology mechanisms. Hence, care must be taken 
when interpreting the results obtained from animal trials. Another major drawback of 
conducting animal experiments is the high cost and special skills required. Due to 
these disadvantages of in vivo trials, in vitro experiments have become a very 
popular approach for studying the microbiota in human GI tract. As reviewed in 
Section 2.3, a number of artificial gut simulators have been designed and built, and 
they all have their own advantages and disadvantages. A common drawback of 
various in vitro gut simulators is their limited complexity, when compared with the 
real microbial population in the human GI tract. It is estimated that at least 40-60% 
microbial species in the human GI tract cannot be cultured in vitro. Also, most gut 
simulators do not simulate the absorption function of the human digestive system, the 
peristaltic movement of the GI tract, or the interaction with the immune system. High 
time cost is another major drawback of in vitro experiments. A rigorous in vitro 
study can often take several months to run the complete fermentation process, while 
the repeatability is questionable.
Some of the aforementioned difficulties associated with in vivo trials and in vitro 
experiments can be overcome by mathematical / computational models. Using 
computational simulation based on appropriate mathematical models, one can easily 
take into account the physiological interactions and metabolic processes that are 
difficult to implement through in vitro experiments. Also, issues like high cost and 
questionable repeatability are no longer a worrying problem.
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The potential benefit from mathematical modelling has long been recognized for the
research of human GI microbial ecosystem, with early papers dated back to the 80's. 
The total number of publications in this area is, however, very small (until now, 
fewer than 30 journal papers in total), which implies limited impact. But the research 
on mathematical modelling of human gut microbiota never stopped in the past two to 
three decades. Every five years or so, there were one or two new research groups 
attracted to this topic, with the old groups leaving. Over all, unlike the in vitro 
experiment research theme reviewed in Section 2.3, the research progress in 
mathematical / computational modelling for human gut microbiota presents a mixed 
picture, for which a comprehensive and critical review is given below in a 
chronological order.
2.4.1 Science publications in the early 80*s
Published in Science, Hansen et al. (1980) studied two microorganisms competing 
for a single nutrient in a chemostat. For the growth history of microbiota, they 
compared the results directly measured from the in vitro cultivation and the 
theoretical predication based on the classic Monod growth model. With notable 
differences between the experimental and theoretical results, the authors claimed the 
agreement between the theory and the experiment, and made a conclusion that two 
microorganisms competing on a single nutrient cannot coexist in a chemostat 
environment. In this paper, Hansen et al. (1980) did not explicitly address the human 
gut ecosystem, but the mathematical model used in their work and the related 
conclusion has had a profound impact on the later work in mathematical modelling 
of human gut microbiota. The mathematical model they used is
^  SNy fi2 SN2 
y t KSi+S y2 KS2+S
(2 .1)
dNt gSN ,
(2.2)
dt Kg +S
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thSN2 _ DN p . 3 )
dt Ks +S  2
where S  denotes the concentration of nutrient in the chemostat, t time, SQ the 
nutrient concentration of the inflow, D the dilution rate, the maximum growth 
rate of the microorganism i , y i the yield coefficient, Ks the half-velocity 
constant, and N t the concentration of microorganism i .
Soon after Hansen et al.'s Science publication, Fredrickson et al. (1981) published a 
review article in Science on the topic of microbial competition. At the conceptual 
level, Fredrickson et al. summarized and classified various possible forms of 
microbial competitions, and envisaged the complexity of the microbial ecosystem as 
the result of the multidimensional competition. Hansen et al.'s conclusion of 
competitive exclusion (1980) was generalized in this paper to the so called pure and 
simple competition, which refers to a microbial community with only one nutrient 
whose availability affects the growth rates of the populations, and competition for 
this nutrient is the only interaction between the populations. Following the basic 
Monod growth model in Eqns. (2.1-2.3), it is easy to prove that multiple 
microorganisms cannot coexist at a steady state in pure and simple competition. 
However, this "nice and clean" conclusion directly contradicts the common 
observation that bacteria always coexist in the real-world environment. Indeed, pure, 
or single population, cultures are almost always the creations of microbiologists. To 
address this contradiction, Fredrickson et al. attributed its cause to external factors, 
such as time-varying inputs, environmental heterogeneity and diversity of resources. 
This general opinion significantly influenced the later research of mathematical 
modelling of gut microbiota, despite that Fredrickson et al. (1981) did not explicitly 
target the human gut microbial environment.
2.4.2 Other pioneering work in the 1980’s
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Rolf Freter is perhaps the first researcher who attempted to apply mathematical 
modelling to gut microbiota. In a series of publications, Freter et al. (1983a, 1983b, 
1983c, 1983d) presented a systemic investigation of microbial competition in the 
large intestine, which includes continuous-flow cultures, mouse trials and 
mathematical modelling. Freter (1983d) extended the chemostat model in Eqns. 
(2.1 -2.3) by adding the wall adherence effect. That is,
ds ^  ^ S ( N I +Nl)  ^ S ( N 1+NI)
= _  £>n  _ a N lV  + Af,*A +  ° AA (2.5)
dt Ks +S Ks + S W  + 0AA
jffz. = ^2SN2 _ DN _ a N  W + + JhSN i— 0 A A _
dt Ks +S Ks + S W  + 0.1A
(2.6)
dNL = j t !SN1 W_ N 'fx  + aN JV  (2.7)
dt Ks + S W  + 0.lA
d N j =M2SN-2 W _ - A + 
dt Ks + S W  + 0.lA  2 2
(2 .8)
where N t denotes the concentration of microbe i in the lumen, N* the 
concentration of microbe i that adheres to the wall, A the total wall sites, 
W = A - N \  -N*2 the free wall sites, X the rate of wall microbes moving into
lumen, and a  the rate of lumen microbes adhering to the wall. By incorporating 
the wall attachment effect into the model, this is clearly a step forward in simulating 
the gut environment. It is noted that in the above model, the newly grown
wall-attached bacteria are further divided into two subgroups, with one
KSj+S
group remaining on the wall and the other moving into the lumen. This treatment is 
questionable following a simple comparison between the magnitudes of the 
right-hand-side terms in the equation. The amount of newly grown bacteria coming
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into the lumen -----OAA— .g ^  or(jer smaller than the other term N*X
Ks + S W  + 0AA
which is proportional to the total number of wall-attached bacteria.
Freter et al. concluded that, in order to allow coexistence of many microbial species 
in the GI tract, there must be numerous nutrients such that each species has a 
competitive advantage over all other species for at least one specific type of nutrient. 
This conclusion may look odd based on today's common knowledge, but at the time, 
Freter et al.'s pioneering attempt did inspire a group of mathematicians to look into 
the mathematical aspect of the problem (Waltman (1984); Freedman et al. (1989)). 
These pure mathematical investigations focused on the stability and asymptotic 
properties of the solution to Eqns. (2.1-2.8) and other similar ordinary differential 
equations (ODE) encountered in mathematical biology. The associated results and 
conclusions are interesting in their own sense, but have limited practical implication 
to the understanding of gut microbial ecosystem. As an attempt to explain the 
coexistence phenomena widely observed in real-world microbial populations, 
Freedman et al. (1989) invented a time delay coefficient r, to modify the Monod 
growth model (2.1-2.3) into
—  = (S0- S ) D - B   Bl  S‘-’zNl
dt Vo ’ y i KSi+S,_ri y2 KSt + S,_ri
(2.9)
dN,
dt KSi + S,_T]
DN„ (2 .10)
dN2
dt KSi+S,_ri
- DN , (2.11)
where St denotes the concentration of nutrient at time t-Tr  After a long and
tedious mathematical derivation, coexistence is proved to be one possibility of the 
modified model. But the result cannot be easily extended to the general case of 
multiple bacteria species competing on multiple nutrients. Also, the time-delay
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assumption does not have any direct supporting evidence from in vitro or in vivo 
investigations.
2.4.3 Theoretical study of mathematical models
Mathematical/computational modelling of gut microbiota arose as a research topic in 
the 1980's, and it soon diverted into two research themes. One route focused on the 
theoretical aspect of mathematical models, and tried to show from the ODE model 
the existence and some general structure of a steady-state gut microbial ecosystem. 
The other route focused on computational modelling, i.e. to simulate using numerical 
programs the dynamic development of gut microbiota and their interactions with the 
host.
The theoretical research theme was driven mainly by a single research group led by 
Hal Smith at Arizona State University, USA. In a series of publications (Ballyk et al. 
(1998, 1999, 2001); Stemmons et al. (2000); Jones et al. (2000); Jones et al. (2002)), 
they presented mathematical studies of various simplified gut models including the 
plug flow model (Ballyk et al. (1998, 1999, 2001); Jones et al. (2000, 2002)), the 
chemostat model (Stemmons et al. 2000; Ballyk et al. 2001), the random motility 
effect (i.e. the diffusion effect) (Ballyk et al. (1998, 2001); Jones et al. (2002)), the 
wall attachment effect (Ballyk et al. (1999, 2001); Stemmons et al. (2000); Jones et 
al. (2000, 2002)). As it is hard to perform theoretical analysis for multiple bacteria 
species, it was assumed in all these studies that there were only two bacteria species 
competing against each other. The wall attachment model used in these studies is 
essentially the same as the model proposed by Freter (1983d), as summarized in 
Eqns. (2.4-2.8). Following the analogue of Brownian diffusion, the random motility 
of microbes was modelled with a diffusion term, and the hydraulic transport of 
nutrient S  and microbes N t were assumed to obey the following partial 
differential equations:
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as J d2S  8S
 = dQ— r - V -
dt
dN,
dt
L = d>
dx dx
d2N i dN,
dx7
-v -
dx
(2.12)
(2.13)
where ds and dN are diffusion coefficients for nutrient and microbes respectively,
v is the velocity of gut media, and x  denotes the spatial coordinate along the GI 
tract. These assumptions are valid in the context of mathematics, but have little 
relevance to the real-world gut environment. In particular, due to the high viscosity 
of normal gut media, the diffusion effect (or random motility effect) in the GI tract is 
negligible in practice.
2.4.4 Progress in computational modelling
The first piece of work on computational modelling of gut microbial ecosystem is 
perhaps Coleman et al. (1996). In this work, the chemostat model (2.1-2.3) was 
adopted, and a C program was coded to simulate the growth of 6  microbe groups 
competing on 5 nutrients (glucose, lactose, starch, sorbose and serine). Rather than 
being a conclusive study, this work demonstrated the feasibility of computational 
modeling in the investigation of human colonic ecosystem. Unfortunately, the 
authors did not continue their research after this.
The second notable computational study was reported by Michael Wilkinson (2002a, 
2002b, 2002c). The gut was modelled as a rigid axisymmetric tube, and the spatial 
discretization was done using a heuristic finite difference scheme in the 3D space 
based on the rotational symmetry. The hydraulic transport was driven purely by 
diffusion caused by the concentration difference between neighboring finite 
difference sections. The microbial metabolism was based on the basic Monod model, 
with a series of ad hoc extensions to take into account toxin inactivation, symbiotic 
food interactions, binding site competition etc. This study was completely 
disconnected from in vivo trials or in vitro experiments, but the work marked a
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notable effort towards building a comprehensive computer simulator for human gut 
microbial ecosystem. It should be noted that this model has some fundamental 
mistakes for both hydraulic transport and microbial metabolism. The GI tract is 
elastic not rigid, and the diffusion motion is negligible due to high viscosity of 
normal gut media. Despite of various additional terms, the growth model adopted by 
Wilkinson is essentially similar to Hansen et al. (1980) as illustrated in Eqns. 
(2.1-2.3), Freter (1983d) as illustrated in Eqns. (2.4-2.8), and Smith et al. (Ballyk et 
al. (1998, 1999, 2001); Stemmons et al. (2000); Jones et al. (2000, 2002)). As a 
result, steady-state coexistence of multiple bacteria is a rare event and unstable 
following this metabolic model.
Wilkinson's approach (2002a, 2002b, 2002c) contains a large number of parameters 
which are very difficult, if not impossible, to be determined from experiments. 
Hence, de Jong et al. (2007) moved back to the simple chemostat model as in Eqns. 
(2.1-2.3), and designed a relative simple simulation framework incorporating both 
small and large intestines. They demonstrated how to interpret in vivo experimental 
data using the simulation-based approximation.
More recently, Munoz-Tamayo et al. (2010, 2011) simulated the human large 
intestine using three pairs of chemostat models connected to each other, representing 
the ascending, the transverse, and the descending colon respectively. Each section of 
the GI tract is represented by two chemostats, representing the lumen and the mucus 
layer respectively. Modelling the mucus layer in the same way as the lumen space is 
fundamentally different from the previous wall attachment models (e.g. Freter 
1983d), where the mucus layer is assumed static. Justification of such a treatment has 
not been presented by Munoz-Tamayo et al. (2010, 2011). The other contribution 
made in their work is the classification of functional groups for the gut microbiota 
and the associated fermentation pathways. Very recently, Lawson et al. (2011) 
presented a statistical estimation method to help determine the parameters of their 
gut model. They modelled the GI tract as a chemostat and similar to Munoz-Tamayo 
et al. (2 0 1 0 , 2 0 1 1 ), they also treated the gut microbiota at the functional level.
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2.4.5 A comparison summary
To give a clear global picture for the mathematical / computational study of gut 
microbial ecosystem, the related research works are compared in Table 2.2. The 
research field has continuously attracted researchers from both biological and 
mathematical backgrounds. However, due to the high complexity of the gut 
microbial ecosystem and the advanced mathematical / computational skills it 
requires, no researcher has been able to stay long and make continuous progress 
along this research direction. Overall, the progress in this theme of research has been 
very limited and many fundamental problems remain outstanding.
Table 2.2 Mathematical / computational modelling of gut microbial ecosystem
Freter 
et al.
Smith 
et al.
Coleman 
et al.
Wilkinson de
Jong 
et al.
Tamayo 
et al.
Lawson 
et al.
Date 1983 1998-
2002
1996 2002 2007 2010-
2011
2011
Theoretical
analysis
Y Y N N N N N
Computational
Simulation
N N Y Y Y Y Y
Chemostat Y Y Y N Y Y Y
Plug flow N Y N Y N N N
Monod growth 
model
Y Y Y Y Y Y Y
Wall
attachment / 
mucus layer
Y Y N Y N Y N
Multiple 
species (>2)
N N Y Y Y Y Y
Multiple 
substrates (>1)
N N Y Y Y Y Y
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Abstract
The human colon is a highly dynamic anaerobic ecosystem in the gastrointestinal 
(GI) tract. The main function of the human colon is absorption and excretion. 
However, the complex microbiota in the human colon is recognized as a key 
component in GI tract homeostasis, and both the composition and metabolism of the 
gut microbiota are strongly related to human health and disease. To make the thesis 
self-contained and more accessible by engineers and mathematicians who are not 
necessarily familiar with gut microbiology, this Chapter summarizes some 
background knowledge of the human colon, including the physiology and anatomy, 
microbiota composition and metabolism of human colonic microbiota. The concepts 
of probiotic, prebiotic and synbiotics are also introduced in this Chapter.
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3.1 A short overview
The human colon (also called large intestine) is a highly dynamic anaerobic 
ecosystem in the gastrointestinal (GI) tract. Until the 80's, the classical view of the
the orderly disposal of waste products or digestion. It is now clear, however, that it 
has a major role (Table 3.1) in digestion to salvage energy from carbohydrate and 
protein not digested in the upper intestine (Macfarlane et al., 1991). This is achieved 
by the metabolism of anaerobic bacteria and is known as fermentation. A brief 
description of this ecosystem is presented below.
Table 3.1: Major functions of the human large intestine 
Process Products
human colon is an organ which absorbs salt and water and provides a mechanism for
Digestive
Carbohydrate fermentation Short chain fatty acid (SCFA); 
H2, C02, CH4 ;
Biomass
Short chain fatty acid; 
Branched chain fatty acid;
H2, C02;
Phenols, Amines, Ammonia
All the above except biomass; 
Na, K, Cl, HCO3 , H20;
Bile acids
Biomass;
Food residues;
Epithelial cells;
Mucus;
H20, H2, C02, CH4 ;
Toxic waste
Protein breakdown and 
amino acid fermentation
Absorptive
Excretory
Hormonal Neurotensin;
Enteroglucagon;
Somatostatin
Vitamin B and K
For control of defaecation
Synthetic
Storage
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Metabolic (bacteria) Bile acid dehydroxylation;
Sulphate —► Sulphide;
Nitrate —►Nitrite —►Ammonia;
Many other hydrolytic and reductive reactions
3.2 Physiology and anatomy
The human colon lies with loops and flexures through the pelvis in the abdominal 
cavity. Cummings et al. (1980) studied the large intestine of 46 sudden death victims 
from both Africa and the UK, the large bowel was 154 cm (113-207 cm) in length
9  9and had a surface area of 1,274 cm (731-2,509 cm ). The main function of the colon 
is absorption. It absorbs over 90% of the contents passing through it, reducing them 
from 1 or 2 liters of thick fluid to about 250 ml of semi-solid faecal matter. The 
faeces contain 75% water and the remainder is solid material, of which 30% consists 
of bacteria and other matter (food residues and desquamated mucosal cells). The GI 
tract normally contains about 2 0 0  ml of air including carbon dioxide, hydrogen and 
methane which is produced by normal bacterial flora from intestinal contents. The 
socially unacceptable component of flatus mainly includes hydrogen sulphide, 
ammonia, volatile amino and fatty acids. A more detailed description on the 
composition in the GI tract can be found in Cheshire et al. (1997).
The human colon is a unique biochemical environment which is characterized by low 
redox potential and controlled at 37°C (Mackie et al. (1999); Savage (1977)). The 
human colon consists of four sections: the ascending colon, the transverse colon, the 
descending colon, and the sigmoid colon (the proximal colon is usually referred to as 
the caecum and ascending colon, and the distal colon is usually referred to as the 
descending colon, the sigmoid colon and rectum). The caecum, colon, rectum and 
anal canal make up the large intestine (Figure 3.1). Mouth to anus transit through the 
human gut takes about 60 h in UK adults with women 72 h and men 55 h, of this 4-6 
h will be mouth to caecum transit times so residence in the colon is around 54 h 
(Cummings et al., 1992). Transit in Africans is reported to be much quicker in the 
region of 24 to 48 hours (Burkitt et al., 1972). The volumes of the anatomical regions
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o f the colon have been calculated based on the dimensions in the literature (Table 
3.2) (De Jong et al. (2007); Rajilic-Stojanovic (2007)).
Figure 3.1: Representation o f the human GI tract (Source: W ikipedia)
The colon receives the undigested food material from the ileum and passes the 
digesta to the proximal and distal colon and then excretes from the rectum. The 
passage o f the digesta takes place in the intestinal lumen by peristaltic movements. 
During this travel, the digesta such as carbohydrates and protein not digested in the 
upper gut has been fermented by anaerobic bacteria (Minekus 1999). The principle 
fermentation products (e.g. short-chain fatty acid) confer a spatial distribution of 
metabolites and a pH profile with values o f about 5.5 in the ascending colon, 6.2 in 
the transverse colon and 6.9 in the descending colon (Macfarlane et al., 1991). 
Intestinal contents move relatively slowly through the colon so that it allows time for
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water and sodium to be absorbed. The rate of movement is about 5-10 cm/hour in the 
proximal colon (Cheshire et al., 1997).
Table 3.2: Approximate dimensions of the human colon
Anatomical region
Length
(cm)
Volume of lumen 
Microhabitat (1)
Volume of mucus* 
Microhabitat (1)
Cecum 6
Proximal colon 0.41 0.017
Ascending colon 15
Transverse colon 50 0.98 0.042
Descending colon 25
Distal colon Sigmoid colon 40 1.63 0.070
Rectum 18
Total 154 3.02 0.129
The volume of the mucus Vm is calculated assuming a perfect cylinder shape as 
Vm = 0 .2 5 /r^ 2 — — 2*em)2jz, .The thickness of the mucus em is taken to be
approximately equal to 0.0830 cm; <j> is the diameter of the colon (5 cm), and L is the 
length of each section. The volume of the lumen is calculated as 0.257T<f>2L -  Vm .
The intestine is lined with the epithelium which is specialized for mucous secretion, 
salt and water absorption. A mucus gel layer that is bound to the surface of the 
colonic epithelium can be partitioned into an inner layer and a sloppy outer layer 
(Matsuo et al. (1997); Atuma et al. (2001)). The outer layer with soluble mucus is 
quite viscous but mixes with the luminal juice. The soluble mucus allows easy 
movement of solid material in the lumen and acts primarily as a lubricant. This helps 
to prevent damage to the underlying epithelial cells (Allen et al., 1985). The inner 
layer is a shear-resistant gel that provides a stable protective barrier by keeping the 
microbes and toxins at bay, on the outer mucosal surfaces (Allen et al., 1985). Mucus 
thickness varies from 26pm to 300pm (Lichtenberger (1995); Matsuo et al. (1997); 
Pearson et al. (2005); Swidsinski et al. (2007)).
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3.3 Human colonic microbiota
The normal microbiota of humans is an extensive and diverse microbial community, 
which is composed primarily of bacteria from numerous phylogenetic clusters 
(Simon et al. (1984); Macfarlane et al. (1991); Tannock (1995); Mitsuoka (1996); 
Hooper et al. (2002); Clemente et al. (2012)).The gastrointestinal (GI) tract of 
humans can be divided into three anatomical regions, namely, the stomach, small 
intestine (comprising duodenum, jejunum, and ileum) and large intestine or colon. 
The short transit time, acidic pH, secretion of bile and pancreatic juice of the upper 
GI tract restrict the levels of microbial colonization of this region (Holzapfel et al., 
1998). Bacterial population levels in the stomach and the upper two-thirds of the 
small intestine are 1 0 2 - 1 0 4  bacterial cells per milliliter of contents such as some 
aciduric Gram-positive bacteria (lactobacilli and streptococci) (Tannock et al., 1995). 
The flow of digesta is somewhat slower in the distal part of the small intestine 
(ileum), and conditions are thus more favorable for microbial colonization. Bacterial
r o
concentrations are 1 0 - 1 0  bacterial cells per milliliter of contents and usually 
contain bacteria similar to those found in the colon (Evaldson et al., 1982). A higher 
diversity of micro-organisms, with the presence of Gram-negative facultative 
anaerobic bacteria (such as members of the family Enterobacteriaceae) and obligate 
anaerobes (including Bacteroides, Veillonella, Fusobacterium and Clostridium 
species) in conjunction with lactobacilli and enterococci are normally predominant in 
the ileum (Simon et al. (1984); Tannock (1995); Holzapfel et al. (1998)).
The human colon has a more neutral environment and a relative abundance of 
nutrients including carbohydrates and protein not digested in the upper GI tract, 
sloughed off epithelial cells and microbial cell debris. The major component of 
colonic contents is bacteria whose numbers exceed 1 0 1 0 - 1 0 1 2 bacterial cells per gram 
of contents (Tannock et al. (1995); Holzapfel et al. (1998); Guamer et al. (2003)). 
Several hundred species have been identified, but 30-40 species belonging to 5 or 6  
genera account for 99% of biomass based on traditional culture dependent testing 
methods (Finegold 1983). The gut microbiome is dominated by only 2 bacterial
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divisions, Firmicutes and Bacteroidetes, which make up over 90% of the intestinal 
microbiota. The remainder consists of Actinobacteria (Tumbaugh et al., 2009a) and, 
to lesser extent Proteobacteria, Verrucomicrobia, and Cyanobacteria (Backhed et al. 
(2005); Ley et al. (2006)). Furthermore, only two archaeal species have been 
described with Methanobrevibacter smithii being more predominant than 
Methanosphaera stadtmanae (Eckburg et al. (2005); Mihajlovski et al. (2008)). 
Minor populations of Eukarya have been recently reported (Scanlan et al., 2008). 
Viruses and bacteriophages are also found in the human large intestine (Breitbart et 
al. (2003); Lepage et al. (2008)). The majority of members of the colonic microbiota 
are obligate anaerobic genera, including Bacteroides, Bifidobacterium, Clostridium, 
Enterococcus, Eubacterium, Fusobacterium, Peptococcus, Peptostrepotococcus and 
Ruminococcus (Macfarlane et al. (1991); Tannock (1995); Suau A et al. (1999)). 
Table 3.3 lists bacteria commonly isolated from the human colon (Macfarlane et al., 
1995).
Table 3.3: Bacteria, their substrates and products in the human large intestine
Bacteria Descrip-tion
Number 
Log 10/g 
dry wt faeces 
Mean Range
Substrate
Fermenta­
tion
products
Bacteroides G- rods 11.3 9.2-13.5 Saccharolytic A, P,S
Eubacteria G+rods 10.7 5.0-13.3
Saccharolytic, some 
amino acid 
fermenting species
A, B, L
Bifidobacteria G+rods 10.2 4.9-13.4 Saccharolytic A, L, f, e
Clostridia G+rods 9.8 3.3-13.1
Saccharolytic and 
amino acid 
fermenting species
A, P, B, L, 
e
Lactobacilli G+rods 9.6 3.6-12.5 Saccharolytic L
Ruminococci G+cocci 10.2 4.6-12.8 Saccharolytic A
Peptostrepto-
G+cocci 10.1 3.8-12.6 As for the clostridia A,L
cocci
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Peptococci G+cocci 10.0 5.1-12.9 Amino acid fermenters A, B, L
Methanobrevi-
bacter
G+cocco
bacilli 8.8 7.0-10.5 Chemolithotrophic CH4
Desulphovibrios G- rods 8.4 5.2-10.9 Various A
Propionibacteria G+rods 9.4 4.3-12.0 Saccharolytic, lactate fermenting A, P
Actinomyces G+rods 9.2 5.7-11.1 Saccharolytic 
Carbohydrate and
A, L, S
Streptococci G+cocci 8.9 3.9-12.9 amino acid 
fermenting
Amino acid
L, A
Fusobacteria G- rods 8.4 5.1-11.0 fermentation carbohydrate also 
assimilated
B, A, L
Escherichia G- rods 8.6 3.9-12.3 As for streptococci Mixedacids
A= acetate; P = propionate; B = butyrate; L= lactate; f = formate; e = ethanol; S = succinate
The human colonic microbiota is mainly located in lumen and mucus. The bacteria 
that colonize the gut must be able to proliferate at a rate that resists washout. 
Adherence to the intestinal mucosal surface is an important factor in intestinal 
bacterial colonization. The mucus gel mainly consists of water (95%) and mucins, 
which are mostly of glycoproteins and serves as a lubricant and a protective lining 
over the mucosa (Laux et al. (2005); Pearson et al. (2005)). The main structural 
components of the mucus layer are the mucins or glycoprotein which is a carbon 
source that can support intestinal bacteria in vivo in the absence of any dietary input 
(Macfarlane et al., 1991). Furthermore, under the mucus the surfaces of intestinal 
epithelial cells are covered with an abundance of terminally fucosylated 
glycoproteins and glycolipids which are induced by members of the intestinal 
microbiota (Bry et al., 1996). In particular, bacterial species such as Bacteriodes 
thetaiotaomicron can turn to host glycans for use as an energy source when dietary 
polysaccharides become scarce (Sonnenburg et al., 2005). This commensal microbe
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are modulated by the host with its requirement needs, which gives it a competitive 
colonization advantage within the intestinal niche (Hooper et al., 1999). Thus the 
interaction of microorganisms with the mucosa is a complex one, which involves 
cross-talk between the microbes, and between the microbes and the host (Chow et 
al., 2006).
In terms of the bacterial species presence, the predominant mucosa-associated 
population is host specific and uniformly distributed along the colon but significantly 
distinct from the lumen and faeces (Zoetendal et al. (2002); Eckburg et al. (2005)). 
The different fermentation profiles are also exhibited between planktonic bacteria of 
the lumen and sessile (biofilm) bacteria growing in close association with host cells 
(Probert et al., 2002). In vitro studies with biofilm chemostats in series showed that 
biofilm bacteria made the principle contribution to acetate production, while 
non-adherent planktonic bacteria were largely responsible for the majority of 
propionate and butyrate formation (Macfarlane et al., 2005). The species composition 
of the human intestinal microbiota differs between particle-associated and free-living 
communities (Walker et al., 2008). Their functional differences have also been 
suggested (Macfarlane et al. (1997, 2006b)).
Some researchers focused on lactobacilli (e.g. L. gasseri) as general 
mucosa-associated bacteria because of their potential probiotic effects in the human 
GI tract (Zoetendal et al., 2002). Some lactobacilli, administered as probiotics, 
temporarily colonize the mucosal surface and displace other microorganisms. 
Administration of 19 test strains of lactobacilli (each 5 x 106  cfu/ml) fed to healthy 
volunteers in 1 0 0  ml fermented oatmeal soup, high numbers of adherent lactobacilli 
were still recovered from jejuna samples up to 1 1  days after administration of the 
bacteria had stopped, while clostridia numbers decreased between 1 0 - and 1 0 0 -fold 
in some of the volunteers (Johansson et al., 1993). Lactobacillus plantarum was the 
predominant adherent species, but L.agilis, L. reuteri and L. casei subsp. rhamnosus 
were also present (Johansson et al., 1993).
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The diversity of the human gastrointestinal microbiota can be obtained from 
cultivation-based and molecular studies. Culture based techniques that use 
differential media to select specific populations of bacteria are cost-effective and 
reproducible. However, species or strain level detection is very difficult as the 
culture based analysis is limited to distinguishing between different bacterial 
phylogenetic groups (Sekirov et al., 2010). Modem molecular method such as 16S 
ribosomal RNA clone libraries indicates that the number of species will be even 
higher. The advent of molecular techniques based on 16S rRNA gene analysis is 
allowing a more complete assessment of this complex microbiota ecosystem by 
unraveling the extent of the diversity, abundance and population dynamic of this 
community (Vaughan et al. (2000); Zoetendal et al. (2004)). The microbial diversity 
in the human colon is estimated as about 1 , 0 0 0  species based on molecular 
techniques (Rajilic-Stojanovic et al., 2007). Taking into account inter-individual 
variability, the composition of microbial consortium in the lower human GI tract may 
be over 45,000 bacterial species (Frank et al., 2007). Table 3.4 shows an overview of 
some current methods used to investigate the intestinal microbiota (Fouhy et al. 
(2012b); Amor et al. (2006)).
Table 3.4: Various Methods for investigating the diversity of the human intestinal microbiota
Method Application Comments
Not representative for 
microbiota; insufficient 
selective media; time 
consuming
Large scale cloning is 
laborious; primer bias can be 
an issue
Gives information about 
activity of microbiota; of 
rRNA; comprehensive set of 
probes published
High throughput with image 
analysis software and flow 
cytometry; requires probe 
design comprehensive set of 
probes published
Culturing Isolation of
pure cultures, 
enumeration
16S rRNA gene libraries and sequencing
Dot-blot
hybridization
FISH
Identification
and
phylogeny
Detection, 
quantification 
and activity
Single cell 
detection and 
enumeration
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PCR-DGGE/TGGE Rapid 
profiling of 
total
microbiota
Detection of specific groups 
possible; semi-quantitative 
identification by band 
extraction and sequencing
T-RFLP Rapid 
profiling of 
total
microbiota
Identification by cloning and 
sequencing; bank of T-RF 
under construction
Quantitative real 
time PRC
Detection
and
quantification
Requires probe/primers 
design; very high throughput
High through-put 
sequencing
Rapid 
identify 
bacterial 
profile in 
complex
environments
Sequencing based approaches 
e.g., 454, Illumina, SoLID, Ion 
torrent
Abbreviations: DGGE, denaturing gradient gel electrophoresis; FISH, fluorescent in situ 
hybridization; PCR, polymerase chain reaction; rRNA, ribosomal ribonucleic acid; TGGE, 
temperature gradient gel electrophoresis; T-RF, terminal restriction fragment; T-RFLP, 
terminal restriction fragment length polymorphism. SoLID, sequencing by oligonucleotide 
ligation and detection.
The diversity and composition of the human intestinal microbiota promotes our 
knowledge of the identities of the microbial inhabitants, but it does little to tell us 
about the metabolic function of community members in the ecosystem. Combination 
of composition and function contributions of gut microbial communities to their host 
will provide a complete view of the ecology and functional capacity of the gut 
microbiome (Lozupone et al. (2012); Sekirov et al. (2010)). However, due to the 
complexity of the human colonic microbiota, it is very difficult to elucidate the 
function of microorganisms. The ‘Meta’ family of function-focused analyses 
including metagenomics, metaproteomics, metabolomics and metatranscriptomics 
have greatly improved our understanding of bacterial functionality in the human 
microbiota ecosystem (Tyson et al. (2004); Gill et al. (2006); Gloux et al. (2007) 
Kurokawa et al. (2007); Zoetendal et al. (2008); Verberkmoes et al. (2009); Wikoff 
et al. (2009); Brugere et al. (2009); Mahowald et al. (2009)). Metagenomics gives 
sequence information from the collective genomes of the microbiota, which can be 
used to identify the functional contributions and biological roles of the microbial
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ecosystem residing in the human large intestine. More information related to the 
‘Meta’ family analyses can be found in the review paper by Sekirov et al. (2010).
Today, the complex human microbiota is recognized as a key component in GI tract 
homeostasis, and both the composition and metabolism of the gut microbiota are 
strongly diet related (Flint et al., 2007). Major functions of the gut microbiota 
include metabolic activities in salvage of energy and absorbable nutrients, important 
trophic functions on intestinal epithelial cells and on the immune system, and 
protection of the colonized host against invasion pathogens (Guamer et al., 2003). 
The major metabolic function of colonic microbiota is the fermentation of 
non-digestible dietary residue and dislodged mucus produced by the epithelia 
(Roberfroid et al., 1995). The metabolic endpoint of non-digestible carbohydrate is 
generation of short chain fatty acid (SCFA) which is a major source of energy in the 
colon (Cummings et al., 1996). Anaerobic metabolism of peptides and proteins also 
produce SCFA and other potentially toxic substances including ammonia, amines, 
phenols, thiols and indols (Macfarlane et al. (1986a); Smith et al. (1996)). Colonic 
microorganisms also play a part in essential vitamin synthesis and absorption of 
minerals such as calcium, magnesium and iron (Hill (1997); Younes et al. (2001)).
One of the trophic functions of gut flora is to control epithelial cell proliferation and 
differentiation. All major SCFA stimulate epithelial cell proliferation and 
differentiation in the large and small intestine in vivo (Frankel et al., 1994). However, 
butyrate inhibits epithelial cell proliferation and stimulates cell differentiation in 
vitro (Gibson et al., 1992). Another trophic function of gut flora is the development 
and homeostasis of the host immune system (Guamer et al., 2003). The interactions 
between the intestinal microflora and epithelial cells at the intestinal mucosal 
interface seem to play a part in the development of a competent immune system. The 
interesting observation is that the gut microbiota can act on the production of 
epithelial glycoconjugates, which may serve as receptors for attachment of pathogen 
(Salminen et al., 1998).
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Protection against pathogens is also a main function of gut flora. Resident bacteria 
provide an important line of resistance to colonization by exogenous microorganisms 
and prevent pathogens invasion. Germ-free animals are very susceptible to infection 
(Taguchi et al., 2002). Several mechanisms leading to the barrier effect include 
attachment sites competition, nutrient competition and antimicrobial substance 
production. Attachment of some pathogenic bacteria can be prevented by the 
mutually beneficial crosstalk between the indigenous microbiota and the epithelial 
cells (Umesaki 1989). The symbiotic relationship between the host and bacteria 
prevents overproduction of the nutrient, which would favor the potential pathogen 
for the host (Hooper et al., 1999). Microbiota in the GI tract also can inhibit the 
growth of their competitors by producing antimicrobial substance such as 
bacteriocins (Brook (1999); Lievin et al. (2000)).
3.4 Metabolism of human colonic microbiota
The main function for the microbiota in the colon is the breakdown of carbohydrate 
and protein that escape the digestion in the upper digestive tract or are produced by 
the host. The predominant anaerobes in the colon do not use oxygen as a terminal 
election acceptor, and derive their energy from anaerobic respiration or substrate 
level phosphorylation (Goldin et al., 2006). Most of the bacterial reaction can be 
classified as reductive, hydrolytic or removal of functional groups such as 
dehydroxylation and decarboxylation which are often catalyzed by specific bacterial 
enzymes (Goldin et al., 2006). The major balance of the intestinal microbiota derives 
from the ability to convert the substrates into the energy, SCFA, biomass, CO2 , H2 , 
and CH4  in some individuals (Nicholson, et al. (2012); Cummings et al. (1991)). The 
principle fermentation of carbohydrate and protein are summarized in Figure 3.2 and 
Figure 3.3 (Cummings et al., 1991).
i
I
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Figure 3.2: Carbohydrate fermentation in the human large intestine
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Figure 3.3: Protein breakdown and amino acid fermentation in the human large intestine
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3.4.1 Regional difference
There are differences between the caecum and sigmoid colon in the concentrations of 
SCFA, moisture and pH. SCFA concentrations are highest in the caecum and 
ascending colon and fall towards the descending colon. In contrast, pH is lowest in 
the ascending colon (pH 5.4-5.9) and rises in the descending colon (pH 6.6-6.9). The 
fermentation in the caecum and right side o f the colon is mainly SCFA. The left side 
o f the colon is more carbohydrate depleted, and protein breakdown and amino acid 
fermentation become more dominant. Branched-chain fatty acids are also 
accumulated along with phenols and amines in the descending colon, and the 
characteristics o f the flora change towards a more methanogenic and 
sulphate-reducing type o f flora. These contrasts are summarized in Figure 3.4 
(Cummings et al., 1991).
Ascending colon
Carbohydrate rich 
Moisture rich 
SCFA increase 
pH acid (pH 5-6) 
Residence time 6-16 h 
Bacterial growth fast 
Mainly H2 and CO 2
Descending colon
Protein rich 
Less free water 
SCFA less 
pH near neutral 
Residence time 12-36 h 
Bacterial growth slower 
H2, C 0 2 and CH4 
Amines, phenols and 
ammonia
Figure 3.4: Regional differences in large bowel function in the human.
The human large intestine is a fermentative organ with substantial potential for 
water, electrolyte and organic anion absorption. The marked production and pH 
difference in different part o f the colon may account for different disease activity. 
For example, ulcerative colitis is usually found in the rectum and spreads proximally, 
whilst diverticular disease is mainly a disorder o f the sigmoid colon. About 60% of 
large bowel cancers lie within the rectum, sigmoid and descending colon (Cummings 
et al. (1987a, 1987c)).
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3.4.2 Carbohydrate and protein digestion
Carbohydrate fermentation and protein breakdown are the main metabolic pathway 
of the gut microbiota in the human colon. Fermentation is highly depending on the 
amount and type of substrate available to the bacteria. The major substrates for 
fermentation are shown in Table 3.5 (Cummings et al. (1987a, 1987b, 1989)), where 
the figures are based on people eating western style diets.
Table 3.5: Substrates available for fermentation in the human colon
Type Amount
(g/day)
Carbohydrate Resistant starch (RS) 5-35
Non starch polysaccharide (NSP) 10-25
Oligosaccharides 2 - 8
Sugars and Sugars alcohols 2-5
Synthetic carbohydrate, e.g. lactulose, 
polydextrose, pyrodextrins, modified celluloses
Variable
Protein Dietary (N * 6.25) 1 - 1 2
Endogenous, e.g. pancreatic enzymes and other 
secretions
4-8
Urea, nitrate 0.5
Other Mucus (acidic glycoproteins) 3-5
Bacterial recycling Unknown
Sloughed epithelial cells 30-50
Organic acids Variable
Total Carbohydrate 20-60
Protein 5-20
Carbohydrates are polyhydroxyaldehydes and ketones that have the empirical 
formula (CH2 0 )n. Carbohydrates provide 85% of available substrates for colonic 
microbiota fermentation. From nutritional point, dietary carbohydrates are classified
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primarily according to the degree of polymerization with subdivisions based on 
glycosidic linkages and chemistry of individual sugars. Table 3.6 shows such a 
classification, which provides a logical approach to food carbohydrate (Englyst et al., 
1992). Main dietary carbohydrates that escaped digestion and absorption in the small 
intestine are resistant starch (RS) and non-starch polysaccharides (NSP).
Table 3.6: Classification of dietary carbohydrates
Group DP* Sub-group Digestion in the 
small intestine
Sugars 1 Monosaccharides Glucose, fructose, 
Galactose, sorbitol, 
mannitol
Well absorbed except 
sugar alcohols
2 Disaccharides Sucrose, Lactose, 
Maltose
Well absorbed except 
lactose
Oligosac-c
harides
3-9 a-glucans Mostly starch 
hydrolysis products
Well digested
Non-a-glucans
(NDO)
Fructo-oligosaccharides; 
Galacto-oligosaccharides; 
Raffmose, Starchyose, 
Polydextrose
Probably all reach the 
caecum
Polysac­
charides
> 1 0 Starch (a-glucans) Amylose, Amylopectin Some forms of 
resistant starches
(RS) reach the 
caecum
Non-starch
polysaccharides
(Non-a-glucans)
Cell wall, Cellulose, 
Hemicellulose, Pectins, 
Guar, inulin, etc.
All reach the caecum
* Degree of polymerisation.
Non-starch polysaccharides (NSP) are the major polysaccharide group to be 
fermented in the human colon. They are characterized as being non-a-glucan or non
i
starch polysaccharides and comprise a diverse group of homo and heteropolymers,
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including xyloglucans, glucomannan, arabinoxylans and xylans etc. (Chassard et al., 
2007). A number of physic-chemical factors affect fermentability of NSP include the 
extent of lignifications of the cell wall polymers, water solubility and particle size of 
substance (Adiotomre et al. (1990); Southgate et al. (1990)). For example, the more 
water soluble a substrate is the more highly digestible it is (Stephen et al., 1979). 
Similarly, the fine particle sizes of foodstuffs are easy for breakdown (Heller et al., 
1980). NSP is the major component of dietary fibre which is involved in the 
production of beneficial compounds during the fermentation in the human colon to 
increase bulk, soften stool, and shorten transit time through the intestinal tract. The 
proposed health benefits of NSP are summarised in Table 3.7 (Adiotomre et al. 
(1990); Southgate et al. (1990)).
Table 3.7: Physiological properties and proposed health benefits of non-starch 
polysaccharides
Physiological
property
Health benefit for Other major contributing 
dietary factors
Increased satiety Obesity Total energy, fat
Delayed glucose 
absorption and reduced 
insulin secretion
Diabetes, Ageing Starch
Reduced deoxycholate 
in bile
Gallstones Fat, total energy, other 
carbohydrates
Low blood cholesterol Coronary heart disease Fat, cholesterol, antioxidants
Fermentation Large bowel cancer Other non-absorbed 
carbohydrate, fat, meat
Laxation Constipation, diverticular 
disease, anal conditions, 
irritable bowel
Other non-absorbed 
carbohydrate, protein 
degradation products
However, the amount of resistant starch (RS) may exceed the amount of NSP on a 
high starch diet (Macfarlane et al., 1991). RS is calculated as the starch not 
hydrolyzed after 120 min incubation. RS in food items have shown figures from 3 to 
6  g/d of daily RS intake in 10 different countries (Dysseler et al, 1994). However, in
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countries where starch rich foods form the main source of energy intake are probably 
considerably higher (Cummings et al., 1991).
Oligosaccharides are carbohydrates with a degree of polymerization (DP) of 3-10 
(Southgate 1995). They are readily soluble in water and can be fermented by the 
colonic microflora. Fructo-oligosaccharides (FOS) and galacto-oligosaccharides 
(GOS) have aroused interest in recent years, mostly because of their most important 
property, which may be unique, is to stimulate bifidobacterial growth specifically 
while suppressing the growth of some other species such as Clostridium perfringens 
(Gibson et al., 1995a). The fermentation products of FOS are mostly acetate and 
propionate with some butyrate and lactate, H2  and CO2 . The mechanism for the 
inhibition of clostridia growth is thought to be related to lowering of intestinal pH by 
bifidobacterial fermentation. FOS also affect lipid metabolism, reducing triglyceride 
and cholesterol concentrations in rats and diabetic humans (Yamashita et al. (1984); 
Fiordaliso et al. (1995)). Table 3.8 summarizes the health benefits of 
oligosaccharides (Yamashita et al. (1984); Roberffoid (1993); Fiordaliso et al. 
(1995); K oketal. (1996)).
Table 3.8: Potential health benefits of oligosaccharides
Health benefits of oligosaccharides
Substrates for fermentation
Short-chain fatty acid production 
Biomass (laxative effect)
Reduced nitrogenous end products in colon (ammonia, amines)
Selective stimulation of bifidobacteria
Protection against invading pathogens 
Suppression of growth of clostridia and coliforms 
Lipid metabolism
Decrease in triglyceride synthesis 
Stimulate immune function
Several sources of nitrogen containing compounds that enter the large intestine are 
important substrates for metabolic action by the intestinal microbiota. The sources
! — B a a a a ^ _ S B _ a s .
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include undigested dietary protein, protein from epithelial cells, and digestive 
secretions including digestive enzymes, glycoprotein mucins, free amino acids, and 
peptides including those derived from a bacterial origin (McCartney et al., 2006). In 
addition, ammonia, urea and nitrate are found in the ileal effluent (McCartney et al., 
2006). The amount of protein entering the large bowel can be partly deduced from 
studies of ileostomy subjects that 12-18 g of protein enters the caecum from the 
ileum per day (Chacko et al., 1988). On protein-free diets, about 1 g N/day is lost in 
ileostomy effluent and it rises to about 2 g N/day when normal food is taken (Gibson 
et al., 1976). The approximate relative amount of N is protein (48-51%), peptides 
(20-30%), urea/ammonia/nitrate (10-15%) and free amino acids (Chacko et al. 
(1988); Florin et al. (1990)). Protein comprises mainly pancreatic enzymes with 
normal food amino acid patterns in ileostomy effluent. In contrast, in the feces the 
nitrogen compounds are more than 50% of bacterial origin (Stephen et al., 1980). 
Therefore, although the balance of nitrogen is relatively maintained between the 
amounts of entering and leaving the large intestine, the nitrogen containing 
compounds in the colon can be utilized by intestinal microbiota and are converted 
into bacterial protein which is found in the feces as intact bacteria (McCartney et al., 
2006).
3.4.3 Main fermentation pathways
Microbial metabolism involves catabolic reactions and anabolic reactions which 
could yield energy and lead to bacterial growth. Anaerobic digestion yields lower 
energy compared with aerobic processes. This will force the microbial community to 
cooperate efficiently and obtain enough energy for survival (Schink 1997). 
Syntrophic association is such a cooperation which two metabolic types of 
microorganism depend on each other to degrade the given substrates. The 
fermentation products converted by one microorganism are utilized by another 
microbe to improve the overall substrates (Kleerebezem et al. (2000); Jackson et al. 
(2002)). Several books and literatures have introduced the metabolic pathways of 
anaerobic fermentation, and the main reaction pathways by the human colonic
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microbiota are described below (Gottschalk (1988); Miller et al. (1996); Macfarlane 
et al. (1997); Bemalier et al. (1999); Goldin et al. (2006)).
3.4.3.1 Embden-Meyerhoff-Parnas pathway (EMP)
The Embden-Meyerhoff-Pamas (EMP) pathway has been identified as the most 
common pathway of glucose metabolism. However, alternative catabolic pathway 
such as the Entner-Doudoroff pathway, pentose and pentose phosphoketolase 
pathway can also be used to metabolise hexoses (Gottschalk 1988). EMP is a 
biochemical pathway for the breakdown of glucose into pyruvate. Glucose is broken 
down from a six carbon molecule to a three carbon derivative. The EMP pathway 
includes three stages. The first stage involves the conversion of glucose to 
fructose-1,6 -bisphospate. This phase utilizes energy from ATP. The second phase 
converts the fructose-1,6 -bisphospate product to pyruvate. Two molecules of 
pyruvate are formed by one molecule of hexoses, and NAD+ is reduced to NADH 
and four molecules of ATP are formed. There are a total of ten steps that make up the 
two stages of the EMP pathway. At this final stage, the NADH produced from NAD+ 
is oxidized back to NAD+ in order for EMP pathway to continue. The reaction of 
EMP is shown below.
C6 H1 20 6  +  2NAD+ +  2ADP +  2Pi -* 2CH3COCOOH +  2NADH +  2H+ +  2ATP +  
2H20
3.4.3.2 Pyruvate metabolism
Pyruvate is the central intermediate in fermentation that can be routed to various 
pathways. Pyruvate could be converted into formate, acetate, butyrate or ethanol via 
acetyl coenzyme A (acetyl-CoA) formation (Bemalier et al., 1999). Pyruvate can 
also be converted into propionate, valerate and carproate by a variety of anaerobic 
bacteria, either from glucose or lactate fermentation (Bemalier et al., 1999). The 
overall reactions of 3 main SCFA formations are shown below.
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Acetate formation:
C6 H 1 20 6 — 2 CH3 COOH + 4H2  + 2C0 2  + 4ATP 
Butyrate formation:
C 6Hi2 0 6 -  CH3 CH2 CH2COOH + 2H2  + 2C0 2  + 3ATP 
Propionate formation:
3C6 Hi2 0 6  -  4 CH3 CH2COOH + 2 CH3 COOH + 2C 0 2  + xATP
Acetate is produced by many intestinal bacteria including Ruminococcus and 
Propionibacterium, and is the major acid product of nearly all species of Bacteroides 
(Wolin et al., 1994). Fusobacterium, Eubacterium and Clostridium spp. are major 
butyrate formers in the human intestine (Wolin et al., 1983). Propionate is formed by 
two different pathways i.e. through succinate, or direct reductive process involving 
formation of lactate and acrylyl-CoA (Miller et al., 1979). Bacteroides from the 
human colon are able to decarboxylate succinate to propionate (Miller et al., 1979). 
Valerate and/or caproate can be produced from pyruvate by some species of 
Clostridium or Megasphaera (Prins 1977).
A number of rumen and human studies attempt to draw up the equations for SCFA 
production through carbohydrate fermentation (Livesey et al. (1995); Wolin et al. 
(1981, 1983); Miller et al. (1979); Mathers et al. (1993)). The most valuable 
information needed to write an equation is the ratio of produced SCFA. Taking all 
available evidence into account including the probable metabolism of SCFA by the 
epithelium, a molar ratio of around 60:20:18 (acetate: propionate: butyrate) can be 
justifiably used and the stoichiometry is shown below (Mathers et al., 1993).
59C6 Hi2 0 6  +38H20  — 60CH3COOH + 22CH3 CH2COOH + 18 CH3 (CH2)2COOH 
+ 96C02 + 268H+
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This stoichiometry gives a yield of SCFA, from carbohydrate of 63 g SCFA/lOOg. 
This is close to the figure of 61 g SCFA/lOOg carbohydrate fermentation in the study 
of Livesey et al. (1995). However, a theoretical yield of SCFA (63 g SCFA/lOOg) is 
an upper limit for starch as a major substrate for fermentation (Macfarlane et al., 
1986b). Plant wall polysaccharides such as arabinogalactans and pectins only give 
yields of 35-54 g SCFA/lOOg (Adiotomre et al. (1990); Englyst et al. (1987)). 
According to the above equation, 32-42 g of carbohydrate needs to be fermented in 
the human colon each day to produce 300-400 mmol SCFA (Titgemeyer et al., 
1991).
3.4.3.3 Lactate formation and utilization
Many lactate-producing bacteria are present in the gut (Bacteroides, Eubacterium, 
Clostridium, Streptococcus, Peptostrepococcus, Lactobacillus, Bifidobacterium). 
There are two pathways of lactate production from pyruvate which involves 
producing two lactate isomers (D, L) (Gottschalk 1988). Lactobacillus spp. can 
produce D (-), DL or L (+) lactic acid, whereas Bifidobacterium and Streptococcus 
produce only the L (+) form (Bemalier et al., 1999). Lactate is generally produced by 
the homofermentative or heterofermentative pathway. The homofermentative 
pathway yields 2 mol of lactate per mol of glucose. The heterofermentative pathway 
yields one mole each of lactate, ethanol, C02 and ATP per mol of glucose. The 
overall reactions are shown below.
Homofermentative pathway:
C6 Hi2 0 6  — 2C3 H6 0 3 + 2ATP
Heterofermentative pathway:
C6 Hi2 0 6  — C3 H6 0 3 + CH3 CH2OH + C 0 2  +1 ATP
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Bifidobacteria use a distinctive pathway that yields two moles of lactate, three moles 
acetate and five moles of ATP from two moles of glucose.
2C6 Hi2 0 6  — 2 C3 H6 0 3 + 3CH3COOH + 5ATP
Lactate can be utilized by Propionibacterium acnes, Veillonella spp., Megasphaera 
elsdenii, Clostridium spp. and dissimilatory sulphate-reducers (Bemalier et al., 
1999). It can be converted into acetate, propionate, butyrate and longer chain fatty 
acids. Lactate participates in a reversible reaction with pyruvate. In these 
conversions, lactate is oxidized to pyruvate and the corresponding pathways are 
those described above for pymvate.
3.4.3.4 Hydrogen formation and utilization
The total amount of gas produced each day from fermentation varies with values of 
0.5-4 1/d which is mainly related to diet (Calloway et al. (1968); Flemings et al. 
(1983)). The average amount of hydrogen is around 19% in the total amount of gas 
(Levitt, 1971). In the colon, hydrogen can be formed by bacteria as a result of 
oxidation of pymvate, formate, reduced pyridine nucleotides (NADH, NADPH) and 
reduced ferredoxins (Macfarlane et al., 2003). Hydrogen is used by three main routes 
in the human colon.
Methanogenesis
Human colonic methanogenic bacteria (MB) have been found only in 30-50% of 
healthy subjects in studies of Western populations (Fritz et al. (1985); Mckay et al. 
(1985)). Methanogenic bacteria in the large bowel have an obligate requirement for 
H2. Only two species, belonging to two different genera have been identified in the 
large intestine, namely Methanobrevibacter smithii and Methanosphaera 
stadtmaniae which carry out the conversion through two different pathways (Miller 
et al., 1986).
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Methanobrevibacter smithii is the principal CHj-producting species found in human 
colon samples. It derives energy from the reduction of CO2  with H2 , according to the 
following equation (Miller et al. (1982, 1984, 1985, 1986)). H2  and CO2 , or formate, 
are the sole substrates.
4H2 +C0 2  -> CH4 +2 H2 O
Methanosphaera stadtmaniae is also widespread species isolated from some faecal 
samples, yet consistently observed at lower population levels than M. smithii. This 
species combines methanol with H2  as shown in the equation below (Miller et al. 
(1983, 1985)):
H2 +CH3 OH -» CH4 +H2 O
Sulphate reduction
An alternative pathway for consumption of H2  generated from colonic fermentation 
is through the activities of dissimilatory sulphate-reducing bacteria (SRB).The 
growth of SRB in the presence of sulphate, reducing it to sulphide, is the principle 
reaction of SRB. They utilize H2  according to the equation:
4H2+ SO4 2' + H* —► SH" + 4H20
SRB can be found in the intestinal contents of humans and they are able to use 
gaseous hydrogen as an electron-donor for the reduction of sulphate to sulphide, and 
account for substantial consumption of hydrogen within the colon (Cummings et al., 
1991). A three-stage continuous-culture study showed that SRB preferred to grow in 
the distal colon and confirmed in vivo at autopsy (Gibson et al. (1988a); Macfarlane
et al. (1992b)). A review of the physiology and ecology of SRB showed that there is
•  •  • 0an inverse relationship between SO4 ’ reduction and methanogenesis existing in the
large bowel (Gibson 1990a). Mixing of SRB and methanogens in in vitro study 
demonstrated that colonic SRB were able to directly outcompete MB for the
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available H2  (Gibson et al., 1988b). Species belonging to the genera Desulfovibrio 
and Desulfobulbus are particularly efficient H2  utilizing bacteria (Gibson et al., 
1990b).
Acetogenesis
The existence of other potential pathway of H2  disposal by colonic bacteria is also 
known as reductive acetogenesis (Gibson et al., 1990b). Homoacetogenic bacteria 
could grow in the human colon. These organisms are able to combine 4 mol of H2  
with 2 mol of CO2  to produce acetate in the equation below (Lajoie et al. (1988b); 
Durand et al. (1995)).
4H2 +2C02  -► CH3 C00H+2H20
Bemalier et al. (1996a) have isolated a few species of genus Clostridium from faeces 
of five non-methanogenic subjects which have been identified as acetogenic strains 
and a new species of the genus Ruminococcus, named R. hydrogenotrophicus were 
also described in Bemalier et al. (1996b). However, acetogenesis is a less favorable 
route of hydrogen disposal than either sulphate reduction or methanogenesis and 
acetogenic bacteria under normal circumstances. Thus, significant levels of 
acetogenic activity would only be expected when conditions unfavorable for 
methanogenesis or sulphate reduction occur.
3.4.3.5 Amino acids as substrates
Amino acid fermentation is also an additional source of SCFA in the human colon 
(Macfarlane et al., 1992a). Approximately 30% of protein is converted to SCFA. 
Protein breakdown could potentially account for about 17% of the SCFA found in 
the caecum, and 38% of the SCFA in the distal colon (Macfarlane et al., 1992b). 
There are five major bacterial pathways for amino acids breakdown including four 
direct pathways and one indirect pathway. The direct pathways include reduction 
resulting in saturated fatty acid production, oxidation resulting in the formation of
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keto acids, hydrolysis causing the formation of an alpha-hydroxy fatty acid, and 
removal of the elements of ammonia, producing an unsaturated fatty acid (Rowland 
1988). A fifth indirect pathway is carried out by clostridia to degrade amino acids in 
pairs and form a keto acid and a saturated fatty acid through a couple of redox 
reactions (Rowland 1988).
Reduction reactions are the major pathway for the breakdown of amino acids in the 
colon. The reduction products of colonic microorganisms include acetate, propionate, 
butyrate, and isobutyrate, isovalerate and 2-methylbutyrate (Kiijavainen et al., 1999). 
Other reduction products are ammonia, amines, CO2  and H2  (Mallett et al., 1998). 
Some products that result from reductive degradation of aromatic amino acids 
include phenol, p-cresol, phenylactic acid, phenylpropionate acid, indole, 
indoleacetic acid, and indolepropionine acid (Mallett et al., 1998).
Decarboxylation is a second major pathway for the degradation of amino acids 
(Clifford 1999). Bacterial decarboxylases act on amino acids to form amines and 
CO2 . There are a number of intestinal bacteria containing decarboxylase activity 
including enterobacteria, enterococci, lactobacilli, clostridia, bacteroides, and 
bifidobacteria (Mallett et al., 1998).
3.5 The probiotic, prebiotic and synbiotics concepts
Probiotic may be defines as ‘living microorganisms which when administered in 
adequate amounts confer a health benefit on the host’ (WHO 2002). Probiotics are 
non-pathogenic microorganisms which survive passage through the GI tract and are 
believed to have potential beneficial health effects. Many desirable characteristics of 
probiotic bacteria include being ‘generally regarded as safe’, having stability in 
gastric juices acid and bile salt, adherence to intestinal mucosa, persistence for 
certain time in the gut, having antagonism against pathogenic and putrefactive 
organisms and modulation of the immune response (Thomas et al. (2010); Dunne et 
al. (2001)). Probiotic activity to modulate the intestinal microbiota has been 
associated most commonly with lactobacilli and bifidobacteria. But other
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non-pathogenic bacteria including species of streptococci and enterococci, 
non-pathogenic E. coli Nissle 1917, and the yeast Saccharomyces boulardii have 
been used (Soccol et al. (2010); Shanahan 2001). Table 3.8 lists microbes commonly 
used as probiotics (Dunne et al. (2001); Mack et al. (1999); Mattila-Sandholm et al. 
(1998); Ventura et al. (2002); Gardiner et al. (2002); Cummings (2009)).
Table 3.9: Organisms commonly used as probiotics in humans and animals
Lactobacillus Bifido-
Bacterium
Other probiotic organisms
L. acidophilus B. adolescentis Enterococcus faecalis
L. brevis B. animalis/lactis Enterococcus faecium
L. casei B. bifidum Lactococcus cremoris
L. crispatus B. breve Lactococcus lactis
L. delbrueckii B. infantis Leuconostoc mesenteroides
L. fermentum B. lactis Pediococcus acidilactici
L. gallincarum B. longum Pediococcus pentosaceus
L. gasseri B. thermophilum Saccharomyces boulardii
L. johnsonii Sporolactobacillus inulinus
L. lactis Streptococcus thermophilus
L. paracasei
L. plantarum
L. reuteri
L. rhamnosus
The effect of probiotics may be classified into three modes of action including 
modulating the host defences, preventing infections and restoration of the microbial 
equilibrium in the gut, affecting microbial products to inactive toxins and 
detoxification of host products (e.g. bile salts). Probiotics have been investigated in 
many clinical trials, including atopic disease in children, lactose intolerance, 
antibiotic-associated diarrhoea, traveler's diarrhoea, constipation, irritable bowel 
syndrome (IBS), ulcerative colitis and Crohn’s disease, urogenital tract infection, 
inflammatory bowel disease (IBD) and colon cancer (Gardiner et al. (2002); Fooks et 
al. (2002); Mountzouris et al. (2002); Salminen et al. (2005)). Table 3.10 summarizes 
the effects of probiotics on humans (Gibson et al., 1996).
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Prebiotics offer an alternative strategy to selectively stimulate the proliferation and 
activity of the gastrointestinal microbiota, while the probiotic approach aims to 
deliver supplemental beneficial live bacteria to the gut. Prebiotics are selectively 
fermented ingredients that remain largely undigested during passage through the 
stomach and small intestine and stimulate only beneficial population of bacteria in 
the human colon. To date, most prebiotics are non-digestible carbohydrates, 
particularly oligosaccharides such as lactulose, galacto-oligosaccharides (GOS), 
inulin, fructo-oligosaccharides and others (Macfarlane et al. (2006a, 2008)).
Table 3.10: Proposed effects of probiotics in human
Proposed benefits of probiotics in human health
Antitumour properties 
Reduction of cholesterol 
Improved lactose digestion 
Relief from constipation
Stimulation of immune function through non-pathogenic means
Improved resistance to gastrointestinal infections
Treatment of traveller’s diarrhoea
Reduction of antibiotic associated effects
Vitamin production
Induction of digestive enzymes
The health benefits of prebiotic in the gut include positive effect of the composition 
of the colonic microbiota, protection against enteric infections, improvement of 
mineral absorption, mimic cellular binding sites for pathogens, immunomodulation, 
suppressing production of proinflammatory cytokines, trophic and anti-neoplastic 
effects of SCFA, faecal bulking, and reduced toxigenic microbial metabolism 
(Kanauchi et al. (2008); Bouhnik et al. (2004); Gibson et al. (2004); Abrahms et al.
(2005); Shoaf et al. (2006); Cummings et al. (2000, 2002); Pierre et al. (1997); Sands 
(2004)).
Some colonic bacteria can use prebiotic directly, and some other colonic bacteria can 
use prebiotic indirectly through cross-feeding, i.e. utilizing the metabolic products
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from prebiotic (Ohtsuka et al. (1989); Belenguer et al. (2006)). There is little doubt 
from the human and animal studies that prebiotics can have microbiological effects 
on the dynamics of the colonic microbiota including increasing numbers of 
bifidobacteria and lactobacilli in the human colon (Bouhnik et al. (2004); Bartosch et 
al. (2005); Roberfroid, (2005)). The International Scientific Association for 
Probiotics and Prebiotics (ISAPP) and the International Probiotic Association (IPA, 
including over 150 probiotic manufacturers and distributors of probiotics) are two 
groups to work on probiotics and prebiotics (Vyas et al., 2 0 1 2 ).
Synbiotics are combinations of probiotics and prebiotics which can be defined as ‘a 
mixture of pro- and pre-biotics which beneficially affects the host by improving 
survival and implantation of live microbial dietary supplements in the 
gastrointestinal tract (Gibson et al., 1995b). Health effects of synbiotics such as 
bifidobacteria and lactobacilli with dietary fiber (e.g. FOS and GOS) have been 
observed and synbiotic products may be a method of improving the stabilization of 
the probiotic activity (Schrezenmeir et al. (2001); Barrangou et al. (2006); Goh et al.
(2006); Saulnier et al. (2008)).
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Chapter 4 Growth of Lactobacilli and 
Bifidobacteria in an In Vitro Batch 
Fermentation Model
Abstract
The aim of the work presented in this Chapter was to extend our knowledge of the 
physiological behavior of lactobacilli, bifidobacteria and their mixture, and to 
determine kinetic parameters during their growth in an in vitro batch fermentation 
model. The experiments were carried out in a nutritionally complex gut medium with 
glucose as the sole carbohydrate source, to gain a better understanding of the growth 
behaviors of different probiotic strains. For comparison, the batch cultures were also 
conducted using MRS (de Man Rogosa and Sharp) broth. These experimental data 
will also be used in later chapters for validation of the mathematical models.
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4.1 Introduction
The important roles played by the commensal intestinal microbiota include 
contributing to host nutrition, scavenging energy, shaping the development of the 
immune system, providing a natural defence mechanism against invading pathogenic 
bacteria and protecting against allergy development (Wilson (1995); Falk et al. 
(1998); Cebra (1999)). The colonization of the neonatal gut starts immediately after 
birth. The major components of the neonatal gut include enterobacteria, streptococci, 
bifidobacteria, lactobacilli, bacterioides and clostridia detected in the infants’ faeces 
which are initially strongly influenced by the mode of birth, and subsequently by the 
diet, genetic background and environment of the individual. Lactobacilli and 
bifidobacteria are the predominant bacteria in the faeces of breast-fed babies which 
are thought to impart protection against infection (Mackie et al. (1999); Harmsen et 
al. (2000); Seale et al. (2013); Fernandez et al. (2013)). In general, the complex range 
of micro-organisms is thought to be stabilized after two years of age in the gut 
(Hentges 1993). These bacteria could be traditionally classified into groups such as 
eubacteria, clostridia, bacteroides, bifidobacteria and lactobacilli. Bifidobacteria 
make up approximately 5% of the large intestinal bacteria and lactobacilli are present 
as less than 1% of the bacteria, but they are very important in terms of their probiotic 
effect (Cummings 2009).
Research has been expanding rapidly to provide evidence for roles of the gut 
microbiota in human health and disease, several chronic diseases such as 
gastrointestinal tract infections, irritable bowel syndrome (IBS), inflammatory bowel 
disease (IBD), antibiotic-induced diarrhoea, colon cancers, cardiovascular disease 
and obesity have been found to relate to the perturbation of the intestinal microbiota. 
The administration of probiotics has led to a beneficial way to manipulate the gut 
microbiota in the hope of achieving health benefits in the host (McNaught et al. 
(2001); Saadetal. (2013)).
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| Probiotics are defined as ‘live microorganisms that when administered in adequate|
amounts confer a health benefit on the host’ (FAO/WHO, 2002). However, ‘adequate 
amounts’ of probiotic has not been quantitatively defined in this statement. It is 
believed that the number of microorganism which has a metabolic activity in the 
human intestine must be over 1 0 6 per gram of food at the time of consumption 
(Gilliland, 1989). The main health benefits of regular consumption of probiotic 
include the improvement of the intestinal microbial balance (Alhaj et al., 2007); 
managing lactose intolerance through the production of lactase (Sanders 2000); 
improving the immune function and prevent infections (Reid et al., 2003a); reducing 
the risk of colon cancer (Saikali et al., 2004); reducing some forms of food allergies 
(Alhaj et al., 2007); lowering the blood cholesterol levels (Ataie-Jafari et al., 2009); 
lowing suppression of blood pressure of hypertensive individuals (Sanders 2000); 
playing a key role in the prevention of diarrhoea (Van Niel et al. (2002); Allen et al. 
(2004)); reducing antibiotic-associate diarrhoea (Hickson et al., 2007); reducing 
inflammation (Kirjavainen et al., 2003) and inhibiting the growth of some pathogenic 
bacteria (Alhaj et al., 2007).
The main mechanisms of the action of probiotics include the production of 
antimicrobial substances to inhibit the pathogen replication (e.g. hydrogen peroxide, 
short chain fatty acid, diacetyl, bacteriocins and deconjugated bile acids) (Ouwehand
1 et al. (1999); Maqueda et al. (2008)); blocking adhesion of pathogens and toxins to
epithelial cells (Lee et al. (2002); Gill (2003); Mack et al. (2003)); blocking 
invasiveness of pathogens to epithelial cells (Hess et al., 2004); modulation of 
non-specific and specific host immune response in diseased and healthy subjects (e.g. 
stimulating production of secretory IgA and mucus and attenuating pro-inflammatory 
responses) (Malin et al. (1996); Mack et al. (1999); Neish et al. (2000); Wold,
(2001)). The effect of probiotic intake on the human health and disease can be 
assessed through in vivo and in vitro models.
Probiotics consist mostly of Lactobacillus spp. and Bifidobacterium spp., but strains 
of Enteroccoccus spp., Bacillus spp. and some yeast such as Saccharomyces
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boulardii have also been found as suitable candidates. Lactobacilli and bifidobacteria 
are both gram-positive bacteria that differ in the G+C content. The growth of 
lactobacilli is optimum at pH 5.5-5. 8  and temperature 35-45°C, while the growth of 
bifidobacteria is optimum at pH 6.5-7.0 and temperature 20-46°C (Arunachalam, 
1999). There is only a small number of Lactobacillus species that are indigenous 
inhabitants in the GI tract, and most of them are allochthonous members. 
Bifidobacteira is the third most common bacteria population in the human gut after 
bacteroides and eubacteria (Charteris et al., 1997). Some of the beneficial effects of 
lactobacilli are (i) stimulating the vitamin synthesis and enzyme production; (ii) 
competing with pathogens for nutrition and space; (iii) antimicrobial substances 
production; (iv) reducing the serum cholesterol and (v) detoxification of carcinogens 
produced by colon cancer patients (Naidu et al., 1999). Some of the beneficial effects 
of bifidobacteria are (i) suppressing harmful bacteria by producing SCFA to control 
the pH of the large intestine (Gibson et al., 1995b); (ii) stimulating vitamin B 
production (Gibson et al., 1995b) (iii) promoting immunological response against 
malignant cells (Reddy et al., 1993); (iv) reducing serum cholesterol (Pereira et al., 
2002) and (v) managing lactose intolerance (Fooks et al., 1999)). Due to their 
phylogenetic relations, metabolic properties, and incorporation in the functional food 
and daily supplement industry, lactobacilli are aligned with bifidobacteria as 
probiotic LAB & B (lactic acid bacteria and bifidobacteria) which provide many 
beneficial effects to the host via the human GI tract (Vaughan et al. (2002); Reid et 
al. (2003b)).
The global market of probiotic ingredients, supplements and food was worth $14.9 
billion in 2007 and 15.9 billion in 2008, and was expected to reach 19.6 billion in 
2013 (Agheyisi 2008). Some probiotic products in the market are listed in Table 4.1. 
However, health benefits obtained from probiotic bacteria are strain specific, not 
species- or genus-specific. There does not seem to be one probiotic strain that can 
provide all proposed benefits. National and international authorities have the 
obligation to ensure that consumers could be able to choose the probiotic food 
correctly rather than just look at the product which may not contain adequate
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amounts of probiotic strains. Research on specific probiotic products and their health 
benefits is required to ensure the effectiveness of this particular product.
Table 4.1: Commercial probiotic microorganisms
Strain Commercialproducts Source
L. acidophilus NCFM /
B. lactis Bi-07 /
B. lactis HN019 (DR10) /
L. rhamnosus HN001 (DR20)
Sold as ingredient Danisco (Madison Wl)
L. fermentum VRI003 (PCC) Sold as ingredient Probiomics (Eveleigh, Australia)
Saccharomyces cerevisiae 
boulardii Florastor Biocodex (Creswell OR)
L. rhamnosus R0011 / 
L. acidophilus R0052 Sold as ingredient
Institut Rosell lallemand (Montreal, 
Candada)
B. lactis Bb-12 /
L. acidophilus LA5 /
L. paracasei CRL 431 /
L. paracasei F-19 / L. 
fermentum VRI003 (PCC)
Sold as ingredient Chr. Hansen (Milwaukee WI)
B. lactis Bb-12
Good Start Natural 
Culture infant 
formula
Nestle (Glendale, CA) Chr. Hansen 
(Milwaukee WI)
L. casei Shirota /
B. breve strain Yakult Yakult Yakult (Tokyo, Japan)
L. casei DN-114 001 (‘Z. 
casei Immunitas’) / B. 
animalis DN173 010 (‘Bifidis 
regularis’)
DanActive 
fermented milk 
Activia yogurt
DAnone (Paris, France) 
DAnnon (Tarrytown, NY)
L. reuteri RC-14 / 
L. rhamnosus GR-1 Femdophilus
Chr. Hansens (Milwaukee WI)
Urex Biotech (London, Ontario, 
Canada)
Jarrow Formulas (Los Angeles, CA)
L.johnsonii Lj-1 (same as 
NCC533 and formerly L. 
acidophilus La-1)
Nestle (Lausanne, Switzerland)
L. plantarum 299V / 
L. rhamnosus 271
Sold as ingredient 
Good Belly juice 
product
Probi AB (Lund, Sweden); 
NextFoods (Boulder, Colorado)
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L. reuteri ATCC 55730 
(‘Protectis’)
BioGaia Probiotic 
chewable tablets or 
drops
Biogaia (Stockholm, Sweden)
L. rhamnosus LB21 / 
Lactococcus lactis LI A Sold as ingredient Essum AB (Umea, Sweden)
L. rhamnosus GG (‘LGG’)
Culturelle Valio Dairy (Helsinki, Finland) 
Dannon (Tarrytown, NY)
L. salivarius UCC118 University College (Cork, Ireland)
B. longum BB536 Sold as ingredient Morinaga Milk Industry Co., Ltd. (Zama-City, Japan)
L. acidophilus LB Sold as ingredient Lacteol Laboratory (Houdan, France)
L. paracasei FI9 Sold as ingredient Medipharm (Des Moines, Iowa)
L. paracasei 33 /
L. rhamnosus GM-020 / 
L. paracasei GMNL-33
Sold as ingredient GenMont Biotech (Taiwan)
Source: http://cdrf.org/home/checkoff-investments/usprobiotics (Anonymous, 2011)
Commercial probiotic products must fulfill a number of criteria such as safety and 
stability (activity and viability in products); resistance to gastric acid, bile salts and 
pancreatic enzymes; adherence to colonic mucosa and ability to colonize in vivo; and 
functional and physiological aspects (invasive potential, antimicrobial activity, 
against pathogens and clinical side effects in volunteers/patients) (Gorbach et al.
(2002); Vasiljevie et al. (2008); Soccol et al. (2010)). To ensure probiotic stability 
and improve the high cell yield at large scale, more efficient processing technologies 
of probiotics have been developed rapidly in recent years such as membrane systems 
with continuous fermentation, appropriate selection of acid and bile resistant strains, 
incorporation of micronutrients such as peptides; use of oxygen impermeable reactor, 
cell immobilization and microencapsulation technology to get the high cell yield 
(Lacroix et al. (2007); Soccol et al. (2010)). With these developed technologies plus 
the exciting scientific and clinical findings of various probiotic organisms, probiotics 
have become an important functional food ingredients, expanding to the 
pharmaceutical and supplement industries.
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Probiotic products on the daily supplement market are presented in the forms of 
powders, tablets, liquid suspensions and sprays, and are intended to be used by 
humans, farm animals and pets. Most preparations destined for human consumption 
are powders or tablets. Cultech Ltd. and Obsidian Research Ltd. (part of the sponsor 
of this project) is a UK based nutraceutical company which developed a range of 
high quality, viable, stable probiotic products in various packaged formats. LAB4® 
probiotic is the name given to the probiotic bacteria strains developed by Cultech 
Ltd. Cultech is the only company holding a license to supply probiotics as 
Investigative Medicinal Products (IMPs) for use in clinical trials. LAB4 is for adults 
and LAB4B is for pregnancy, and infants from birth to four years. Both types have 
substantial independent evidence to support their benefits, such as reduced total 
symptoms and improved quality of life in diagnosed IBS sufferers, prevention of 
atopic sensitization and atopic eczema and reduced overgrowth of undesirable and 
potential harmful bacteria after antibiotic therapy (Plummer et al. (2004, 2005); 
Madden et al. (2005); Williams et al. (2009); Allen et al. (2010)).
LAB4 consists of four specially selected probiotic bacteria: Lactobacillus 
acidophilus -  strain 1, Bifidobacterium bifidum, Lactobacillus acidophilus -  strain 2 
and bifidobacterium animalis subsp lactis. LAB4B consists of Lactobacillus 
salivarius, Lactobacillus paracasei, Bifidobacterium animalis subsp lactis and 
Bifidobacterium bifidum. All the above probiotic strains profiles have been 
established in Cultech including taxonomy and identity, acid tolerance, bile salt 
tolerance, bile salt hydrolase activity, pepsin and pancreatic resistance, adherence to 
human intestinal cells (Caco-2 cells), antimicrobial activity against pathogens, 
antibiotic susceptibility and haemolytic activity. All these items fulfill the above 
mentioned criteria for commercial probiotic products.
Since the recognition of the beneficial effects of lactobacilli and bifidobacteria, there 
has been considerable research dealing with carbohydrate fermentation by these two 
groups of organisms. Some carbohydrates are capable of promoting the selective 
growth of lactobacilli and bifidobacteria in the colon. Such compounds have been
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called prebiotics. By combining probiotic and prebiotic into the so-called synbiotic 
products, a twofold positive effect on the intestine microflora can be expected 
(Gibson et al. (1995b); Ziemer et al. (1998)). Several types of in vitro fermentation 
systems have been employed to investigate the growth behavior and fermentative 
capabilities of these two organisms (Shene et al. (2005); Perrin et al. (2001); Rossi et 
al. (2005); Gibson et al. (1994a); Hopkins et al. (1998)). Using in vitro fermentation 
systems, they can be categorized with respect to the number of bacterial strains 
cultivated (pure or mixed culture), the carbohydrate sources for bacterial growth and 
the operation model (batch, semi-continuous or continuous).
So far, no quantitative comparison of the physiological behavior of LAB4 and 
LAB4B in the human gut has been done. The purpose of the present work was to 
extend the knowledge of the physiology of lactobacilli and bifidobacteria, and to 
determine the kinetic parameters during growth in an in vitro fermentation system 
that simulates the human gut environment. These parameters will be important in the 
design and operation of the production processes of probiotic. The initial 
experiments in this Chapter were carried out in a nutritionally complex gut medium 
with glucose as the sole carbohydrate source in an in vitro batch fermentation model. 
The individual probiotic strains {Lactobacillus salivarius, Lactobacillus paracasei, 
Lactobacillus acidophilus, Bifidobacterium bifidum and Bifidobacterium animalis 
subsp lactis from Cultech Ltd. UK) and their co-cultures were fermented in either a 
simple non-stirred batch culture without pH control or a stirred batch culture with pH 
control. The studies were also performed in batch cultures using MRS (de Man 
Rogosa and Sharp) broth as a comparison. An anaerobic workstation was purposely 
designed, built and used to simulate the anaerobic environment in the human colon. 
A mathematical model for the growth of different probiotic strains in batch cultures 
was developed, which will be explained in the later chapters. The kinetic growth data 
were fed into this model in order to provide the comparison results of the different 
probiotic strains in the simulated environment of the human colon. Here, we choose 
glucose as the sole carbohydrate source because it is the simplest sugar that can be 
used by any bacteria. A major consideration is to reduce the complexity of the gut
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medium so that the experimental data can be more readily fed into the simplified 
mathematical model based on glucose utilization of different probiotic strains.
4.2 Materials and methods
4.2.1 Commercially available probiotic strains
Table 4.2: Freeze-dried powders of six probiotic strains stock
Cultech/Obsidian 
Reference No.
Organism Broth
medium
Agar
medium
CUL08 Lactobacillus paracasei MRS1 MRS2
CUL61 Lactobacillus salivarius MRS MRS
CUL60 Lactobacillus acidophilus MRS MRS
CUL21 Lactobacillus acidophilus MRS MRS
CUL20 Bifidobacterium bifidum MRSX3 MRSX4
CUL34 Bifidobacterium animalis subsp lactis MRSX MRSX
LAB4 Lactobacillus acidophilus -CUL60; 
Lactobacillus acidophilus -CUL21; 
Bifidobacterium bifidum -CUL20; 
Bifidobacterium animalis subsp lactis 
-CUL34
MRS & 
MRSX
MRS & 
MRSX
LAB4B Lactobacillus paracasei -CUL08; 
Lactobacillus salivarius -CUL61; 
Bifidobacterium bifidum -CUL20; 
Bifidobacterium animalis subsp lactis 
-CUL34
MRS & 
MRSX
MRS & 
MRS-MUP5
1 MRS broth: de Man Rogosa and Sharp (CM0359, Oxoid, UK);
2MRS agar: de Man Rogosa and Sharp (CM0361, Oxoid UK);
3MRSX broth: Modified MRS broth containing 0.2% Lithium Chloride (L0505,
Sigma-Aldrich, UK), 0.3% Propionic Acid (PI880, Sigma-Aldrich, UK) and 0.05% 
I-cysteine Hydrochloride (C/9152/48, Fischer, UK);
4MRSX agar: Modified MRS agar containing 5% Defibrinated Sheep Blood (TCS SB054, 
Cruinn Diagnostics Ltd., Ireland), 0.2% Lithium Chloride, 0.3% Propionic Acid and 0.05% 
L-cysteine Hydrochloride;
5 MRS-MUP agar: Modified MRS Agar containing 5% Defibrinated Sheep Blood, 0.3% 
Ropionic Acid, 0.05% L-cysteine Hydrochloride and 50ug/ml Lithium-mupirocin 
supplement (69732, Sigma-Aldrich, UK).
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Six probiotic strains were selected for investigation of the growth behavior in gut 
medium, and they include Lactobacillus salivarius CUL61 NCIMB 30211, 
Lactobacillus paracasei CUL08 NCIMB 30154, Lactobacillus acidophilus CUL60 
NCIMB 30157 Lactobacillus acidophilus, Lactobacillus acidophilus CUL21 
NCIMB 30156, Bifidobacterium bifidum CUL20 NCIMB 30153 and 
Bifidobacterium animalis subsp lactis CUL34 NCIMB 30172. These were screened 
due to their extensive use as a terrestrial probiotic supplement in numerous 
commercial products from Cultech/Obsidian Ltd. (this project’s industrial sponsor). 
Choosing these six probiotic strains also makes it convenient to access large 
quantities of homogeneous bacterium for experiments. As listed in Table 4.2, 
freeze-dried powders of six individual strains and their mixture were used in this 
study. These strains are all approved by the probiotic strains profile identification in 
Cultech/Obsidian Ltd. The organisms from freeze-dried powder is recovered by 
taking a spoon of powder into 4.5 ml sterile Maximal Recovery Diluent (MRD) 
((CM0733, Oxoid, UK)), streaking 20pi aliquots onto the appropriate solid medium 
(see Table 4.2), and incubating the agar plates anaerobically at 37°C for 72 hours.
4.2.2 Chemicals and media
The culture medium used in this study is Modified Macfarlane’s Gut Medium 
(MMGM) (Macfarlane et al. 1998) which replaces the polysaccharides simply with 
glucose as the solo carbon source. It consisted of the following constituents (g/liter) 
in distilled water: glucose (Sigma-Aldrich, UK) 15.0; casein (BDH Ltd., UK) 3.0; 
peptone water (Oxoid, UK) 5.0; tryptone (Oxoid, UK) 5.0; bile salts No.3 
(Sigma-Aldrich, UK) 0.4; yeast extract (Oxoid, UK) 4.5; FeS0 4  • 7 H2 O (BDH Ltd., 
UK) 0.005; NaCl (BDH Ltd., UK) 4.5; KC1 (BDH Ltd., UK) 4.5; KH2P 0 4 (BDH 
Ltd., UK) 0.5 ; MgS04 • 7H20  (BDH Ltd., UK) 1.25; CaCl2 • 6H20  (BDH Ltd., 
UK) 0.15; NaHC03 (BDH Ltd., UK) 1.5; cysteine (Sigma-Aldrich, UK) 0.8; hemin 
(BDH Ltd., UK) 0.05; Tween 80 (Sigma-Aldrich, UK) 1.0.
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MRS broth (Oxoid, UK) was also used in this study as a control medium to compare 
the growth behavior of different probiotic and co-cultures in various initial 
conditions.
4.2.3 Batch cultivation conditions
Batch culture incubations were carried out in a 500ml glass vessel with a 250ml 
working volume. The medium was first autoclaved at 121°C for 15 min. After 
cooling down, the fermentor was inoculated (1%, v/v) with an exponential phase 
pre-culture of individual probiotic strains. Growth was monitored by collecting 
samples from the cultures at appropriate intervals. The medium pH was either 
non-regulated or regulated to 5.5 or 6.5 by the automatic addition of 1 mol/1 NaOH 
which was chosen to simulate the pH of the ascending colon (pH 5.5-5.9) and 
descending colon (pH 6.5-6.9). The fermentor was maintained in a specially 
designed anaerobic workstation, with temperature controlled at 37°C. An 
autoclavable pH electrode (51343111 pH ELECTRODE INLAB POWDER PRO, 
VWR International Ltd, UK) was connected to a pH controller (RZ-56022-87 DLX 
pH-RX/MBB SERIES METERING PUMP, Cole-Parmer, USA) via a cable 
(662-1240 Cable ISM-Multi Pin 1.8m, VWR International Ltd, UK), to provide 
continuous monitoring as well as servo-controlled addition of IN NaOH to maintain 
the pH at the set value of 5.5 or 6.5. During the whole period of batch culturing, the 
vessel was continuously stirred by using the mini stirrer (FB70800 E-STEM 
Standard MiniStirrer, Fisher Scientific, UK).
4.2.4 Growth of individual Lactobacilli strain under different culture conditions
Using MRS agar, a streak plate of Lactobacillus salivarius CUL61 organism or other 
organism (L.paracasei CUL08, L. acidophilus CUL60 or L. acidophilus CUL21) was 
directly generated from 10'1 dilution (0.5 g into 4.5 ml of sterile MRD) of freeze 
dried powder (See 4.2.1). Then, a single well-isolated colony of the pure CUL61 
organism from streak MRS agar plate was inoculated into 10 ml MRS broth medium, 
after which it was placed in the anaerobic workstation at 37°C for overnight to get
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the exponential phase pre-culture. Next, 2.5 ml o f CUL61 pre-culture was inoculated 
into 250 ml sterilised MRS broth and MMGM (modified M acfarlane’s gut medium) 
at initial pH 6.5 and 5.5 respectively. The testing was carried out by taking 5 ml of 
samples from the cultures at fixed intervals (0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 22, 
24, 26, 28, 30, 48 hours). Another separate testing was conducted under controlled 
pH condition. For this, 2.5 ml o f CUL61 pre-culture was inoculated into 250 ml 
sterilised MMGM at controlled pH 6.5 and 5.5 respectively. The pH was controlled 
by dosing with 1 mol/1 sterilised NaOH. The testing was similarly conducted by 
taking 5 ml o f samples from the cultures at fixed intervals (0, 4, 6, 8, 10, 24, 26, 28, 
30, 32, 48 hours). Finally, for all testing samples, the growth profile and pH profile 
o f individual lactobacilli strain under different culture conditions were measured. 
The detailed measurement procedures are explained in Sections 4.2.5 and 4.2.6.
4.2.5 Enumeration of lactobacilli and bifidobacteria
4.2.5.1 Anaerobic condition
Figure 4.1: Anaerobic workstation (The design is specified by Lei Jiang and the 
manufacturer is Electrotek Ltd., Yorkshire, UK)
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All the inoculation and sample collection were operated in an anaerobic workstation 
(Figure 4.1). The design of the anaerobic workstation was specified by Lei Jiang 
during this research work and it was manufactured by Electrotek Ltd., Yorkshire, 
UK. The workstation was supplied with an anaerobic growth mixture gas (BOC 
Special Gases, Manchester, UK) containing a gas mixture of 10% CO2 , 10% H2  and 
80% N2 . Air in the workstation was checked for oxygenation on a daily basis using 
an anaerobic indicator solution containing a saturated solution of sodium 
bicarbonate, glucose anhydrous and a 1% methylene blue solution (Electroteck Ltd., 
Yorkshire, UK). Air from the workstation was bubbled through a tube into the 
solution. A colour change from pale brown to blue indicates the presence of oxygen. 
The cabinet temperature was maintained at 37°C and humidity was maintained at 
70%.
4.2.5.2 Enumeration of lactobacilli and bifidobacteria
A sample of 5ml of batch culture was taken from the fermentor in the anaerobic 
workstation and added into a 30 ml plastic sterile universal. The universal was 
transferred outside the workstation and placed in an operator safety cabinet (Envair 
Bio+2, Lancashire, UK) with a filtered air flow. A volume of 0.5 ml batch culture 
was added to the bijou containing 4.5 ml pre-reduced Maximum Recovery Diluent 
(MRD) (Oxoid, UK) to form a 10'1 dilution. Then, a volume of 0.5 ml of the 10'1 
dilution was added to 4.5 ml MRD to produce the 10' dilution. A decimal dilution
o
series was prepared to 10' following these steps.
A modified version of the Miles and Misra Technique (1938) was used to enumerate 
viable microorganisms. Ten 10 pi drops of the -5 to -8 dilution were pipetted onto 
MRS, MRSX and MRS-MUP agar plates (see Table 4.2) using an eLINE electronic 
pipette (Biohit, Finland). Plates were allowed dry, inverted, and incubated in an 
anaerobic workstation at 37°C for 3 days.
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4.2.6 pH analysis
After enumeration of lactobacilli and bifidobacteria, the pH values of batch culture 
samples in the 30 ml plastic sterile universal were tested using a pH controller 
(RZ-56022-87 DLX pH-RX/MBB SERIES METERING PUMP, Cole-Parmer, USA) 
with a pH electrode (RZ-27013-22 ELECTRODE PH 25 FT CABLE, Cole-Parmer, 
USA).
4.2.7 Estimation of growth curves
Growth parameters, estimated by using a modified six-parameter Gompertz model, 
are: logio (cfu ml_1)t (cell concentration at time t); logio (cfu ml_1)o (cell concentration 
at time 0); A (increase of biomass between log io (cfu ml_1)o and logio (cfu m l'1) max); 
p (maximum specific growth rate (h'1)); td (biomass doubling time (h)); and X 
(duration time of lag phase (h)) (Zwietering et al. (1990); Juarez Tomas et al. 
(2002)).
4.2.8 Growth of LAB4B and LAB4
The compositions of LAB4B and LAB4 can be found in Table 4.2. The overnight 
broth of 6 probiotic strains (L.salivarius CUL61, L.paracasei CUL08, L. acidophilus 
CUL60, L.acidophilus CUL21, B.lactis CUL34 and B. bifidum CUL20) were 
prepared following the procedure described in Section 4.2.4 (for the preparation of 
CUL34 and CUL20 overnight broth, MRSX broth and agar were used instead of 
MRS broth and agar). Then, 2.5 ml broth of CUL61, CUL08, CUL34 and CUL20 as 
LAB4B was inoculated into two sterilized 250 ml MMGM broth at pH 6.5 and 5.5 
respectively. At the same time, 2.5 ml broth of CUL60, CUL21, CUL34 and CUL20 
as LAB4 was inoculated into two sterilized 250 ml MMGM broth at pH 6.5 and 5.5 
respectively. For testing, 5 ml of samples were withdrawn from the cultures at 
appropriate intervals (0, 4, 6, 8, 24, 28, 32 and 48 hours).
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4.3 R esu lts
4.3.1 Growth of Lactobacillus salivarius CUL61
Growth profile and pH profile o f L.salivarius CUL61 under different culture 
conditions were determined (See Sections 4.2.5 and 4.2.6) and the maximum specific 
growth rate p was calculated from the slopes o f the growth curve in the log 
coordinates (See Section 4.2.7). Doubling time was determined by the maximum 
specific growth rate (See Section 4.2.7). Figure 4.2 and Figure 4.3 show the growth 
curve and pH trend o f L. salivarius CUL61 in combinations o f two culture media 
(MRS broth or MMGM), two uncontrolled pH values (6.5 or 5.5) and two controlled 
pH values (6.5 or 5.5). The temperature o f all these batch cultures was set at 37°C.
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Figure 4.2: Growth o f  L.salivarius CUL61 under different culture conditions.
85
Chapter 4 The Batch Fermentation Model
7.00
6.50
6.00
5.50
= 5.00 
4.50
4.00
3.50
3.00
0 10 20 30 40 50
Time (hours)
CUL61 in MRS at initial pH 6.5 —• — CUL61 in MRS at initial pH 5.5
CUL61 in MMGM at initial pH 6.5 CUL61 in MMGM at initial pH 5.5
Figure 4.3: pH changes o f  L.salivarius CUL61 under different culture conditions.
Table 4.3: Estimation o f growth parameters o f L.salivarius CUL61 under different culture 
conditions
Conditions logjo (Cfu m r ')0 A M h 1) td (h) X (h)
MRS at initial pH 6.5 7.41 2.00 0.92 0.75 2.00
MRS at initial pH 5.5 7.28 2.10 0.92 0.75 2.00
MMGM at initial pH 6.5 7.36 1.36 0.35 2.01 2.00
MMGM at initial pH 5.5 7.18 1.30 0.30 2.32 8.00
MMGM at controlled pH 6.5 7.34 1.66 0.62 1.11 0.00
MMGM at controlled pH 5.5 7.34 1.45 0.30 2.32 10.00
Parameters: log]0 (cfu m r ')0, initial biomass; A, increase between initial and final biomass; p, 
maximum specific growth rate ; td, biomass doubling time; X, lag phase.
The results in Figure 4.2 show that the biomass productions and the specific growth 
rate are the same in MRS at initial pH 6.5 and 5.5. There is also the same pH drop 
pattern in MRS broth (Figure 4.3) which indicates that the MRS broth has a strong 
buffer capacity and it will not affect the growth pattern o f CUL61 at different pH 
conditions. The biomass productions and the specific growth rate in MRS are higher 
than in MMGM with controlled and uncontrolled pH which is easily explained by the 
fact that MRS contains more nutrient than MMGM.
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The results in Figure 4.2 also show that it took 6 hours longer to start the log phase 
(or exponential phase) in MMGM at initial pH 5.5 than the case with the initial pH
6.5. Results may indicate lower pH (5.5) can delay the log phase of CUL61 up to 6 
hours. Figure 4.3 shows that the pH drops more slowly in MMGM at initial pH 5.5, 
and this is consistent with the fact that CUL61 got into the log phase a few hours 
later than the case of initial pH 6.5. However, the total biomass production was 
approximately the same in MMGM grown at initial pH 6.5 and 5.5 (1.36 and 1.3 
logio cfu ml"1 respectively). The specific growth rates p were also similar at pH 6.5 
and 5.5 (0.35 and 0.30 respectively). These indicate that, once the bacteria were 
acclimated to the environment conditions, the biomass production and the specific 
growth rate are essentially constant.
The results in Figure 4.2 also show that it took 10 hours longer to start the log phase 
(or exponential phase) in MMGM at controlled pH 5.5 than the case with a 
controlled pH 6.5. The results also prove the previous result that lower pH (5.5) 
would delay the log phase of CUL61 up to 10 hours. The increased biomass 
production in MMGM at controlled pH 6.5 is higher than at controlled pH 5.5 (1.66 
and 1.45 logio (cfu ml"1) respectively). After the lag phase, for these two cases, the 
specific growth rate in MMGM at controlled pH 6.5 was two times higher than it is 
at controlled pH 5.5 (0.62 and 0.30 respectively). This implies that the controlled pH
6.5 of the MMGM has significant effects on all growth parameters tested (increases 
of biomass, growth rate, reduces lag phase and the doubling time). It also indicates 
that controlling the pH condition is an effective way to achieve the maximum 
biomass production yield.
The highest maximum specific growth rate (p) were obtained on MRS, followed by 
MMGM with controlled / uncontrolled pH 6.5, and MMGM with controlled / 
uncontrolled pH 5.5. The highest increased biomass production (A) was obtained on 
MRS, followed by MMGM with controlled pH, and MMGM with uncontrolled pH. 
The detailed figures are given in Table 4.3. MRS broth affected the final biomass and 
specific growth rate significantly because the high nutrition available compared with
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MMGM. However, MRS is the only control medium used in this study, our target is 
to investigate the growth behaviour o f different probiotic strains in MMGM. The 
experiment shows that optimal conditions for the growth o f L. salivarius CUL61 were 
MMGM with controlled pH 6.5 at 37°C. Under these conditions, the highest biomass 
and specific growth rates, together with shorter lag phases and doubling time, were 
obtained.
4.3.2 Growth of Lactobacillus paracasei CUL08
This experiment follows a similar procedure as described in Section 4.2.4. Figure 4.4 
and Figure 4.5 show the growth curve and pH trend o f L.paracasei CUL08 in 
combinations o f two culture media (MRS broth or MMGM) , two uncontrolled pH 
values (6.5 or 5.5) and two controlled pH values (6.5 or 5.5) at 37°C.
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Figure 4.4: Growth o f  L.paracasei CUL08.
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Figure 4.5: pH changes o f L.paracasei CUL08.
The results in Figure 4.4 and Figure 4.5 show that the growth behavior and pH trend 
o f L.paracasei CUL08 is similar to L.salivarius CUL61 under different culture 
conditions. However, the specific growth rates o f CUL08 are all lower than CUL61 
which result in the higher doubling time o f CUL08.
Table 4.4: Estimation o f growth parameters o f L.paracasei CUL08
Conditions logio (cfu m r ')0 A F (h ') td (h) X(h)
MRS at initial pH 6.5 6.53 2.11 0.35 2.01 2.00
MRS at initial pH 5.5 6.51 2.19 0.35 2.01 2.00
MMGM at initial pH 6.5 6.41 1.29 0.21 3.34 2.00
MMGM at initial pH 5.5 6.45 1.17 0.14 5.02 4.00
MM GM  at controlled pH 6.5 6.41 1.55 0.28 2.51 2.00
MMGM at controlled pH 5.5 6.45 1.70 0.35 2.01 10.00
Parameters: logio (cfu m f ’V  initial biomass; A,  increase between initial and final biomass; p, 
maximum specific growth rate; td, biomass doubling time; X, lag phase.
The maximum specific growth rate o f CUL08 was similar on MRS and MMGM with 
controlled pH 6.5 and 5.5, while the lowest values were obtained from MMGM with 
uncontrolled pH 6.5 and 5.5 (Table 4.4). With uncontrolled pH setup, the pH drops
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continuously during the log phase, and the acid environment may inhabit the cell 
division resulting in the lower specific growth rates.
The results in Figure 4.4 also show that it took 8 hours longer to start the log phase in 
MMGM at controlled pH 5.5 than at controlled pH 6.5. The same trend was obtained 
from CUL61, and this indicates that lower pH (5.5) will delay the log phase. After 
the bacteria were acclimated to the environment conditions, the biomass production 
and the specific growth rate were essentially constant.
4.3.3 Growth of Lactobacillus acidophilus CUL60 or Lactobacillus acidophilus 
CUL21
This experiment follows a similar procedure as described in Section 4.2.4. Figure
4.6, Figure 4.7, Figure 4.8 and Figure 4.9 show the growth curves and pH trends of 
L. acidophilus CUL60 and CUL21 in combinations o f two culture media (MRS broth 
or MMGM), two uncontrolled pH values (6.5 or 5.5) and two controlled pH values 
(6.5 or 5.5) at 37°C.
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Figure 4.6: Growth o f  L.acidophilus CUL60.
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Figure 4.8: pH changes o f L.acidophilus CUL60.
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Figure 4.9: pH changes o f L.acidophilus CUL21.
Table 4.5: Estimation o f growth parameters o f  L.acidophilus CUL60
Conditions log,o (cfu m f'jo A H (h ') td (h) X(h)
MRS at initial pH 6.5 5.95 2.86 0.62 1.11 2.00
MRS at initial pH 5.5 6.11 2.67 0.62 1.11 2.00
MMGM at initial pH 6.5 5.90 1.68 0.35 2.01 2.00
MMGM at initial pH 5.5 6.00 1.48 0.35 2.01 4.00
MMGM at controlled pH 6.5 6.08 2.00 0.32 2.15 0.00
MMGM at controlled pH 5.5 6.00 1.90 0.25 2.74 4.00
Parameters: log)0 (cfu m r ')0 initial biomass; A, increase between initial and final biomass; p, 
maximum specific growth rate; td, biomass doubling time; X, lag phase.
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Table 4.6: Estimation of growth parameters of L.acidophilus CUL21
Conditions logio (cfu ml'1)o A M h’1) td(h) X(h)
MRS at initial pH 6.5 6.26 2.56 0.58 1.20 4.00
MRS at initial pH 5.5 6.48 2.35 0.64 1.08 2.00
MMGM at initial pH 6.5 6.38 1.45 0.28 2.51 2.00
MMGM at initial pH 5.5 6.34 1.24 0.32 2.15 4.00
MMGM at controlled pH 6.5 6.20 2.06 0.32 2.15 0.00
MMGM at controlled pH 5.5 6.08 1.84 0.28 2.51 4.00
Parameters: logio (cfu ml'1^  initial biomass; A, increase between initial and final biomass; p, 
maximum specific growth rate; td, biomass doubling time; X, lag phase.
The results in Figure 4.6, Figure 4.7, Figure 4.8 and Figure 4.9 show that the growth 
behaviour and pH trend of L.acidophilus CUL60 and CUL21 were the same. They 
both have the similar growth pattern with L.salivarius CUL61 and L.paracasei 
CUL08 under different culture conditions. They all have S shape growth curves. All 
the pH values dropped down from the initial pH to the end point (at around pH 3.5). 
However, the specific growth rates of CUL60 and CUL21 are higher than CUL08 
and lower than CUL61 under different culture conditions. The biomass productions 
of CUL60 and CUL21 are higher than CUL61 and CUL08.
The maximum specific growth rate of CUL60 and CUL21 was similar on MMGM 
with uncontrolled and controlled pH (between 0.25-0.35 h’1). There is only a short 
lag phase (0-4h) under different pH conditions, while CUL61 and CUL08 have a 
longer lag phase (8-1 Oh) under the lower pH (5.5). It indicates that L.acidophilus 
CUL60 and CUL21 have higher acid tolerance and are less affected by the acid 
environment.
The optimal conditions for the growth of L.acidophilus CUL60 and CUL21 were still 
in MMGM with controlled pH 6.5 at 37°C. Under these conditions, the highest 
biomass and specific growth rates were observed.
|i
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4.3.4 Growth of LAB4B and LAB4
4.3.4.1 Growth of the mixture of Bifidobacterium lactis CUL34 and 
Bifidobacterium bifidum CUL20
The preliminary trials for the growth of CUL34 and CUL20 in MRSX or MMGM at 
different initial pH have also been completed. The results show CUL34 and CUL20 
can grow in the MRSX broth and exhibit an S-shape growth curve (results are not 
shown in this Chapter due to the lack of space). The specific growth rates were quite 
low compared to lactobacilli. However, CUL34 and CUL20 did not grow very well 
in MMGM at batch culture fermentation. Both bifidobacteria could only survive in 
MMGM at initial pH 6.5 but they could not be detected in MMGM at lower pH (5.5). 
It may be because that bifidobacteria could not adapt to the acidic environment 
because the accumulation of fermentation products (e.g. SCFAs) reduced the pH in 
the closed batch fermentation system. Due to the lack of space, the results are not 
shown here. In order to maintain the survival of the bifidobacteria, the continuous 
stages fermentation model has been used to investigate the growth of bifidobacteria, 
which will be addressed in Chapter 5.
4.3.4.2 Growth behaviour of LAB4B and LAB4
LAB4B and LAB4 strains of probiotic have been incorporated into many probiotic 
products in Cultech Ltd. LAB4 has benefits for people who suffer from IBS. LAB4B 
is of benefit for pregnancy and infants from birth to four years to prevent atopic 
sensitization and atopic eczema (Allen et al. (2010); Williams et al. (2009); Madden 
et al. (2005); Plummer et al. (2004, 2005)). In this initial trial, the growth behavior of 
co-cultured probiotic strains LAB4B or LAB4 was investigated in batch fermentation 
with modified Macfarlane’s gut medium (MMGM) at initial pH 6.5 and 5.5 without 
pH control (See Section 4.2.2 and Section 4.2.8). Lactobacilli group and 
bifidobacteria growth profile were determined (Figure 4.10 and Figure 4.11). The pH 
was also monitored in these trials (Figure 4.12).
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Figure 4.10 Growth of CUL61& 08 and CUL34&20 as two groups of LAB4B in MMGM at 
initial pH 6.5 and 5.5.
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Figure 4.11 Growth of CUL60& 21 and CUL34&20 as two groups of LAB4 in MMGM at 
initial pH 6.5 and 5.5.
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Figure 4.12: pH changes o f LAB4B and LAB4 in MMGM
Table 4.7: Estimation o f growth parameters o f Lactobacilli group in MMGM at different 
initial pH
Conditions logio (cfu ml ')0 A P ( h ' ) td (h) M h )
CUL61&08 at initial pH 6.5 8.11 0.91 0.32 2.15 0.00
CUL61&08 at initial pH 5.5 8.23 0.97 0.23 3.01 0.00
CUL60&21 at initial pH 6.5 7.91 1.01 0.14 5.02 10.00
CUL60&21 at initial pH 5.5 7.48 0.70 0.09 7.53 10.00
Parameters: logio (cfu m r ')0 initial biomass; A, increase between initial and final biomass; p, 
maximum specific growth rate; td, biomass doubling time; X, lag phase.
The results in Figure 4.10 and Figure 4.11 show that the growth behaviours of 
lactobacilli groups are similar to the individual lactobacilli strains. They all have 
S-shape growth curves. CUL61 & 08 started the log phase (0-8h) without lag phase 
followed by the long stationary phase in MMGM batch fermentation. CUL60 & 21 
had 10 hours lag phase before starting the log phase (10-24h), then followed by the 
stationary phase. This can also be verified by the pH drop pattern in Figure 4.12. The 
pH dropped sharply from 6.5 (5.5) to 3.5 during the log phase o f CUL61 & 08 
fermentation, but the pH decreased steadily from 6.5 (5.5) to 4.5 as CUL60 & 21 did 
not grow in the first 10 hours during the lag phase.
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There is no lag phase of CUL61 & 08 co-cultures compared to the longer lag phase 
(4-8h) of their individuals at lower pH (5.5), which may be explained by their higher 
competition capacity in the batch fermentation system with the 4 strain mixture.
The specific growth rates of CUL61 & CUL08 together are higher than CUL60 & 
CUL21 in MMGM at both initial pH (Table 5.7). These all indicate that CUL61 & 
CUL08 have higher fermentation capacity compared to CUL60 & CUL21. Also it 
will take the co-culture of CUL60 & CUL21 a few hours to adapt in the gut medium 
environment and start to grow exponentially.
The results of Figure 4.10 and Figure 4.11 also showed that bifidobacteria groups 
maintained lower viable count in the first 10 hours batch fermentation and viable 
count dropped very fast after the lactobacilli went into the log phase. These 
co-cultures further proved that bifidobacteria could not adapt to the acidy 
environment (pH 5.5) as the accumulation of fermentation products (e.g. SCFAs) 
reduced the pH in the closed batch fermentation system. The continuous stages 
fermentation model will be used to investigate the survival of the bifidobacteria as 
explained in Chapter 5.
4.4 Discussion
The physiology of probiotic bacteria are of interest for two reasons. First, during 
growth in the lower intestine, these organisms compete with other bacteria for 
available substrates, and the metabolic products (acetate and lactate) act to buffer the 
intestinal pH, thus inhibiting pathogens, and are absorbed by the host. Secondly, in 
the food or daily supplement industry, these bacteria are cultivated, either in situ in a 
food (e.g. yoghurt) or in a fermentor from which they may be harvested and added to 
a food as supplement. In this case, it is useful to extend our knowledge of the 
metabolic behavior of different probiotic strains and investigate the kinetic 
parameters on their own or their co-cultures.
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Mlobeli et al. (1998) illustrated that Bifidobacterium bifidum can metabolise a range 
of different sugars, among which glucose is clearly superior in terms of growth rate, 
biomass concentration and yield, and metabolite formation. In addition, their results 
demonstrated a major effect of pH on biomass production. Most studies carried out 
with lactobacilli and bifidobacteira have used complex media, such as TPY 
(Trypticase-Phytone-Yeast extract) or MRS, to which one or several carbohydrates 
were added (McKellar et al. (1989); Desjardins et al. (1990); Wang et al. (1993); 
Gibson et al. (1994b); Hopkins et al. (1998); Sghir et al. (1998); Kaplan et al. 
(2000)). Based on these studies, it is noted that in a medium such as TPY, the 
bifidobacteria could grow without any addition of carbohydrates. This means that the 
results observed with complex media to which carbohydrates had been added could 
not be due to this supplement alone but to some other components of the medium. 
Perrin et al. (2001) compared the physiological behaviour o f Bifidobacterium in f antis 
growing on synthetic oligofructose, glucose and fructose. In his study on a pure 
culture of B. in f antis, glucose was the best substrate for growth and global biomass 
production but less so for the production of major metabolites.
Based on the literature investigation, the present studies were carried out on a 
modified Macfarlane’s gut medium with glucose as the sole carbohydrate. In this 
study, modified Macfarlane’s gut medium (MMGM) with and without pH control at 
either 6.5 or 5.5 has been used to investigate the growth behaviour of 4 lactobacilli 
probiotic strains. MRS broth at either initial pH 6.5 or 5.5 was also used as control. 
In these fermentations, it is clear that there are similar growth patterns of all 4 
lactobacilli strains under different conditions. All these batch fermentations have an 
S-shaped growth curve in the low cell densities inoculation. All the pH dropped 
down from initial pH (6.5 or 5.5) to the end point at around pH 3.5.
MRS broth affected the final biomass and specific growth rate significantly because 
the higher nutrition of MRS broth is available compared with MMGM. Without 
considering the fermentation in MRS broth, the maximum biomass yield and specific 
growth rate were both observed in MMGM at controlled pH 6.5 and the lowest
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values were observed with uncontrolled pH 5.5. It is observed that the controlled pH
6.5 of the MMGM have significant effects on all growth parameters tested (increases 
of biomass, specific growth rate, reduces lag phase and the doubling time).
The optimal conditions for the growth of L.salivarius CUL61 were MMGM with 
controlled pH 6.5 at 37°C. Under these conditions, the highest biomass and specific 
growth rates, together with shorter lag phases and doubling time, were obtained. The 
growth behaviour of L.paracasei CUL08 is similar to L.salivarius CUL61 under 
different culture conditions. However, the specific growth rates of CUL08 are all 
lower than CUL61 which results in the higher doubling time of CUL08. It means 
CUL61 grow faster than CUL08 in any tested culture conditions. Both CUL61 and 
CUL08 had a relative longer lag phase (8-1 Oh) in MMGM at controlled pH 5.5 than 
pH 6.5. It may indicate that the lower pH (5.5) will delay the log phase. After the 
bacteria were acclimated to the environment conditions, the biomass production and 
the specific growth rate were relatively consistent.
There is no major difference of the growth behaviour of L.acidophilus CUL60 and 
CUL21 under different conditions. CUL60 & 21 has a shorter lag phase (0-4h) than 
the CUL61 and CUL08 (8-10h) at the lower pH (5.5). It indicates that L.acidophilus 
CUL60 and CUL21 may have higher acid tolerance than CUL61 and CUL08. 
CUL60 and CUL21 are less affected by the acid environment.
The growth behaviors of co-cultured probiotic strains LAB4B or LAB4 were also 
investigated in the modified Macfarlane’s gut medium (MMGM) at initial pH 6.5 
and 5.5. It is found that the growth behaviors of lactobacilli groups were similar to 
the individual lactobacilli strains. However, the viable counts of bifidobacteria 
groups dropped very quickly after the lactobacilli group went into the log phase. It 
may be because that bifidobacteria could not adapt to the acidic environment as the 
accumulation of fermentation products (e.g. SCFAs) reduced pH in the closed batch 
fermentation system. In order to maintain the survival of bifidobacteria, the 
continuous stages fermentation model with fresh medium and controlled pH is used 
to investigate the growth of bifidobacteria, and this will be addressed in Chapter 5.
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4.5 Conclusion
An in vitro batch fermentation model was employed to investigate the growth 
behavior of individual lactobacilli strains in combinations of two culture media 
(MRS broth or MMGM), two uncontrolled pH values (6.5 or 5.5) and two controlled 
pH values (6.5 or 5.5) at 37°C. The growth parameters and pH trend were monitored 
during the series of experiments. The results suggest that glucose sustains growth and 
cell production. MMGM with controlled pH 6.5 led to the highest growth rate and 
cellular yield, whereas MMGM with uncontrolled pH 5.5 was the worst condition for 
the probiotic growth. The results demonstrate a major effect of pH on biomass 
production. Hence, production processes should pay attention to this parameter. The 
use of pH control would be necessary to maintain high growth rates and yields.
However, the in vitro batch fermentation model is not suitable for the co-culture of 
lactobacilli and bifidobacteria as it becomes deplete of nutrient supply over time and 
together with the accumulation of toxic products, results in arrested growth. Complex 
experimentation such as the microbial community and microbial metabolic 
modulation requires single or multi-stage continuous fermentation models for 
nutrient replenishment, as substrate depletion restricts the operational time of batch 
fermentations to several hours and prevents the establishment of steady-state 
conditions in vitro.
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Chapter 5 Growth of Mixture Strains 
with Probiotic in an In Vitro 
Continuous Fermentation Model
Abstract
The aim of this part of the work is to develop an in vitro continuous fermentation 
system as a simplified model to simulate the physicochemical environment of the 
human colon. This system is highly flexible allowing frequent sampling and 
long-term studies under a controlled environment without disruption to the 
anaerobiosis. The entire fermentation apparatus is maintained inside a specially 
designed anaerobic workstation with a gaseous mixture of 80% N2 , 10% CO2  and 
10% H2 . The in vitro continuous fermentation system, which consists of commercially 
available probiotic strains and 3 residential microbial strains in the human gut, is used 
to investigate the stability of microbiota composition and survivability of probiotic. 
The experiments simulate the interaction between the probiotics and the residential 
microflora and show that the addition of probiotic does not affect significantly the 
total number of bacteria growing in the continuous culture. The growth data obtained 
in these experiments are then used to validate the new mathematical model of the 
microbial ecosystem in the human GI tract, and the details will be explained in later 
chapters.
Chapter 5 The Continuous Fermentation Model
5.1 Introduction
Bifidobacteria and lactobacilli are predominant bacteria of the gut microbiota and are 
well known for their beneficial and health promoting properties (Suvama et al., 
2005). These bacteria could produce acetate and lactate, which can be converted to 
propionate and butyrate through cross feeding by other bacteria (e. g. Eubacteirum 
halii, Faecalibacterium prausnitzii) (Duncan et al. (2004); Belenguer et al. (2006); 
Morrison et al. (2006)). SCFA can lower the gut pH and may inhabit pathogens. In 
addition, they are nutrients for the colonic epithelium after absorption by the 
colonocyte, and also impact on the gastrointestinal disease such as IBD, colitis and 
colon cancer (Cook et al. (1998); Gibson et al. (1999)).
Various different in vivo and in vitro approaches have been used to evaluate the 
efficacy of probiotic. It is important that the survivability should be determined in the 
‘challenge tests’. The ultimate test for probiotic functionality is the in vivo model 
such as laboratory animals or well-controlled humans. Animals, usually rats or mice 
have been used to investigate the effect of substrate on the gut microbiota. 
Gnotobiotic rats have also been used to investigate the interactions between the host 
and the microorganisms. Human flora-associated rats give a representation of the 
environment in the human colon. However, difference exists between animal and 
human microbiota that makes comparative results difficult. Obviously, the best 
model is a well-controlled human trial with placebo control and double-blind 
samples. However, drawbacks still exist and the trials may be difficult and expensive 
to set up (Gibson et al., 2000).
Since the healthy intestine is not easily accessible for most research purposes, 
attempts have been made to simulate the intestinal microbial ecosystem in vitro. 
Batch culture allows short periods (24-48h) fermentation of various substrates. 
However, marked differences between the ascending and descending colon exist in 
substrate availability and environmental conditions, which cannot be simulated in a 
batch fermentation model (Allison et al., 1989). In contrast, in vitro systems using
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multi-stage systems to permit spatial or temporal heterogeneity have advantages to 
model more complex environmental conditions (Marsh et al., 1995).
The multistage system has clear economical advantages and is also versatile to suit 
various study purposes. So far, several authors have described successfully a 
continuous multi-stage culture system for simulating the microbial community in the 
large intestine (Gibson et al. (1988a); Molly et al. (1993); Macfarlane et al. (1998); 
Cinquin et al. (2004); Belenguer et al. (2006); Chassard et al. (2006); Zihler et al. 
(2010); Van den Abbeele et al. (2010)). These systems have been employed to study 
the dynamics of bacterial populations, the actions of probiotic bacteria, and other 
features of the human GI tract (Freter (1983d); Alander et al. (1999)). The 
advantages include accessibility and ability to reproduce a range of environmental 
and nutritional parameters characteristic of the ascending and descending colons. The 
composition and retention time of supply of the growth medium can be easily 
controlled. The microbiota responses to changing substrate availabilities and other 
environmental conditions can be investigated together with effects of introducing 
defined populations and marked strains of bacteria (Olano-Martin et al. (2000); 
Hopkins et al. (2003)).
The typical in vitro continuous fermentation models such as the Reading model 
(Gibson et al., 1988a) and the simulated human intestinal microbial ecosystem 
(SHIME) (Molly et al., 1993) have a similar design. This design facilitates the 
spatial, temporal, nutritional and physicochemical properties of the gut microbiota by 
combining a few vessels in series representing the small intestine and the large 
intestine. Adaptation, survival and proliferation of gut microbiota in an in vitro 
continuous fermentation models are dependent on strict control of environment such 
as pH, temperature, retention time, anaerobiosis and flow rate etc. (Payne et al., 
2012a). Strict control of these parameters will help to establish a steady-state 
environment for both microbial composition and metabolic activities. With this 
steady-state condition established, a reproducible system is achieved for studying the
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gut microbial community modulation and metabolic function. More information 
regarding the in vitro continuous fermentation models can be found in Chapter 2.
A further development of an in vitro model to simulate the bacterial adhesion on the 
mucus layer in the human colon has been made recently by the SHIME group, in 
Gent University, Belgium. In the M-SHIME, a mucosal compartment 
(mucin-covered microcosms coated with mucin type II-agar) has been introduced in 
the ascending colon vessel to reproduce the bacterial adhesion to the gut wall mucus 
(Van den Abbeele et al., 2012). This improvement may lead to more in vivo-like 
communities in such dynamic long-term in vitro simulations and allow evaluation of 
the colonization of unique mucosal microbiota in health and disease (Van den 
Abbeele et al., 2012). Although this is a novel developed model to simulate the 
mucus-associated fermentation in the human colon, the big disadvantage is that the 
whole system will lose the anaerobic environment after the mucin-covered 
microcosms are taken out from the fermentation vessel. All the experiments are then 
exposed to atmospheric oxygen and the whole process must be terminated. This 
restricts the long-term dynamic fermentation in the M-SHIME model.
A major achievement of this project is the establishment of a uniquely designed in 
vitro continuous fermentation model in which the entire fermentation apparatus is 
maintained inside a tailor made anaerobic workstation filled with a gaseous mixture 
of 80% N2 , 10% CO2  and 10% H2 . This unique design allows easy processing, 
culture and examination of samples without exposure to atmospheric oxygen. The 
system facilitates adding and removing samples from the vessels in an absolute 
oxygen-free environment, and supports long-term dynamic fermentation trials.
In this work, a two-stage continuous culture-based model is developed for the growth 
of probiotic strains and three residential microbial strains in the human colon, which 
serves as a simplified model to investigate the effect of interaction between these 
microorganisms. The aims of this work are twofold. The first objective is to 
investigate the competitive abilities and survivability of commercially available 
probiotic strains in the simplified continuous fermentation model. In the same
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experiment, therefore, the survival of three marked residential strains in the human 
colon was examined following their introduction into the continuous stages 
fermentation model. The second aim is to prepare first-hand data for validating the 
mathematical model of human GI tract, which will be introduced in later chapters.
5.2 Design of an in vitro continuous fermentation model
5.2.1 A novel designed anaerobic workstation
An anaerobic workstation (Figure 5.1) has been specially designed according to the 
project requirement. It has many unique features to assure good safety and economy 
of operation and to make it more convenient for the operator to use. The entire 
fermentation apparatus is maintained inside the anaerobic workstation with a gaseous 
mixture of 80% N2 , 10% CO2  and 10% H2  to help to easily process, culture and 
examine samples without exposure to atmospheric oxygen.
58* (1473mm)
39* (990mm)
.Control panel
Condensation Plate 
Cooling air inlet v
Clear acrylic window
Anaerobic indicator bottle
Bubble bottle'
Rushing interlock 
60 Petri dish capacity
Single plate entry
Bara hand operation gauntlets
Figure 5.1: Schematic diagram of the anaerobic workstation
This specially designed anaerobic workstation has a removable front panel that 
allows moving the big pieces of equipment into the chamber. It has several airtight 
glands fitted in the ceiling of the chamber to allow cables and tubes to be introduced
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from outside to inside without compromising internal conditions. The workstation is 
fitted with two electrical outlets/sockets. One of these is used for the anaerobic 
indicator pump and the other is for operation of any internal equipment. This socket 
supplies an extension with 10 sockets so that the pH controllers, the peristaltic pumps 
and the magnetic stirrers can be located internally.
The length of the workstation is 1473 mm giving more room inside the incubator 
section of the unit. This will be an advantage for fixing the pipes, tubes, sensors and 
pumps etc. that need installing inside the unit. The large 14 liter interlock chamber 
with internal door provides effective sample and equipment transfer in the fastest 
possible time whilst ensuring the minimum amount of oxygen is introduced into the 
incubator chamber. A high level of illumination is provided within the chamber. All 
internal fittings have been designed to make intelligent use of the available space, 
whilst ensuring unimpeded arm movement. A detoxification system provides the best 
possible growth conditions and prolongs catalyst life in the anaerobic workstation. A 
bespoke trolley is available in the airlock chamber to facilitate movement of the 
equipment.
5.2.2 Single-stage continuous fermentation model
The single fermentor culture vessel 500 ml (Q. No.FV500 borosilicate glass culture 
vessel, VWR International Ltd., UK) covered by the lid with 5 ports (Q. No. 
MAF1/75 borosilicate glass flask cover, VWR International Ltd., UK) was connected 
to a source of fresh modified Macfarlane’s gut medium (MMGM) and to an exit port 
for the collection of spent medium. Flow in the system was maintained by a 
peristaltic pump (RZ-77120-32 PUMP MFLEX C/L 6-RPM 115/230, Cole-Parmer, 
USA), which was set to assure one complete medium change (250 ml) every 24 
hours. An autoclavable pH electrode (51343111 pH ELECTRODE INLAB 
POWDER PRO, VWR International Ltd, UK) with the cable (662-1240 Cable 
ISM-Multi Pin 1.8m, VWR International Ltd, UK) connected to a pH controller 
(RZ-56022-87 DLX pH-RX/MBB SERIES METERING PUMP, Cole-Parmer, USA) 
provided continuous monitoring and servo-controlled addition of IN NaOH to
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maintain the pH at the set point 5.5. The vessel was continuously stirred by the mini 
stirrer (FB70800 E-STEM Standard MiniStirrer, Fisher Scientific, UK). Fresh 
medium in the reservoir was maintained at pH 5.5.
The system consisting o f the MMGM and 3 important intestinal strains (Table 5.1) 
was controlled at pH 5.5 to mimic the conditions o f the ascending colon. The entire 
fermentation apparatus was maintained inside the anaerobic workstation. Figure 5.2 
shows the single-stage continuous flow fermentation model.
Figure 5.2 The single-stage continuous flow fermentation model.
Following 1% (2.5 ml) o f overnight broth o f E.coli QC1, E. cloacae QC4 and E. 
faecalis QC9 inoculation into the single culture vessel with 250 ml MMGM, the 
system was left at least 24 h as a batch culture to enable stabilization o f microbial 
populations. Growth medium (MMGM) was introduced into the culture vessel 24 h 
after inoculation o f the above 3 strains, and the medium flow rate was equivalent to 
one turnover per day, which gave a dilution rate o f 0.042 h’1. Simultaneously each 
capsule (See Section 5.2.5) o f LAB4B or LAB4 was administered separately to the 
culture vessel. The whole system was run for 8 days (192 h) and 5 ml o f fermentation 
culture was sampled daily. The bacterial population was enumerated by using
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standard selective media (see Table 5.1) and characterized and identified by 
screening the profile (See Section 5.2.6). The collected samples were centrifuged 
(5,000 X g, 10 min) to remove the microbial cells. The glucose residue in the culture 
medium was measured by glucose test kits (See Section 5.2.7).
5.2.3 Two-stage continuous fermentation model
The two-stage continuous fermentation model was developed to simulate the basic 
environment of ascending colon and descending colon which are around pH 5.5 and
6.5 respectively. The system comprised two glass vessels aligned in series. The first 
vessel (500 ml, the same as Section 5.2.2) in the system had an operating volume of 
250 ml with the growth medium (MMGM) introduced into it. The second vessel also 
had an operating volume of 250 ml and was sequentially fed from the first vessel 
through the peristaltic pump. Culture medium from the second vessel was pumped to 
the waste reservoir. Each vessel was continuously stirred. The pH of the vessels was 
maintained at 5.5 and 6.5 for vessels 1 and 2 respectively, by the addition of IN 
NaOH using pH controllers. The entire system (medium reservoir and waste 
reservoir included) was operated in the anaerobic workstation. The volume of the 
medium in both vessels was kept constantly at 250 ml and the flow rate of fresh 
medium was set equivalent to one turnover per day, which gave a dilution rate of 
0.042 h"1. Figure 5.3 shows the two-stage continuous fermentation model.
Two experiments were carried out using the two stages continuous fermentation 
model with either LAB4B or LAB4 as test probiotic strains. Each vessel contained 
250 ml MMGM with inoculation of 1% (2.5 ml) of overnight broth of E.coli QC1, E. 
cloacae QC4 and E. faecalis QC9. Vessels 1 and 2 were left at least 24 h as a batch 
culture to enable stabilization of microbial populations. After this stabilization 
period, a fresh growth medium (MMGM) was introduced into vessel 1 and 
continuously fed to vessel 2, at a rate controlled by the peristaltic pump. The flow 
rate should be constant and maintain a complete medium change (250 ml) every 24 
h. The flow rate was 10.4 mlh'1 and the dilution rate was 0.042 h '1. Simultaneously
108
Chapter 5 The Continuous Fermentation Model
each capsule (See Section 5.2.5) either LAB4B or LAB4 was added separately to the 
vessel 1 and 2. The whole system was run 10 days (240 h) and 5 ml o f fermentation 
culture were sampled daily. The bacterial population was enumerated by using 
standard selective media (See Table 5.1). The collected samples were centrifuged 
(5,000 X g, 10 min) to remove the microbial cells. The glucose residue in the culture 
medium was measured by glucose test kits (See Section 5.2.7).
Figure 5.3 The two-stage continuous fermentation model 
5.2.4 Continuous culture microbiota
The microbiota introduced into the fermentation system consists o f 3 residential 
strains belonging to species most commonly isolated from the human GI tract. These 
include Escherichia coli QC1 (N CTC10002), Enterobacter cloacae QC4 
(N CTC10005) and Enterococcus faecalis  QC9 (NCTC 12697) which were provided 
by Obsidian Research Ltd.
To prepare overnight broth o f these 3 strains, the organisms were grown from freezer 
stocks. Each organism was streaked out onto the appropriate medium from the
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freezer stock and incubated aerobically at 37°C for 24 h. A single colony was 
selected from the plate and inoculated into 10 ml nutrient broth (CM0001, Oxoid, 
UK) and incubated aerobically at 37°C for overnight. Table 5.1 gives an overview of 
the microbial groups, the selective media and incubation conditions.
Enumeration of microorganisms was done by serial dilution in Maximum Recovery 
Diluent (MRD) and spread plating onto the following solid culture media: 
MacConkey agar (CM0007, Oxoid, UK) for Escherichia coli and Enterobacter 
cloacae; Kanamycin Aesculin Azide Agar (KAA) (CM0591, Oxoid, UK) for 
Enterococcus faecalis. The bacteria were enumerated after aerobic incubation at 
37°C for 24 hours.
Table 5.1 Media and incubation conditions used for enumeration of continuous culture 
microbiota
Microbiota Ref No. Medium* Incubation
conditions
Escherichia, coli QC1 MacConkey agar Aerobic, 37C, 24h
Enterobacter cloacae QC4 MacConkey agar Aerobic, 37C, 24h
Enterococcus faecalis QC9 KAA agar Aerobic, 37C, 24h
Lactobacillus salivarius CUL61 MRS Anaerobic, 37C, 72h
Lactobacillus paracasei CUL08 MRS Anaerobic, 37C, 72h
Lactobacillus acidophilus 
strain 1
CUL60 MRS Anaerobic, 37C, 72h
Lactobacillus acidophilus 
strain 2
CUL21 MRS Anaerobic, 37C, 72h
Bifidobacterium animalis 
subsp lactis
CUL34 MRS-MUP Anaerobic, 37C, 72h
Bifidobacterium bifidum CUL20 MRS-MUP Anaerobic, 37C, 72h
*The detail of each medium can be found in Section 5.2.4 and Section 4.2.1.
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5.2.5 Commercially available probiotic strains
The commercial probiotic product of LAB4B and LAB4 were provided in the form 
of gelatine capsules containing a freeze-dried mixture of lactobacilli and 
bifidobacteria provided by Cultech Ltd., UK. Each capsule of LAB4B consists of 
Lactobacillus salivarius (CUL61) (2.5 x 109 cfu), Lactobacillus paracasei (CUL08) 
(2.5 x 109 cfu), Bifidobacterium animalis subsp Lactis (CUL34) (0.25 x 109 cfu) and 
Bifidobacterium bifidum (CUL20) (4.75 x 109 cfu). The total viable count of LAB4B 
is 1 x 1010 cfu/capsule. Each capsule of LAB4 consists of Lactobacillus acidophilus 
strain 1 (CUL60) and Lactobacillus acidophilus strain 2 (CUL21) (3 x 1010 cfu), 
Bifidobacterium animalis subsp Lactis (CUL34) (1 x 109 cfu) and Bifidobacterium 
bifidum (CUL20) (1.9 x 1010 cfu). The total viable count of LAB4 is 5 x 1010 
cfu/capsule. Enumeration of probiotic strains was done by serial dilution in MRD 
and spread plating onto the different solid culture media. Table 5.1 shows the 
organisms and the selective media and incubation conditions used.
5.2.6 Screening the profile of mixture strains 
. 5.2.6.1 Gram stain
A 1 ml disposable sterile pipette was used to place one drop of sterile water onto a 
microscope slide. A single colony from a relative agar plate was picked and smeared 
into a drop of water to mix well, until it became a homogenous milky solution. The 
slide was allowed to air dry before it was passed over a flame source to heat-fix. 
Then it was flooded with Crystal Violet Oxalate solution (BioMerieux, Basingstoke, 
UK) for 1 minute. Next, the slide was washed with sterile water and flooded with 
stabilized Gram's Iodine solution (BioMerieux, Basingstoke, UK) for 2 minutes. 
Following further washing with de-colorizing solution (25% acetone, 75% 
iso-propanol), sterile water was washed over the slides. Finally, the slide was flooded 
with Saffanin solution (BioMerieux, Basingstoke, UK) for 1 minute and then washed 
with sterile water. When the slide is dry, it was viewed using an x 100 oil immersion 
lens under an optical microscope (Ceti, Belgium).
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§.2.6.2 Biochemical identification
If the organism type could not be conclusively identified by Gram stain alone, further 
biochemical identification was carried out using the Analytical Profile Index (API) 
biochemical identification system (BioMerieux, Basingstoke, UK). The API is a 
miniaturized panel of biochemical tests compiled for identification of groups of 
closely related bacteria. APIs were prepared and read according to the 
manufacturer’s instructions. The reactions are read according to the reading table and 
identification is obtained by using the identification software which can be accessed 
through the API website. The result indicates the percentage likelihood of a named 
organism being present. Table 5.2 lists the API types used for different colony type 
classification.
Table 5.2 API biochemical tests and Organisms identifiable
API Organism Classification Organism Species
RapID 20E Gram Negative Organisms Acineto/Pseudo spp. 
Enterobacter spp. 
Escherichia spp. 
Serratia spp. 
Shigella spp.
Rapid ID 32A Anaerobic organisms Actinomyces spp. 
Bacteroides spp. 
Bifidobacterium spp. 
Clostridium spp. 
Eubacterium spp. 
Fusobacterium spp. 
Peptostreptococcus spp. 
Prevotella spp. 
Propionibacterium spp.
API 50CHL Facultative Gram Positive Lactobacillus spp.
organisms Leuconsostoc spp. 
Pediococcus spp.
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5.2.6.3 RAPD-PCR (Random Amplification of Polymorphic DNA- Polymerase 
Chain Reaction)
RAPD-PCR is a rapid fingerprinting method that has already been used by several 
researchers for lactobacilli differentiation (Du et al. (1995); Roy et al. (2000); 
Tynkkynen et al. (1999)) and thus may represent a good technique for the molecular 
characterization and identification of probiotic strains. The standard RAPD 
technology utilizes short synthetic oligonucleotides (10 bases long) of random 
sequences as primers to amplify nano-gram amounts of total genomic DNA under 
low annealing temperatures by PCR. This primer may bind in several places in any 
one genome on either strand of DNA, allowing amplification of several bands, of 
different lengths during a single reaction. It is unknown where the primer will bind 
and therefore what pattern of banding will occur; however when the same DNA 
template is used with the same primer the same banding pattern will always occur. 
Thus if a different DNA template is used a different pattern will result. This allows us 
to uniquely identify a strain of bacteria for example, even if the species is the same, 
since each strain has a different genome. This technique can be used to track 
probiotic organisms, for example by comparing the patterns from isolates from 
unknown samples with the known controls we can identify which samples are 
positive for the probiotic organisms. RAPD-PCR for different probiotic organism’s 
identification in this study is followed the internal work protocol in Obsidian Quality 
Manual.
5.2.7 Glucose content
As the glucose is the sole carbohydrate source in the modified Macfarlane’s gut 
medium (MMGM), the glucose residue either in the single or two stages 
fermentation trial will be tested according to the D-glucose test kits instruction 
(Cat.No. 10716251035, R-biopharm, Germany). It is a UV-method for the 
determination of D-glucose in food stuffs and other materials such as fermentation 
samples. The principle of this test, is that D-glucose is phosphorylated to 
D-glucose-6-phosphate (G-6-P) in the presence of the enzyme hexokinase (HK) and
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adenosine-5’-triphosphate (ATP) with the simultaneous formation of 
adenosine-5’-diphosphate (ADP). The fermentation sample should be centrifuged 
and the supernatant (diluted according to the dilution table in the test kits instruction) 
will be used for assay. The absorbance of the solutions before and after reaction has 
been measured at 340 nm, the content of D-glucose is calculated based on the 
equation below.
V x MW  r n
c = ------ ----------- ——— x AA [g/l]
e x d x v  x 1000
c = concentration of D-glucose [g/l];
V = final volume [ml] (3.020 ml); 
v = sample volume [ml] (0.100 ml);
MW = molecular weight of the substance to be assayed [g/mol] (D-glucose = 
180.16);
d = light path [cm] (1 cm);
s = extinction coefficient of NADPH at 340 nm [1 x mmol'1 x cm'1] (6.3);
AA = (A2 -A 1) sample -  (A2 -A1) blank (subtract the absorbance difference of the blank 
from the absorbance difference of the sample).
If the sample has been diluted during preparation, the result must be multiplied by 
the dilution factor F.
5.3 Results
5.3.1 Pre-trial of the stabilization of 3 residential strains
In order to obtain the stabilization environment using 3 residential strains in the 
MMGM, the single continuous culture fermentation was carried out in the anaerobic 
workstation as described by Section 5.2.2. Following 1% (2.5 ml) of overnight broth
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o f E.coli QC1, E. cloacae QC4 and E. faecalis QC9 inoculation into single culture 
vessel containing 250 ml MMGM, the system was left at least 24 h as a batch culture 
to enable stabilization o f microbial populations. Growth medium (MMGM) was 
introduced into the culture vessel at 24 h after inoculation o f the above 3 strains, and 
the medium flow rate is equivalent to one turnover per day, which gave a dilution 
rate o f 0.042 h '1. The system was set at pH 5.5 to mimic the acid condition o f the 
ascending colon. The whole system was run 7 days (168 h) and 5 ml o f fermenter 
culture was sampled daily, and the bacterial population was enumerated by using 
standard selective media (see Table 5.1).
3 mixture strains in a single stage fermentation 
at controlled pH 5.5
9.00 
8.50
£ 8.00 
£  7.50 
5* 7.00 | 
j  6.50 j
6.00 \
5.50
5.00 ------------------
0 25 50 75 100 125 150 175
Time (hours)
1 QC1 E. coli —■— QC4 E. cloacae QC9 E.faecalis
Figure 5.4: Growth o f 3 mixture strains in the single-stage continuous fermentation at 
controlled pH 5.5 over the experimental period.
These bacterial groups were found to be relatively constant after the exponential log 
phase in the first 24 hours (Fig. 5.4). The bacteria viable count is ranging from 8.78 
to 7.45 logio cfu m l'1 for E.coli, and 9.08 to 7.70 logio cfu m l'1 for E.cloacae, and
7.15 to 7.90 logio cfu ml"1 for E.faecalis between 24 h and 168 h. During this trial, it 
is assumed that the steady state will be reached 24 hours after incubation o f the 3 
residential strains in the single-stage fermentation model.
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5.3.2 Single-stage continuous fermentation with LAB4B
Following the procedure o f single-stage continuous fermentation trial (See Section 
5.2.2), the system will become steady state 24 hours after incubation with 1% (2.5 
ml) o f overnight broth o f E.coli QC1, E. cloacae QC4 and E. faecalis  QC9. Then, 
growth medium (MMGM) was introduced into the culture vessel with controlled pH
5.5 and the flow rate was set equivalent to one turnover per day. Simultaneously, one 
capsule o f LAB4B was administered to the culture vessel and the amounts added to
*7 8  • • • •the system contained between 10 and 10 viable bacteria per ml for each probiotic 
strain. The whole system was run 8 days (192 h) and 5 ml o f fermentation culture 
was sampled daily. Bacterial counts were obtained for each bacterial species by using 
the selective media (see Table 5.1). The bacterial population was characterized and 
identified by screening the profile (see Section 5.2.6). The glucose residue in the 
culture medium was measured by glucose test kits (see Section 5.2.7).
LAB4B single stage fermentation
10.00 at controlled pH 5.5
9.00
8.00
m 7.00
6.00
5.00
1000 25 50 75 125 150 175 200
Time (hours)
QC1 E. coli — QC4 E. cloacae
QC9 E.faecalis x CUL61&08 L.salivarius& L.paracasei
— CUL34&20 B.lactis & B.bifidum
Figure 5.5: Growth o f 3 mixture strains and LAB4B in the single-stage continuous 
fermentation at controlled pH 5.5 over the experimental period.
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Glucose content in the single stage fermentation
of LAB4B
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Figure 5.6: Glucose changes in the single-stage continuous fermentation with LAB4B at 
controlled pH 5.5 over the experimental period.
Results from administration of LAB4B on the 3 residential strains are presented in 
Figure 5.5. The results show that the amount of lactobacilli group (L.salivarius and 
L.paracasei CUL61&08) increased by about 1.5 logio cfu ml'1 during the treatment 
of LAB4B in the single-stage fermentation model at controlled pH 5.5. The 
bifidobacteria group (B.lactis and B.bifidum CUL34&20) maintained a similar viable 
count during the experimental period. The number of E.coli QC1 and E. cloacae QC4 
increased sharply during the first 24 hours of batch incubation and start to drop after 
the probiotic administration. However, E.coli QC1 became relatively stable after 120 
hours fermentation, E.cloacae QC4 dropped gradually from 9.0 to 5.9 logio cfu ml'1 
during the experiment period (192 h). The number of E.faecalis QC9 slightly 
increased after the probiotic administration and it became stable 120 h after 
incubation which is similar to E.coli QC1.
In summary, the number of lactobacilli group, bifidobacteria group, E.coli QC1 and 
E.faecalis QC9 became relatively stable after 120 h in the single-stage fermentation 
at controlled pH 5.5 except that the number of E.cloacae QC4 gradually decreased 
between 24 to 192 hours fermentation. However, the number of all strains started to 
drop after 168 h which may relate to the limited glucose. Glucose content sharply
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dropped from the initial concentration to zero after 24 hours (Figure 5.6). It shows 
that the glucose as the sole carbon source in the MMGM would be instantly used by 
co-cultures under the given flow rate (one turnover per day, lOAmlh'1) and that at 
this flow rate, the growth of the mixed population was substrate limited.
5.3.3 Single-stage continuous fermentation with LAB4
Similar results (Figure 5.7) were observed for the administration of LAB4. The 
results show that the amount of lactobacilli group (L. acidophilus CUL60&21) 
increased by about 1.5 logio cfu ml"1 during treatment of LAB4 in the single-stage 
fermentation model at controlled pH 5.5. The number of bifidobacteria group 
(B.lactis and B.bifldum CUL34&20) also increased by about 1.4 logio cfu ml'1 during 
the experimental period which was not shown in the LAB4B fermentation trial. It 
may be explained by the stronger growth competition of L.salivarius and L.paracasei 
CUL61&08 than L. acidophilus CUL60&21.
The growth pattern of E.coli QC1 and E.cloacae QC4 are similar to the trial 
described in Section 5.3.2. Both bacteria increased sharply during the first 24 hours 
batch incubation and started to drop after LAB4 probiotic administration. However, 
E.coli QC1 became relatively stable after 120 hours fermentation, and E.cloacae 
QC4 dropped gradually from 8.40 to 5.99 logio cfu ml'1 during the experiment period 
(192h). The number of E.faecalis QC9 increased by about 1.4 logio cfu ml'1 after the 
probiotic administration and became stable after 148 h incubation.
In summary, the number of lactobacilli group, bifidobacteria group, E.coli QC1 and 
E.faecalis QC9 became stable after 148 h in the single-stage fermentation at 
controlled pH 5.5 except that the number of E.cloacae QC4 gradually decreased 
during 192 hours fermentation. Glucose content sharply dropped from the initial 
content to zero after 48 hours compared with 24 h for LAB4B (Fig. 5.7).
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LAB4 single stage fermentation at controlled pH 5.5
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Figure 5.7: Growth o f 3 mixture strains and LAB4 in the single-stage continuous 
fermentation at controlled pH 5.5 over the experiment period.
Glucose content in the single stage fermentation
of LAB4
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Figure 5.8: Glucose changes in the single-stage continuous fermentation with LAB4 at 
controlled pH 5.5 over the experiment period.
5.3.4 Results of screening the profile of probiotic strains
All colonies isolated from selective agar (see Table 5.1), were initially characterized 
from colonial appearance and gram stains (see Figure 5.9). Biochemical
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identification reactions on API were also noted (see Section 5.3.4.2). In the work, 
randomly amplified polymorphic DNA-polymerase chain reaction (RAPD-PCR) was 
applied to the identification at species level o f different probiotic strains from the 
co-cultures. RAPD-PCR analysis o f the types o f strains for different probiotic gave 
distinctive band profiles that allowed a clear differentiation o f all the considered 
species (see Section 5.3.4.3).
5.3.4.1 Gram stains of six probiotic strains
Gram stains have been checked from the single colony selected from the relative 
agar, they all matched the below images against six probiotic strains.
Lactobacillus salivarius CUL61 Lactobacillus paracasei CUL08
Lactobacillus acidophilus CUL60 Lactobacillus acidophilus CUL21
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I
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Bifidobacterium lactis CUL34 Bifidobacterium bifidum  CUL20
Figure 5.9 Gram stains o f typically isolated organisms o f  six probiotic strains (Source from 
Obsidian Research Ltd.).
5.3.4.2 API test results
According to the test procedure described in Section 5.2.6.2, the result indicates that 
the percentage likelihood o f 3 residential strains and probiotic strains respectively in 
the co-cultures are all over 99%.
5.3.4.3 RAPD-PCR results
RAPD-PCR fingerprinting was carried out as described in Section 5.2.6.3. The 
RAPD fingerprint patterns for six isolated probiotic strains from the co-culture were 
confirmed against each standard strain profile (Figure 5.10).
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Bifidobacterium lactis CUL34 Bifidobacterium bifidum  CUL20
Figure 5.10: RAPD-PCR Fingerprint patterns o f  six probiotic strains against standard 
individual probiotic strains. Lane M is molecular size marker in bp. Lanes 1 and 2 are 
standard control o f  each probiotic strain and lanes 3-6 are the isolated strains from the 
co-culture.
5.3.5 Results of the two-stage continuous fermentation with LAB4B
Following the procedure o f two-stage continuous flow fermentation trial (See 
Section 5.2.3), the whole system was run for 10 days (240 h) and 5 ml of 
fermentation culture was sampled daily. The bacterial population was enumerated by 
using standard selective media (see Table 5.1). The collected samples were 
centrifuged (5,000 X g, 10 min) to remove the microbial cells. The glucose residue 
in the culture medium was measured by glucose test kits (See Section 5.2.7).
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Figure 5.11: Growth of 3 mixture strains and LAB4B in vessel 1 at controlled pH 5.5 over 
the experiment period.
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Figure 5.12: Growth of 3 mixture strains and LAB4B in vessel 2 at controlled pH 6.5 over 
the experiment period.
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Figure 5.13: Glucose changes in the two-stage continuous fermentation with LAB4B over 
the experimental period.
Results o f administration o f LAB4B on the 3 residential strains in vessel 1 and vessel 
2 are presented in Figure 5.11 and Figure 5.12. The results show that the amount o f 
lactobacilli group (L.salivarius and L.paracasei CUL61&08) increased by about 1.7 
and 1.5 logio cfu ml"1 during the treatment o f LAB4B in vessel 1 and vessel 2. The 
bifidobacteria group (B.lactis and B.bifidum  CUL34&20) maintained a similar viable 
count during the experiment period in vessel 1 and vessel 2. The number o f E.coli 
QC1 and E. cloacae QC4 increased sharply during the first 24 hours after batch 
incubation and started to drop after the probiotic administration in both vessels. 
However, E.coli QC1 became relatively stable after 144 hours o f fermentation, 
E.cloacae QC4 dropped gradually from 9.0 to 5.78 or 5.3 logio cfu m l'1 during the 
experiment period (240 h) in vessel 1 and vessel 2 respectively. The number o f 
E.faecalis QC9 slightly increased after the probiotic administration and it became 
relative stable or slightly decreases 168 h after incubation in both vessels. Glucose 
content sharply dropped from the initial content to zero after 24 hours in the two 
vessels (Figure 5.13).
The main difference between vessel 1 and vessel 2 is that the viable count o f E.coli 
QC1 after stabilization is higher in vessel 2 (7.6 logio cfu m l'1) compared with vessel
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1 (6.5 logio cfu m l'1). A similar pattern has been found for E.faecalis that the viable 
count o f E.faecalis QC9 after stabilization is higher in vessel 2 (7.4 logio cfu m l'1) 
compared with vessel 1 (6.9 logio cfu ml"1). This may indicate that both E.coli and 
E.faecalis like a neutral environment more than acidy conditions.
5.3.6 Results of the two-stage continuous flow fermentation with LAB4
Following the procedure o f two-stage continuous flow fermentation trials (See 
Section 5.2.3), LAB4 was administered instead o f LAB4B in the whole system. 
Changes in the mixture strains and glucose residue are given in Figure 5.14, Figure
5.15 and Figure 5.16.
LAB4 Vessel 19.50
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CUL34&20 B.lactis & B.bifidum
Figure 5.14: Growth of 3 mixture strains and LAB4 in vessel 1 at controlled pH 5.5 over the 
experiment period.
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Figure 5.15: Growth o f 3 mixture strains with LAB4 in vessel 2 at controlled pH 6.5 over the 
experiment period.
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Figure 5.16: Glucose changes in the two-stage continuous fermentation with LAB4 over the 
experiment period.
As shown in Figure 5.14 and Figure 5.15, the amount o f lacotobacilli group 
(L.acidphilus CUL60&21) increased by about 1.5 and 1.2 logio cfu ml*1 during 
treatment o f LAB4 in vessel 1 and vessel 2. The bifidobacteria group {B.lactis and 
B.bifidum  CUL34&20) also increased by about 1.0 and 1.4 logio cfu m l'1 during the
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experiment period in vessel 1 and vessel 2 which was not observed in the LAB4B 
continuous fermentation trial. The number of E.coli QC1 and E.cloacae QC4 
increased sharply during the first 24 hours of batch incubation and started to drop 
after the probiotic administration in both two vessels. E.coli QC1 became relatively 
stable after 144 hours of fermentation, but E.cloacae QC4 dropped gradually from 
8.97 or 8.70 to 6.60 or 7.15 logio cfu ml"1 during the experiment period (240 h) in 
vessel 1 and vessel 2 respectively. The number of E.faecalis QC9 slightly increased 
after the probiotic administration and it became relatively stable 168 h after 
incubation in both two vessels. Glucose content sharply dropped from the initial 
content to zero after 24 hours in both two vessels (Figure 5.16).
It seems that there is no significant difference in the growth patterns of mixture 
strains in vessel 1 and vessel 2 after administration of LAB4. The viable count of 
bifidobacteria group {B.lactis and B.bifidum CUL34&20) is higher in the LAB4 
fermentation trial (8.1 logio cfu ml"1) compared with the LAB4B fermentation trial 
(7.7 logio cfu ml"1). It may suggest that the co-culture of LAB4 will promote the 
bifidobacteria group growth in the in vitro continuous fermentation. However, 
further repeated experiments will be needed to give a reliable conclusion.
5.4 Discussions
The health beneficial effects of probiotics should be claimed on the individual and 
unique properties of each strain. Any claim of a probiotic product should be 
evidenced by well-designed, randomized double-blind clinical trials that confirm its 
health benefit to the host. More than often, clinical trials are not specific for 
screening purposes to compare various probiotic strains. An in vitro model may 
provide an alternative tool to gain knowledge of probiotics and their interactions on 
the intestinal microbiota. In vitro systems can simulate the in vivo conditions to a 
certain degree and have the major advantage that they can be easily set up and offer a 
reproducible way to investigate the specific perturbations on the intestinal microbial 
ecosystem (De Boever et al. (2000); Alander et al. (1999); Kontula et al. (1998);
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Molly et al. (1996)). In vitro models simulating the physicochemical conditions of 
the human colon offer possibilities of studying the interactions of probiotic strains 
with indigenous colon microbiota, e.g. microbial compositions and metabolic activity 
(production of short chain fatty acid, gases, microbial enzymes, bacteriocins, etc.). 
The in vitro results have shown good correlation with results obtained in human 
volunteers’ studies (Johansson et al. (1993); Marteau et al. (1993)).
The single-stage continuous fermentation model is a useful model for specific 
regions of the GI tract under physicochemical controlled conditions. It has several 
advantages that it is simple, easy to operate and economic of materials, but given the 
complexity of the large intestinal fermentation, it cannot reproduce the heterogeneity 
of physical conditions and nutrient availabilities that occur in different parts of the 
colon. Moreover, stability of the microbial community under long term studies is not 
always possible. An extension of the single-stage continuous flow chamber is the use 
of multiple stages which enables the simulation of different parts of the colon and 
allows long time study of the gut microbiota ecosystem. Multistage fermentation 
models are able to closely reproduce the associations of bacteria and have been used 
to investigate various microbial activities.
In this project, an in vitro fermentation model was designed and the entire 
fermentation apparatus was maintained inside a specially designed anaerobic 
workstation flooded with 80% N2 , 10% CO2  and 10% H2 . It is a unique design to help 
to easily process, culture and examine samples without exposure to atmospheric 
oxygen. Thus, it allows the conduction of long-term dynamic fermentation trials in an 
atmosphere and conditions that are oxygen free. To the best of our knowledge, all 
other research groups used continuously O2  free N2  to flush each vessel and the growth 
medium reservoir to keep anaerobic environment. Based on the traditional approach, a 
few models have been recently developed to simulate the mucus-associated 
fermentation in the human colon, but a big disadvantage is that the whole system will 
lose the anaerobic environment after the sample e.g. mucin-covered microcosms are 
taken out from the fermentation vessel and the experiment must stop. This restricts
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long-term dynamic fermentation. Our uniquely designed anaerobic workstation with a 
removable front panel and a sealed side chamber allow easy installation of large 
equipment and convenient sampling without damaging the anaerobic conditions, and 
this is an essential requirement in order to perform prolonged long-term fermentation 
study.
When experiments are designed to monitor the effect of a specific treatment on the 
composition of the in vitro microbial ecosystem, the reliability of the results strongly 
depends on the assumption of stability (Possemiers et al., 2004). It is crucial to start 
from a stable community which is more or less representative for the human 
microbiota ecosystem before investigating the effect of the specific treatment using 
the in vitro fermentation model. Some researchers used in vitro models to establish 
stabilization periods of 24h (Allison et al., 1989), 12 days (Possemiers et al., 2004), 
14 days (Macfarlane et al., 1998), or 48 days (Gibson et al., 1988a), but a motivation 
for the choice of these periods is not apparent. In this present work, we used a 
single-stage and a two-stage continuous fermentation model to test the bacterial 
activities following supplementation of mix probiotic strains (LAB4 or LAB4B). The 
smaller operating volume (250 ml) and turnover rates (one turnover per day) were 
adapted from the three-stage model developed by Macfarlane et al. (1998). 
Temperature (37°C) and pH were automatically controlled. Culture pH in the vessels 
was set as 5.5 in vessel 1, representing the low pH environment of the ascending 
colon and 6.5 in vessel 2, indicative of a more neutral pH in the descending colon. In 
order to get the stabilization environment using 3 residential strains in the in vitro 
model, the batch culture fermentation was run for at least 24 h to establish steady 
stage conditions before the medium pump was started. We tested the stability of 
microbiota composition and survivability of probiotic in these models to give basic 
information to further study the effects between probiotic and intestinal microbiota in 
future research.
Our experiments demonstrate the interaction with the residential microbiota (3 
residential strains) and show that the addition of probiotic did not affect significantly
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the total number of bacteria growing in the continuous culture. The amount of 
lactobacilli group (L.salivarius and L.paracasei CUL61&08 or L. acidophilus 
CUL60&21) increased by about 1.2-1.7 logio cfu ml'1 and both remained at high 
levels throughout the 10 days of sampling either in the single-stage or in the 
two-stage continuous fermentation model. The bifidobacteria group (B.lactis and 
B.bifidum CUL34&20) also increased by about 1.0 and 1.4 logio cfu ml'1 during the 
administration of LAB4 which was not evident in the LAB4B in either single-stage 
and two-stage continuous fermentation models. It may be explained by the stronger 
growth competition of L.salivarius and L.paracasei CUL61&08 than L.acidophilus 
CUL60&21. It may suggest that the co-culture of LAB4 will promote the 
bifidobacteria group growth in the in vitro continuous fermentation. However, 
further repeated experiments are needed to make a firm conclusion. Relative 
numbers of E.cloacae QC4 gradually decreased from day 1 to day 10 in the 
two-stage continuous fermentation model. All the other strains including E.coli QC1, 
E.faecalis QC9, lactobacilli group and bifidobacteria group remained stable from day 
5 to day 10. Similar results have been obtained in a few other studies. Changes in the 
GI microbiota of human volunteers on oral supplementation of lactobacilli were 
shown to be small (Orrhage et al., 1995). Alander et al. (1999) demonstrated a 
maximum increase in lactic acid bacteria of about log 10 cycles after administration 
of five probiotic strains separately in the SHIME model. The same author (Alander et 
al., 1999) also found that the amount of enterobacteriaceae decreased during LAB 
treatment in the SHIME model.
However, the results of this work gave only a relative approximate picture of the 
effects of probiotic treatment on the microbial population. The assessment of any 
individual strain would need more repeated experiments and also the results obtained 
here with all their limitations such as the specific effects of individual strains should 
be discussed. The present model with 3 residential strains in this work is perhaps 
over simplified for representing the complex microbial community in the human 
colon. Most works can be done by using faecal slurry inoculated into the vessel to
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represent the stable microbial community compositions, but even this cannot fully 
represent the microbial ecosystem in the colon.
5.5 Conclusion
A reliable and flexible anaerobic multistage continuous fermentation platform has 
been developed, and it can facilitate various in vitro anaerobic fermentation 
experiments to investigate the human gut microbial ecosystem. Using this new 
system, a series of general testing has been performed to study the interaction of 
commercial probiotics and typical microorganisms found in the human GI tract. The 
experimental observation and measurement are consistent with the literature results, 
which further confirms the feasibility and effectiveness of the new system. Some of 
these experimental findings are also meaningful in guiding the production and use of 
probiotics. In conclusion, the specially designed in vitro continuous fermentation 
model in the anaerobic workstation provides a reliable and relatively inexpensive 
tool for simulating the microbiota ecosystem and investigating the metabolic 
activities under different nutritional and environmental conditions. The system has 
fully met the design requirement. It is also noted that to make more informative 
conclusion on human gut microbiota, more complex microbiota should be employed 
to more closely simulate the in vivo environment of the human gut. However, the 
purposely built in vitro platform has generated a good set of first-hand data for the 
development of mathematical models of the human GI tract.
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Chapter 6 In Vivo Study of Gut 
Microbiota of Infants Based on DNA 
Sequencing
Abstract
This Chapter describes the use of a new sequencing technology 
(454-pyrosequencing) to assess the gut microbiota profiles in healthy infants selected 
from the randomized, double-blinded, placebo-controlled clinical trial conducted by 
Swansea University and Cultech Ltd. Due to the high cost of 454-pyrosequencing 
analysis, the analysis of microbiota profiles is limited to 50 faecal samples from 9 
healthy infants who were taking either probiotic or placebo during the first 6 months 
after birth. The DNA-sequencing data provide representative and comprehensive 
profiles of gut microbiota in healthy infants. The data also provide evidences for 
possible analysis of more neonatal samples obtained from the infants in the birth 
cohort who had high risk of atopy in the Swansea clinical trial. The analysis shows 
that probiotic did alter the composition of the gut microbiota compared with those in 
the placebo group and, hence, the administration of probiotics to healthy infants may 
be an effective way to impact on gut colonization with healthy bacteria. It should be 
noted that these initial conclusions are based on the analysis of a relatively small 
number of samples.
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6.1 Introduction
6.1.1 Background for gut microbiota of infants
Throughout the human lifetime, the healthy intestinal microbiota profile performs 
vital functions, such as protection against pathogens, metabolic reactions, trophic 
effects, and maturation of the immune system. The neonatal period is crucial for 
colonization of the intestinal microbiota. Within days, a rich and dynamic ecosystem 
develops from a sterile environment when the baby is bom and the microbial 
population soon outnumbers the baby’s own cells. The interactions between the host 
and its microbiota are important for human health and these interactions can have 
beneficial nutritional, immunological and developmental effects, or pathogenic 
effects for the host (Penders et al. (2006); MacDonald et al. (2005a, 2005b); Backhed 
et al. (2004)). The infant’s gut microbiota is highly dynamic in the first year of life 
but the microbial diversity is low, and the microbial population starts to stabilize and 
resemble that of the adult after two years old (Marques et al., 2010). There is a big 
difference of the gut microbiota between infants and adults and also the infant’s 
intestinal microbiota shows very significant inter-individual variability. Until now, it 
is still difficult to define a universal standard for intestinal microbiota composition 
and clarify how this is related to health and disease.
It is widely accepted that facultative anaerobic bacteria (e.g. Staphylococcus, 
Streptococcus, Enterococcus and Enterobacteriacease spp.) are the early colonizers 
in the infant’s gut within the first days of life. When these first colonizers consume 
oxygen and reduce the initial high redox potential, the gut favours the obligate 
anaerobes such as Bifidobacterium, Clostridium, Bacteroides, and sometimes 
Ruminococcus (Matamoros et al., 2013). Bifidobacterium is recognized as the 
residential bacterium in the neonatal GI tract (Harmsen et al. (2000); Turroni et al. 
(2012)), while other reports found it occurred in only a small fraction of infants 
(Hopkins et al., 2005). The neonatal colonization pattern can be influenced by a 
broad range of factors including mode of delivery (vaginal delivery or caesarean
134
Chapter 6 In Vivo Study o f Gut Microbiota o f Infants Based on DNA Sequencing
section), type o f feeding (exclusive breast-fed versus formula-fed), gestational time, 
the use o f antibiotic, infant hospitalisation, surrounding environment and maternal 
infection (Marques et al., 2010). Figure 6.1 shows the factors affecting the infant gut 
composition (Matamoros et al., 2013).
Intrauterine
contam ination
T r a n s la t io n  from 
the m other’s 
intestinal microbiota
k Bifidobacterium, 
Loctobaallus, 
tntero coccus
Prenatal
Delivery m od e
Vaginal
. Staphylococcus, * Lactobacillus,
|  Corynebocterium, Prevotello,
1 Propionibactenum Sneathio
First w eeks
Type of feeding
Breastfeeding  
I Bifidobacterium
Formula feeding
t
i tnterobocteriaceoe 1
Treatments
Prpbipfts-Prcbfttfg
Bifidobacterium
Lactobacillus
Antibiotics
Reduction o f 
microbial diversity
Figure 6.1: Effect o f  external factors on the intestinal microbiota o f infants. (Green arrows 
siow positive modification and red arrows show negative modification for human health).
Gestation time is a strong factor that influences the establishment o f the infant 
iitestinal microbiota. The composition o f gut microbitoa differ significantly between 
fill-term and preterm neonates. Preterm infants show higher levels of 
Lnterobacteriaceae and other potentially pathogenic bacteria such as E.coli, 
Klebsiella spp. and Clostridium difficile (Arboleya et al., 2012a). However, the 
dversity o f the microbiota in full-term infants is much higher and it favours some 
om m on genera such as Bifidobacterium, Lactobacillus and Streptococcus (Arboleya 
e al., 2012b). In addition, preterm infants are often cared for in the neonatal
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intensive care units and receive broad spectrum antibiotics which further delay the 
establishment of beneficial bacteria (Prescott et al., 2008).
Mode of delivery is believed to have the most significant influences on early gut 
cobnization (Biasucci et al., 2010). The meconium of neonates analysed by 
pyiosequencing shows that the microbial communities are strongly related to the 
mother’s vaginal delivery (e.g. Lactobacillus, Prevotella, or Sneathia) or caesarean 
section (Staphylococcus, Corynebacterium, and Propionibacterium)
(Dominguez-Bello et al., 2010). These pioneer bacteria usually originate from the 
vagina or the skin depending on the mode of delivery. Bifidobacterium in caesarean 
section babies are much lower than in vaginal delivered babies, and also the diversity 
of ihe microbiota in the former appears to be lower (Biasucci et al., 2008). However, 
there seems to be less influence of mode of delivery on the gut colonization in 
preterm infants (Arboleya et al., 2012a).
Apirt from the delivery mode, type of feeding (exclusively breast-fed versus 
formula-fed) also shows strong influence in the development of the infant intestinal 
microbiota. Full term vaginally delivered, breast-fed neonates show higher counts of 
bifidobacteria and lactobacillus. They are frequently detected in the early life, 
suggesting that breast milk is an important delivery system for probiotic bacteria 
(Fernandez et al., 2013). Streptococcus and Staphylococcus genus are also present as 
earfy colonizers in the gut (Collado et al. (2009); Sahl et al. (2012)). However, 
fomula-fed neonates harbour more diverse microbiota such as Bacteriodes, 
Clostridium coccoides group, Staphylococcus, and Enterobacterium (Fallani et al. 
(2010); Rinne et al. (2005)).
[ 6.12 Effects of probiotics on neonatal gut microbiota
I
If-
! Cobnization of the neonatal intestine plays a key role in the development of the
imnune responses, maturation and function (Round et al, 2010). A few studies 
shewed the important association between the neonatal gut microbiota and host
mucosal and systemic immunity during the first year of life (Martino et al. (2008);
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Sjogren et al. (2009)). The rapid increase in immune-related disorders such as 
eczema, allergic rhinitis and inflammatory bowel disease (IBD) in the past decades is 
hypothesized to be related to microbial disruption in early life (Wang et al. (2008); 
Sjogren et al. (2009); Gam et al. (2007)). Some studies reported the differences in 
neonatal gut microbiota in relation to development of allergic disease (Sjogren et al. 
(2009); Penders et al. (2007); Bjorksten et al. (2001); Kalliomaki et al. (2001)). For 
example, reduced gut microbiota diversity during infancy has been strongly 
associated with atopic eczema in later life (Bisgaard et al. (2011); Abrahamsson et al. 
(2012)). The intestinal microbiota diversity of neonates suffering from atopic eczema 
during the first 18 months was much lower in comparison to healthy neonates 
(Penders et al., 2007). Found in these studies, the general characters of gut 
microbiota of those infants later developing allergy are a reduced diversity, lower 
counts of bifidobacteria and lactobacilli and early Staphylococcus aureus and 
Clostridium difficile colonization.
As neonatal gut microbiota is more variable in its composition and less stable over 
time compared to the adult, the administration of probiotic during the prenatal and 
postnatal period in order to shape neonatal gut colonization with potentially 
beneficial bacteria may be a good opportunity to impact on future health problems 
(Cerf-Bensussan et al. (2010); Yolanda (2011)). Intentional modulation of microbiota 
composition through use of probiotic and prebiotic have been confirmed to stimulate 
the growth of bifidobacteria and help in the treatment and prevention of certain 
illnesses (Storro et al. (2010); Oien et al. (2008)).
Some recent studies reported evidence for the modulation of neonate gut microbiota 
by consumption of probiotics and prebiotics. Consumption of Lactobacillus GG by 
Finnish mothers before delivery and during breastfeeding increased the diversity of 
the Bifidobacterium species (Gueimonde et al., 2006). A double-blind 
placebo-controlled trial in Finland and Germany on the impact of probiotic 
intervention showed higher lactobacilli and enterococci counts in probiotic groups 
compared with placebo groups (Grzeskowiak et al., 2012). Administration of
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Lactobacillus rhamnosus GG (ATCC 53103) in a total of 132 Finnish neonates 
during the first 6 months were followed for 2 years after treatment. The results 
showed a good tolerance and less lactobacilli / enterococci and clostridia in the faecal 
microbiota after two years (Rinne et al., 2006). Ninety premature neonates treated 
with bifidobacteria enriched formula had higher bifidobacteria content in the infants’ 
stool than the placebo group, but no differences were noted for the colonization of 
lactobacilli or staphylococci (Underwood et al., 2009). Full term infants who had 
been bottle-fed with formula containing prebiotic (galacto- and long-chain 
fructooligosaccharides) exhibited a good tolerance and higher stool frequency, and 
also there was a trend to suppress the numbers of clostridia and E.coli and slightly 
increase stool bifidobacteria (Costalos et al., 2008).
Prenatal probiotic administration {Lactobacillus rhamnosus GG) to mothers during 
late pregnancy can increase faecal Bifidobacterium longum in infants at high risk of 
allergy (Lahtinen et al., 2009). A large cohort study of the correlation between mode 
of delivery and the risk of asthma and atopy from Holland showed that the 
colonization of Clostridium difficile in caesarean delivered children increased the 
risk of asthma and eczema throughout the first 6 or 7 years of life (van Nimwegen et 
al., 2011). Lower amount of bifidobacteria were found in breast-milk in allergic 
mothers compared with healthy mothers, and their infants also had lower levels of 
bifidobacteria in the faeces (Gronlund et al., 2007). Reduced numbers of 
bifidobacteria and increased numbers of Staphylococcus aureus have been detected 
in neonates who later on became obese compared with healthy children (Kalliomaki 
et al., 2008). A recent study showed that the proportion of bifidobacteria counts was 
inversely associated with daily amounts of crying in infants (Partty et al., 2012).
Neonates and their mothers seems have a good tolerance of the administration of 
probiotic and prebiotic. There are lots of beneficial effects for neonates by feeding 
probiotic and prebiotic including enteric inflammatory conditions, acute diarrhoea, 
necrotizing enterocolitis, asthma, atopic dermatitis and eczema (Brenchley et al. 
(2012); Rautava et al. (2012); Braegger et al. (2011); Marques et al. (2010)).
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6.1.3 Motivation and objectives of the present in vivo study
Supported by the Knowledge Exploitation Fund, Collaborative Industrial Research 
(project no. HE 09 COL 1002), Welsh Assembly Government and Cultech Ltd. in 
2005, a randomized, double-blinded, placebo-controlled clinical trial was undertaken 
by Swansea University to evaluate administration of probiotic organisms in the 
prevention of atopy in infants and children. This study was approved by the Swansea 
Local Research Ethics Committee in 2004 (International Standard Randomized 
Controlled Trial, ISRCTN 26287422). From a total of 1419 pregnant women 
attending antenatal clinics who were eligible to join this study in the Singleton 
Hospital, Swansea, 454 women were recruited. Among these, 413 (91%) women 
were carrying foetus at high risk of atopy, defined as foetus with a first-degree 
relative with either asthma or eczema; 41 (9%) women from non-atopic families 
were also recruited. The study allocated 220 women to the treatment group and 234 
to the placebo group. A mixture of 4 live probiotic strains (LAB4B: Lactobacillus 
salivarius, Lactobacillus paracasei, Bifidobacterium animalis subsp lactis and 
Bifidobacterium bifidum provided by Cultech Ltd.) was administered to mothers 
during the last month of pregnancy and to infants during the first 6 months of life.
The main objectives of the above project were: 1) To determine the effect of 
probiotic administration on eczema in children aged 0-2 years and asthma in children 
aged 0-5 years; 2) To determine the effect of probiotic administration on changes in 
key immunological parameters associated with atopy; 3) To identify any adverse 
effects (AE) in a potentially vulnerable population; 4) To determine microbiota 
composition in infant stools after birth, 2 and 6 weeks and also at 4 weeks after 
supplementation of the probiotic / placebo ceases at 6 months. All microbial analysis 
was completed using culture-based methods. The findings of this project supported 
the safe use of LAB4B probiotic strains during pregnancy and early infancy (Allen et 
al., 2010).
The present research focuses on determining the gut microbiota profiles in healthy 
neonates with probiotic administration, in the hope of discovering the development
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pattern of gut microbiota in early life. As the first continuing research to make use of 
the large collection of samples obtained from the previous clinical trials, the present 
research will also provide a detailed reference and a solid foundation for later studies 
to investigate the correlation between faecal microbiota composition and the 
prevalence of allergic diseases in late infancy after administration of probiotics. This 
research selects infants from non-atopic families that have participated in the 
previous in vivo trial at the Singleton Hospital, Swansea. The microbiota profile of 
each individual is analyzed using 454-pyrosequencing technology to give a nearly 
comprehensive coverage of known species. Section 6.1.4 gives a brief overview of 
all major methods that have been used for the analysis of gut microbiota.
6.1.4 Analysis methods for gut microbiota
In the past, the infant gut microbiota composition was investigated using 
culture-based methods. The lack of knowledge of the special nutrient requirements 
for the majority of microorganisms could result in up to 90% of bacteria escaping 
culture detection with traditional techniques (O’Toole et al., 2010). Selection of 
correct media (e.g. biochemical selective agents such as bile, esculin or antibiotics), 
temperature control, and time of the growth are critical to cultivate a large portion of 
the GI bacterial community (Fouhy et al. (2012b); O'Sullivan et al. (2000)). These 
approaches are still being employed in some studies for phenotypic and genotypic 
characteristics of specific strains and for developing novel probiotics (Jost et al. 
(2012); Hascoet et al. (2011)). Despite advances in culturing capabilities, these 
approaches have largely been replaced by culture-independent DNA-based 
approaches for characterizing complex microbial environments such as the human 
gut. Table 6.1 compares techniques used to investigate the human gut microbiota 
(Fouhy et al., 2012b).
Molecular tools such as denaturing and temperature gradient gel electrophoresis 
(DGGE and TGGE, respectively) have been applied in microbial ecology (Cani et 
al., 2008). This analysis works by the separation of amplicons (e.gl6S ribosomal 
RNA gene (16S rRNA)) based on their GC content to distinguish the band pattern of
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the specific composition of microbial populations. As 16S rRNA is present in all 
prokaryotes which contains conserved and variable regions, the amplicon generation 
and differentiation can be facilitated by band excision and sequencing (O’Toole et 
al., 2010). Terminal restriction fragment length polymorphism (T-RFLP) is another 
popular molecular approach which uses a set of fluorescently labelled primers in a 
PCR reaction to amplify 16S rRNA from different microbial communities 
(Engelbrektson et al., 2006). It is an effective method to determine a lactobacilli 
community based on lactobacilli 16S rDNA polymorphism (Davis et al. (2010); 
Coolen et al. (2005)). Quantitative Real-Time Polymerase Chain Reaction (qPCR) is 
the most recent popular molecular biological tool used to amplify and simultaneously 
quantify specific bacterial taxa present in a bacterial community. A benefit of qPCR 
over other technologies is the ability of both detection and quantification. qPCR 
using species-specific primers to quantify lactobacilli and bifidobacteria in the 
human GI tract have been investigated in some studies (Lambert et al. (2013); Prasad 
et al. (2013); Bervoets et al. (2013)).
Fluorescence in situ hybridization (FISH) uses DNA-basis but is not based on PCR 
approach. It is a probe-based method to focus on specific populations rather than the 
whole microbiota community. FISH uses a fluorescently-tagged probe which can be 
bound by the bacteria and detected using fluorescent microscopy. Lactobacilli and 
bifidobacteria can also be determined by FISH using specific designed 
oligonucleotide probes and primers (Machado et al. (2013); Kerckhoffs et al. 
(2009)). Phylogenetic microarrays are the next step culture-independent 
technologies. They allow hybridization of greater numbers of sequences 
(fluorescently labelled) attached to one glass slide and their expression can be 
measured using a fluorescence assay. Microarray is also a popular tool for infant gut 
microbiota analysis including lactobacilli and bifidobacteria (Nylund et al. (2013); 
Manuela et al. (2013); Turroni et al. (2012)).
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Table 6.1: Techniques to investigate the human gut microbiota (Fouhy et al, 2012b)
Microflora Culture Culture High
associated dependent independent through-put
characteristics techniques techniques sequencing
Technique The use of Use of selective Identify bacteria Sequencing based
description characteristics media to culture through isolation approaches
associated with specific and amplification of used to rapidly
microbes microorganisms bacterial DNA e.g., identify bacteria
e.g.,SCFA e.g., Man 16S rRNA using bacterial
production to Rogosa Sharpe gene.Includes: DNA as template
identify if (MRS) media PCR, DGGE, e.g., 454,
differences exist for lactobacilli TGGE, T-RFLP, Ulumina, SoLID,
in the gut growth. qPCR, dot blot Ion torrent.
microbial hybridization,
populations FISH, flow
between different cytometry
subject groups.
History of use To date has been Historically, the Increasingly Became
predominantly most frequently popular in past commercially
used as an initial used approach to two decades with available at the
population screen identify bacteria increasing beginning of the
or in present in availability of 21sl century and
epidemiological various computer based becoming
studies. environments. technologies and 
software programs
increasingly 
popular ever 
since.
Advantages Simple; Quick; Relatively Less biased
Inexpensive; Inexpensive; inexpensive; results;
Suitable as an Limited skill Relatively simple; Very detailed
initial screen to required; More detailed information;
test a novel Limited results achievable. Bacterial profile
hypothesis; equipment in complex
Useful for large needed; environments
population Useful as the e.g., gut
screens e.g., in initial screen microbiota can be
epidemiology before more identified;
studies. detailed
investigated.
Huge
phylogenetic 
information 
provided; 
Relatively quick
Disadvantages Provides limited Up to 90% of Prone to PCR bias; Extremely
information; bacteria Requires more expensive;
No bacterial non-culturable; sophisticated Data handling
species Provides limited equipment and requirements are
Identification information; training on their significant;
possible. Need prior use; May need Requires training
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knowledge of several methods in on sample
bacteria to combination to get preparation and
screen for; appropriate level of machine use
Requires further details and experience of
tests for in results. interpreting
species results.
identification.
Examples of Goodman Hascoet et al., Nylund et al., 2013 Fouhy et al.,
studies efficiently et al., 2011 2011 Jost et al., 2012 2012a
using this Tjellstrom et al., Bennet et al., Fallani et al., 2011 De Filippo et al.,
technique 2007
Cardona et al., 
2002
Bottcher et al., 
2000
2002 2010
Vaishampayan et 
al., 2010
Dominguez-Bello 
et al., 2010 
Wu et al., 2010 
Roesch et al., 
2009
Future use in Most likely to be Likely to Likely to remain Increased use
infant gut used to become popular in the since the year
microbiota test novel infrequently coming decade, 2000 as cost is
research hypotheses and to used and to be but decrease decreasing and
be followed up mainly used in thereafter as likely to become
with more combination increased the main
detailed with and verified availability and use approach used in
techniques. by newer 
technologies.
of sequencing 
approaches occurs.
the future
As highlighted by an extensive review in 2008, the focus o f today has shifted to 
‘metagenomic era’ which employs DNA sequencing-based techniques to investigate 
the GI microbiota (Frank et al., 2008). Large scale DNA sequencing 
(high-throughput sequencing) provides detailed information for the whole microbial 
population which contrasts with targeted approaches (FISH, qPCR and microarray) 
(Mardis et al., 2008). High-throughput sequencing technologies such as Roche 454 
pyrosequencing, Illumina and SOLiD (Sequencing by Oligonucleotide Ligation and 
Detection), SMRT (Pacific Biosystems), and nano-pore sequencers technology 
generate millions o f short sequence reads per run, allowing characterization o f an 
entire complex microbial community and comparisons o f microbial composition at 
different phylogenetic levels (Roos et al. (2013); Fouhy et al. (2012b); Clarke et al.
(2009); Strausberg et al. (2008); Mardis (2008); Shendure et al. (2005)).
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These ‘next generation sequencing’ (NGS) technologies have already been employed 
to reveal the role of the GI microbiome in diverse diseases such as Crohn disease 
(Gophna et al., 2006), irritable bowel syndrome (Kassinen et al., 2007), colonic 
cancer (Zhu et al., 2011), obesity (Ley (2010); Tumbaugh et al. (2006)), atopic 
disease (Hong et al. (2010); Fomo et al. (2008)), necrotizing enterocolitis 
(Mshvildadze et al., 2010), the effects of diet (De Filippo et al. (2010); Tumbaugh et 
al. (2009b)) and antibiotics use (Dethlefsen et al., 2008) on the gut microbiota.
6.2 Materials and methods
6.2.1 Neonate faecal samples
In the original clinical trial recapped in Section 6.1.3, women during the last month 
of pregnancy and their infants from birth to six months received daily vegetarian 
capsules containing either 100 mg of LAB4B probiotic strains or identical placebo 
capsules containing maltodextrin. The 100 mg LAB4B capsule consists of 
Lactobacillus salivarius CUL61 (NCIMB 30211) 6.25><109 colony-forming units 
(cfu), Lactobacillus paracasei CUL08 (NCIMB 30154) 1.25xl09 cfu,
Bifidobacterium animalis subsp lactis CUL34 (NCIMB 30172) 1.25><109 cfu, and 
Bifidobacterium bifldum CUL20 (NCIMB 30153) 1.25xl09 cfu (Provided by Cultech 
Ltd., UK). For mothers, the daily dose was one capsule (100 mg powder) taken by 
mouth or by sprinkling the contents of the capsule onto food. For infants, the 
preparations were administered either directly into the baby’s mouth or mixed with 
formula or expressed breast milk.
Infant stool samples were collected according to a prescribed schedule, beginning 
with the first stool produced after birth, then every two weeks with a decreasing 
frequency over the six months period, and finally a further four weeks after the 
probiotic supplementation ceased at the end of 6 months. Fresh faeces in nappies 
were placed into an anaerobic plastic bag and refrigerated until they were transported 
to the laboratory. All samples were stored at -80 °C until further processing.
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Due to the high cost of 454-pyrosequencing analysis, the present research selected 9 
healthy and full term babies (total 50 sample collecting points) bom between 
September 2005 and June 2006 at Singleton Hospital, Swansea to provide 
representative and comprehensive microbiota profiles according to mode of delivery, 
infant diet, and administration of probiotic / placebo. Informed consent was obtained 
from the parents of each infant. Characteristics of the participants in this study are 
summarized in Table 6.2.
6.2.2 Bacterial DNA extraction from faeces
The bacterial DNA was extracted and purified by the QIAamp DNA Stool Mini Kit 
(Cat. No. 51504, Qiagen, West Sussex, UK) in combination with additional bead 
beating step using a FastPrep®-24 System (MP Biomedicals, Solon, OH 44139, 
USA). Briefly, 180-220 mg (wet weight) of stool was weighed into a 2 ml Lysing 
Matrix B Tube (MP Bio) containing 0.1 mm silica beads (BioSpec). Then, 1.4 ml 
buffer ASL was added to the tube and shaken with the Fastprep®-24 for 3x60 s with 
5 min rest in between. The sample was then incubated at 70°C for 5 minutes. After 
centrifugation at full speed for 1 minute, 1.2 ml of supernatant was collected into a 2 
ml tube and the sample was mixed and treated with one Inhibit EX® tablet to remove 
the DNA-damagihg substances and PCR inhibitors. After vortex mixing for 3 
minutes, the suspension was incubated at room temperature for 1 minute. After 3 
minutes of centrifuge at full speed, all supernatant was pipetted into a new 1.5 ml 
tube and centrifuged at full speed for 3 minutes. Next, 200 pi of supernatant was 
treated with 15 pi proteinase K, 200 pi buffer AL, and incubated at 70°C for 10 
minutes. After precipitation with 200 pi ethanol, the supernatant was collected after 
centrifuging. DNA in the sample was further purified on a QIAamp spin column and 
eluted in 200 pL of AE-buffer and stored at -20°C according to the manufacturer's 
instruction.
146
Chapter 6 In Vivo Study of Gut Microbiota of Infants Based on DNA Sequencing
6.2.3 454-pyrosequencing analysis
Genomic DNA isolated directly from frozen baby faecal samples (Section 6.2.2) was 
analyzed using 454-pyrosequencing technique by the Research and Testing 
Laboratory (RTL, Lubbock, TX, USA). Bacterial tag-encoded FLX amplicon 
pyrosequencing (bTEFAP) was used to determine the relative percentages of the 
primary populations of organisms in the baby faecal samples.
This technique is a semi-quantitative universal detection and identification method 
for bacteria based upon the Roche Titanium 454 FLX pyrosequencing platform. The 
theory of this approach is based on sequencing-by-synthesis. For 16S sequencing, 
genomic DNA is fractionated into smaller fragments (300-800 base pairs). Then a 
single-stranded template DNA is used to generate an amplicon library which then 
undergoes an emulsion-based clonal PCR. This PCR uses beads coated in 
oligonucleotides, which are specific to adaptor sequences attached to the amplicons. 
Each bead carries a unique single-stranded library fragment and these 
amplicon-coated beads are added to a PicoTiterPlate™ (the plate consists of 
approximately one million wells, and each well contains at most one bead carrying a 
copy of a unique single-stranded DNA fragment to be sequenced) and sequencing 
ensues. Sequencing involves an enzymatic reaction and, as each nucleotide is 
sequentially added, pyrophosphate is released and ATP is subsequently generated. 
This then enables the conversion of luciferin and the emission and detection of 
photons of light.
Briefly, samples of DNA were amplified for pyrosequencing using a forward and 
reverse fusion primer. The forward primer was constructed with (5’-3’) the Roche A 
linker (CCATCTCATCCCTGCGTGTCTCCGACTCAG), an 8-10 bp barcode, and 
specific primer Gray28F (5’-GAGTTTGATCNTGGCTCAG-3’). The reverse fusion 
primer was constructed with (5’-3’) a biotin molecule, the Roche B linker 
(CCTATCCCCTGTGTGCCTTGGCAGTCTCAG), and specific primer Gray519R 
(5’-GTNTTACNGCGGCKGCTG-3’). Amplifications were performed in 25 ul 
reactions with Qiagen HotStar Taq master mix (Qiagen Inc, Valencia, California), 1
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ul of each 5 uM primer, and lul of template. Reactions were performed on ABI 
Veriti thermocyclers (Applied Biosytems, Carlsbad, California) under the following 
thermal profile: 95°C for 5 min, then 35 cycles of 94°C for 30 sec, 54°C for 40 sec, 
72°C for 1 min, followed by one cycle of 72°C for 10 min and 4°C hold.
Amplification products were visualized with eGels (Life Technologies, Grand Island, 
New York). Products were then pooled equimolar and each pool was cleaned with 
Diffinity RapidTip (Diffmity Genomics, West Henrietta, New York), and size 
selected using Agencourt AMPure XP (BeckmanCoulter, Indianapolis, Indiana) 
following Roche 454 protocols (454 Life Sciences, Branford, Connecticut). Size 
selected pools were then quantified and 150 ng of DNA were hybridized to 
Dynabeads M-270 (Life Technologies) to create single stranded DNA following 
Roche 454 protocols (454 Life Sciences). Single stranded DNA was diluted and used 
in emPCR (emulsion-based PCR) reactions, which were performed and subsequently 
enriched. Sequencing following established manufacture protocols (454 Life 
Sciences) was performed on the Genome Sequencer FLX instrument as described by 
Bailey et al. (2010). For a detailed description of pyrosequencing operation and 
protocol, refer to Ishak and colleagues (Ishak et al., 2011).
6.3 Results
To characterize and compare bacterial succession in the large intestines of neonates, 
fecal samples from 9 healthy and full term babies (total 50 samples collecting points) 
were analyzed from birth to 7 months using 454-pyrosequencing. The study 
population comprised 6 boys and 3 girls. Five infants (56%) were bom by caesarean 
section and 4 infants (44%) were bom by vaginal delivery. Five infants were 
partially breast-fed for 3-5 weeks and 4 infants were not breast-fed. There were 7 
infants in the probiotic group and 2 infants in the placebo group. Faecal samples 
were provided as detailed in Table 6.2. High variability was observed in the profiles 
of faecal microbiota among the infants according to mode of delivery and 
administration of probiotic / placebo.
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6.3.1 Composition of neonatal gut microbiota with different modes of delivery
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Figure 6.2 Microbial distributions at the phylum level for 5 caesarean section babies.
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Differential abundance of bacterial taxa at the phylum levels for 5 caesarean section 
babies and 4 vaginal delivery babies were assessed, see Figure 6.2 and Figure 6.3. 
The profiles were generally dominated by Firmicutes, Actinobacteria, Proteobacteria 
and Bacteroidetes. Over the neonatal period (between 0-7 months according to 
individual samples collection points), the Firmicutes phylum level was significantly 
higher than all other phyla (except for No. 189) in the caesarean babies (Figure 6.2). 
The difference in baby No. 189 can be explained by antibiotic use for 7 days during 
the first 6 months. In general, antibiotic use will disrupt the microbiota profile in the 
human colon. Faecal microbiota profiles were dominated by the four phyla including 
Firmicutes, Proteobacteria, Actinobacteria and Bacteroidetes and showed high 
diversity in the phyla level in the vaginal delivery babies (Figure 6.3). Compared 
with babies who were delivered vaginally, babies bom by caesarean section had 
bacterial communities with absence of Actinobacteira and Bacteroides (except for 
No. 189).
6.3.2 Composition of neonatal microbiota in the placebo group
Differential abundance of bacterial taxa at the phylum and family levels for 2 healthy 
infants without probiotic administration were also assessed. One infant (No. 133) was 
bom by caesarean section and the other (No. 160) was bom by vaginal delivery. The 
relative abundance of residential bacterial phyla and families for each infant is shown 
in Figure 6.2, Figure 6.3 and Figure 6.4.
Over the neonatal period, the Firmicutes phylum level was significantly higher than 
all other phyla, ranging from 73.0-99.6% in the caesarean baby (No. 133). Sequence 
assignments on lower taxonomic levels revealed that the phylum Firmicutes was 
largely made up of the family Staphylococcaceae and consisting mainly of the genus 
Staphylococcus at the first day after birth. The family Streptococcaceae and 
Lactobacillaceae reached the highest relative abundances at 6 and 12 weeks 
respectively (88.5% and 80.9%). However, Lactobacillaceae were not detected after 
24 weeks. Streptococcaceae have a relative low abundance after 12 weeks compared 
with 6 weeks. The relative abundance of the family Enterococcaceae and
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Lachnospiraceae were relatively higher than others from 18 to 32 weeks. The 
relative abundance o f the family Erysipelotrichaceae was detected at 29 and 32 
weeks. The family Enterobacteriaceae within the Proteobacteria phylum and the 
family Clostridiaceae within the Firmictues phylum were also detected at lower 
levels during 6-32 weeks. From the above observation, Staphylococcaceae 
predominated in neonatal faeces on the first day, followed by Streptococcaceae, 
while Lactobacillaceae did not seem to form a stable population and could not be 
detected after 24 weeks in the caesarean baby.
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Figure 6.4 Microbial distributions at the family level for 2 infants from the placebo group.
Faecal microbiota profiles were dominated by the four phyla including Firmicutes, 
Proteobacteria, Actinobacteria and Bacteroidetes in the vaginal delivery baby 
(No.160). Fie showed higher diversity in the phyla level compared with the caesarean 
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two modes o f delivery babies during the first six months. The family 
Lactobacillaceae was also not stable and only detected at 2 and 7 weeks in the 
vaginal delivery baby. The family Coriobacteriaceae within the Actinobacteria 
phylum was detected between 2 to 12 weeks, while it was absent in the caesarean 
baby. The family Enterobacteriaceae was predominant after 20 weeks in the vaginal 
delivery baby, while it was detected at very low level in the caesarean baby.
6.3.3 Composition of neonatal gut microbiota in the probiotic group
Differential abundance o f bacterial taxa at the family levels for 4 healthy infants in 
the probiotic group was also assessed, who have intervention (0-24 weeks) and 
post-intervention samples (after 24 weeks) (Figure 6.5).
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Figure 6.5 Microbial distributions at the family level for 4 infants with intervention and 
post-intervention samples (cease the probiotic administration after 24 weeks) in the probiotic 
group.
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Shown in Figure 6.5, the composition and temporal patterns of the microbiota 
community vary widely from individual to individual. It shows the remarkable 
degree of inter-individual variation in the colonization process. For example, the 
family Streptococcaceae predominated during the first 18 weeks in baby No.25 and 
the family Lactobacillaceae predominated during the first 18 weeks in baby No.76. 
However, the family Bacteroidaceae predominated through the whole sample 
collection period from 4 to 29 weeks in No. 189, but was virtually absent at this stage 
in other babies. The family Staphylococcaceae predominated on the first day in baby 
No.219, while it was not detected in other babies.
The second distinct feature is the relative stability of the microbial community in 
each baby over intervals of weeks to months although there still is considerable 
temporal variation. Bacteroides, for example, dominated the early microbiota of baby 
No. 189 in the first 7 months which may be explained by the antibiotic use in the first 
six months. The family Enterococcaceae became absolutely dominant and very 
stable from 15 to 29 weeks in baby No.219 and the family Streptococcaceae was also 
very stable during the first 18 weeks in baby No.25.
A third striking feature of this dataset is that the family Lactobacillaceae was still 
detectable during the post-intervention period (the probiotic consumption ceased 
after 24 weeks) in the probiotic group. During the post-intervention period, the 
relative abundance of Lactobacillaceae was 7.2-1% in the probiotic group (except 
for No.25). The family Lactobacillaceae disappeared after 25 weeks in one baby, 
while it was still detectable until 28 weeks in some babies. The results show that 
administration of probiotics to healthy infants may be an effective way to change 
their gut colonization with healthy bacteria.
6.3.4 Composition comparison between the probiotic and placebo groups
To characterize and compare the composition of gut microbiota of neonates in the 
probiotic and placebo groups, two babies (one is in the probiotic group and the other 
is in the placebo group) were selected based on the same delivery mode (vaginal
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delivery) and diet (breast feeding) without antibiotic use. Differential abundance of 
bacterial taxa at the family level was assessed, as shown in Figure 6.6.
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Figure 6.6 Microbial distributions at the family level for two infants in the placebo and 
probiotic groups, respectively. They were both vaginal delivery and breast fed during the 
first 3-5 weeks.
Results show that the family Lactobacillaceae reached the highest relative
abundances at 2 weeks (38.5%) while it was not detected after 7 weeks in baby
/
No.160 (placebo group). However, the family Lactobacillaceae was detected in the 
first week in baby N o.76 (probiotic group) and the relative abundance was quite high 
in the first week and 18 weeks (44.2% and 33%, respectively). It was also detected at 
a high relative abundance (7.2%) in the post-intervention period (28 weeks). From 
the above observation, Lactobacillaceae did not seem to form a stable population in 
the placebo group, while it could still be detected for the probiotic group in the 
post-intervention period (28 weeks). In contrast, Enterobacteriaceae significantly 
decreased over the supplementation period in the probiotic group compared with the 
placebo group. The relative abundance o f the family Enterobacteriaceae was 
significantly higher at 20 and 25 weeks in the placebo group (70.4% and 82%,
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respectively). However, Enterobacteriaceae reduced from 14.2% (18 weeks) to 0.7% 
(28 weeks) in the probiotic group.
The above results show that Lactobacillaceae still had a quite high relative 
abundance in the probiotic group even in the post-intervention period. Also, 
Enterobacteriaceae significantly reduced in the probiotic group compared with the 
placebo group.
6.4 Discussion
This study applies the high-throughput gene sequencing technology to characterize 
the gut microbiota of healthy infants. Among a few studies on the investigation of 
neonatal gut microbiota diversity using gene sequencing methods, most were 
conducted on restricted populations, such as caesarean section or vaginal delivery 
infants, breast-fed or formula-fed infants, and preterm infants with necrotizing 
enterocolitis (Nakayama et al. (2011); Hong et al. (2010); Mai et al. (2011)).
This study uses the 454-pyrosequencing technology to analyse the microbiota 
profiles of 50 faecal samples from 9 healthy infants, which are selected from the 
randomized, double-blinded and placebo-controlled trials conducted by Swansea 
University and Cultech Ltd. These nine infants include different modes of delivery 
and different modes of feeding, and they received either probiotic supplement or 
placebo during the first 6 months after birth. The study provides comprehensive 
profiles of the neonatal gut microbiota in healthy babies, and it also provides 
guidance for future analysis of neonatal samples from those infants with high risk of 
atopy, the second trial group in Swansea's clinical trials.
Historically, the gut microbiota has been studied using culture-based methodologies 
to examine individual organisms. However, accurate analysis of the entire microbial 
community in the neonatal GI tract has been difficult since up to 80% of intestinal 
microorganisms are believed to be un-cultivable (Fouhy et al. (2012b); Fraher et al. 
(2012)). Recent progress in molecular techniques using high-throughput sequencing
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called pyrosequencing enables comprehensive detection of microbiota profiles and 
permits simultaneous characterization of entire microbial communities (Bailey et al.
(2010); Hong et al. (2010); Stecher et al. (2010); Nakayama (2010); Zoetendal et al. 
(2008)). This approach provides a clear view of neonatal microbiota diversity and 
overcomes the limitations of target-specific microbiota analyses such as quantitative 
real-time PCR (q-PCR), fluorescence in situ hybridization microscopy (FISH), or 
colony counts.
The profiles were generally dominated by four phyla including Firmicutes, 
Actinobacteria, Proteobacteria and Bacteroidetes. Compared with infants who were 
delivered vaginally, the Firmicutes phylum level in the caesarean section babies was 
significantly higher than all other phyla (except for one baby who took an antibiotic 
for 7 days during the first 6 months) during the neonatal period (between 0-7 
months). This shows that antibiotic may disrupt the microbiota profile in the human 
colon. Vaginal delivery babies showed high diversity in the phyla level including the 
four phyla mentioned above. These results show that microbiota development is 
strongly influenced by the mode of delivery which matches the previous study for 
gut microbial composition in early infancy (Penders et al., 2006). Caesarean delivery 
leads to a delayed increase in population density of the major gut-associated 
microbes because these babies have not been in contact with the maternal vaginal 
and faecal flora (Adlerberth et al., 2007).
Sequence assignments on lower taxonomic levels in this study revealed that 
facultative anaerobic bacteria, mainly the family Staphylococcaceae, 
Streptococcaceae, Lactobacillaceae, Enterococcaceae* and Enterobacteriaceae are 
the pioneering colonization bacteria in early infancy. These bacteria can originate 
from the vagina, the skin, mouth and the surrounding environment. The results also 
show a large inter-individual variability amongst infants during the first six months 
of life, which matched the results in a few studies that observed high variability of 
gut microbiota between infants (Abrahamsson et al. (2012); Roger et al. (2010); 
Hong et al. (2010); Palmer et al. (2007); Penders et al. (2006)). Despite considerable
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composition and temporal variation of microbial communities between individuals, 
most individuals were relatively stable over time and the distinct structures of each 
neonatal microbial community were noticeable. Prior to 6 months of age, faecal 
sample analysis from 9 healthy infants indicate that the differences from baby to 
baby were much greater than the changes over periods of weeks or months in the 
composition of any individual neonatal gut microbiota.
Recent reports indicate that routine use of probiotic in the neonatal intensive care has 
been safe and well tolerated over a period of several years (from 5 to 12 years) 
(Manzoni et al. (2011); Luoto et al. (2010); Allen et al. (2010)). There is an interest 
in full term infants given probiotics or prebiotics to focus on prevention of allergic 
disease and food hypersensitivity. The question to answer is whether or not probiotic, 
prebiotic or synbiotics can favourably alter the infant gut microbiota in early life to 
benefit atopic children. Several clinical trials associated with administration of 
specific probiotic in early life to decrease risk of developing eczema have been 
reported (Rautava et al. (2012); Johansson et al. (2011); Kim et al. (2010); Dotterud 
et al. (2010); Niers et al. (2009); Wickens et al. (2008); Kukkonen et al. (2007); 
Kalliomaki et al. (2001)). These published trials include both prenatal and postnatal 
probiotic administration and have shown benefits in reducing disease risk.
On the basis of available evidences, it appears that probiotic intervention is most 
effective in reducing the risk of eczema in the infant if started during pregnancy. 
Tang et al. (2010) comprehensively reviewed the clinical effect of probiotic and 
prebiotics in allergic diseases. The meta-analysis used in the review suggests that a 
prenatal administration of probiotic is important for beneficial effects and it is also 
important to continue the treatment for the maximum effect. For example, maternal 
probiotic supplementation during pregnancy and breast-feeding have shown 
promising potential in reducing the risk of eczema in infants (Rautava et al., 2012). 
For children with allergic parents, higher levels of lactobacilli in early life did reduce 
the risk of allergy development at age 5 years (Johansson et al., 2011). However, one 
study with both prenatal and postnatal interventions shows lack of effect (Kopp et al.,
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2008). Another two clinical trials in which probiotic administration is given only 
postnatally and directly to the infants have negative results (Taylor et al. (2007); Soh 
et al. (2009)). Treatment of probiotics solely in the postnatal period has not proved 
beneficial (Tang et al., 2010).
Indeed, all the above clinical trials have involved administration of specific strains, 
highlighting the importance of assessing each probiotic strain individually. A major 
strength of this study is the application of new high-throughput gene sequencing 
technology (454-pyrosequencing) to characterize the complex gut microbiota in 9 
healthy infants with specific probiotic strain / placebo administration from Cultech 
Ltd. The probiotic product was administrated at the last week of pregnancy and to 
baby for the first 6 months. Faecal samples from 7 infants (probiotic group) and 2 
infants (placebo group) were collected during the first six months of life and 4 weeks 
post-supplementation. The results show that probiotic did alter the composition of 
the gut microbiota compared with those in the placebo group. The family level of 
Lactobacillaceae was still detectable in the probiotic group until 28 weeks of the 
post-intervention period, while it was usually colonized in the first few weeks in the 
placebo group and did not seem to form part of the stable population at 24 weeks.
In contrast, Enterobacteriaceae significantly decreased over the supplementation 
period in the probiotic group compared with the placebo group. This observation has 
also been found in other studies (Fouhy et al. (2012b); Kitajima et al. (1997)). 
However, as we only analyzed the samples from a small number of babies, the 
general nature of our findings need to be tested in studies involving a larger number 
of individuals.
One notable discrepancy between our study and many others is the relatively low 
frequency and abundance of bifidobacteria in the faecal microbiota as part of the 
dominant microbiota during the neonatal period. There are several possible reasons 
for this. In general, samples from the GI tract use universal primers for amplification 
o f the bacterial 16S rRNA gene followed by pyrosequencing to reveal the gut 
microbiota diversity. The universal primers aim to amplify as many 16S rRNA gene
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sequences as possible from a wide range of microorganisms. However, there are no 
suitable primer to amplify 100% conserved regions of the gene. Also, 
underestimation of diversity may result from differential PCR amplification caused 
by differences in the efficiency of primer binding (Wang et al., 2005). In the GI tract, 
bifidobacteria are a key genus, but are often under-represented in 16S rRNA surveys 
of diversity (Sim et al., 2012). The study of Palmer et al. (2007) revealed that the 
overall efficiency of amplification of DNA from bifidobacterial species was eight 
fold lower than that from non-bifidobacterial species using the 8F/1391R primer pair. 
The presence of thick cell walls may be another reason that Gram-positive organisms 
(such as bifidobacteria) can be underrepresented in microbial profiling studies (de 
Boer et al., 2010).
Sim et al. (2012) have modified the universal primers for bifidobacteria, which could 
detect bifidobacterial gene sequence at 2% abundance. However, the modification 
did not improve the detection of other microorganisms in neonatal faecal samples. 
For future studies of the microbiota diversity in the neonatal gut, careful selection of 
primers will be the key step in order to ensure effective detection of bifidobacteria.
Based on culture-dependent analysis conducted at Cultech Ltd., UK the viable counts 
of bifidobacteria in all 9 neonatal faecal samples selected for this study are quite 
high, ranging from lxlO8 to lxlO10 cfu/g (personal communication). Thus, even with 
the advent of advanced high-throughput gene sequencing technology, culture and 
isolation still remains a valuable and practical approach for studying phenotypic and 
genotypic characteristics of specific strains of interest (e.g. probiotics). Thus in order 
to provide strong and unbiased evidence when studying the complex microbiota in 
the neonatal gut, the combining of culture-dependent and culture-independent 
methods should be considered.
6.5 Conclusion
This study employed the 454-pyrosequencing technique to characterize the gut 
microbiota in healthy infants, and assessed the effects of diet, environment and
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probiotic administration. These findings advance our understanding of gut 
microbiota diversity in healthy infants. The current study concerns only the first 
subject group (healthy infants) in the clinical trials conducted by Swansea University 
and Cultech Ltd. But the results obtained also provide a useful reference for future 
investigation of the second subject group (atopic infants), to examine the correlation 
between faecal microbiota composition and the prevalence of allergic diseases in late 
infancy. However, due to the cost constraint, the sample size is rather small here and 
the interpretation of results must be made with caution. More studies need to be 
undertaken to learn about the infant gut microbiota, together with its role in health 
and disease. What constitutes a healthy gut microbiota ecosystem? How long do they 
persist? Are bacterial richness and diversity fundamentally important? How 
environmental and genetic factors, infections during infancy, or antibiotic use drive 
the colonization of the infant gut? How does early establishment of the gut 
microbiota influence the host’s health and disease later in childhood? All these 
questions will be important goals for future investigations.
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Chapter 7 Computer Simulation of In 
Vitro Fermentation Experiments
Abstract
Mathematical / computational modelling provides an alternative approach to study 
the gut microbial ecosystem, and it can overcome some of the difficulties faced by in 
vivo trials and in vitro experiments. A new microbial growth model is proposed in 
this Chapter. The new model is a natural extension of the classic Monod model, but 
instead of predicting competitive exclusion, the new model intrinsically supports 
steady-state coexistence of microorganisms. Based on the new microbial growth 
model, a robust and versatile computational framework is developed to simulate in 
vitro fermentation experiments, including batch, chemostat and multi-stage 
chemostat fermentations. The new computational model is extensively validated 
using the in vitro experiments described in the earlier chapters, and very good 
agreement is observed in all validation examples. This Chapter also shows how the 
computer simulation can help to better interpret experimental data and predict new 
results.
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7.1 Introduction
As a promising approach that can overcome some of the difficulties faced by in vivo 
trials and in vitro experiments, the potential of benefit from mathematical / 
computational modelling to the study of gut microbial ecosystem has long been 
recognized (see the review in Section 2.4). These potential benefits and advantages 
include:
• Interpretation of experimental results. Conditions in mathematical / 
computational modelling are fully controlled, and by correlating the virtual 
experiment results with the data from in vivo or in vitro testing, a better 
insight can be gained to the real experiments.
• Time and cost saving on similar experiments. Once the effectiveness of the 
mathematical / computational model has been proved, it can be used to 
predict the results for similar experiments, significantly reducing the time and 
cost required for new in vivo and in vitro testing.
• Implementation of increased complexity and prolonged testing period. 
Through mathematical / computational modelling, it is relatively easy to 
simulate complex conditions that are difficult to measure or implement in in 
vivo or in vitro testing, and the virtual experiment can also allow simulation 
for longer period, which are often difficult, or even impossible, to achieve in 
real testing.
• Quick examination of hypothesis and parameter sensitivity to eliminate 
unnecessary in vivo or in vitro experiments. Mathematical / computational 
modelling allows hypothesis and parameter sensitivity to be quickly tested, 
such that those assumptions that result in effects contrary to evidence and 
those parameters that have little impact on the results can be eliminated when 
planning in vivo or in vitro experiments.
• Scaling up from component-level experiments to system-level simulation. 
Once the mathematical / computational models have been validated for 
individual functional components, they can be integrated to predict the
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behavior of the whole system, which is often too expensive or too 
time-consuming, to study using in vivo or in vitro approaches.
The aim of this part of the work is to develop appropriate mathematical models and 
computer programs, to simulate various in vitro fermentation experiments with 
different microbial species, nutrient supplies and environmental factors. The 
objectives include:
• To critically review the existing computer simulation approaches for in vitro 
fermentation and microbial competition.
• To develop an accurate and versatile mathematical model and build a robust 
simulation platform for in vitro fermentation and microbial competition.
• To verify and validate the proposed mathematical model and associated codes 
using the in vitro fermentation experiments conducted in the first part of this 
research.
• To explore feasibility, accumulate experience and prepare building blocks for 
the development of a complete computational model for the human gut and 
the gut microbial ecosystem.
As reviewed in Section 2.4 (see Table 2.2), previous research works in mathematical 
/ computational modelling of gut microbiota have either adopted the chemostat 
model or the plug flow model to simulate the GI tract. When the chemostat model is 
adopted (Freter et al. (1983a, 1983b, 1983c, 1983d); Freedman et al. (1989); 
Coleman et al. (1996); Stemmons et al. (2000); Ballyk et al. (2001); De Jong et al. 
(2007); Munoz-Tamayo et al. (2010, 2011); Lawson et al. (2011)), the evolution of 
the virtual system is predominantly driven by the fermentation activity of 
microorganisms. When the plug flow model is adopted (Ballyk et al. (1998, 1999,
2001); Jones et al. (2000, 2002)), depending on whether or not the random motility 
assumption of bacteria is made, the evolution of the virtual system is driven in two 
different ways. Without the random motility assumption (Jones et al. 2000), the plug 
flow model is purely driven by the fermentation activity of microorganisms, same as
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the chemostat model. With the random motility assumption (Ballyk et al. (1998, 
1999, 2001); Wilkinson (2002a, 2002b, 2002c); Jones et al. (2002)), the plug flow 
model is jointly driven by the fermentation activity and the diffusion effect.
Fermentation activity is a core module in all previous virtual gut models, and its 
simulation has always been based on the classic Monod growth model (see Table 
2.2). Named after Jacques Lucien Monod, the Monod growth model is an empirical 
formula for microbe growth, and it states that the specific growth rate fi of a 
microbe growing on a single nutrient supply is
M = (7 n
K  + S
where S  is the concentration of the limiting substrate, ju ^  is the maximum 
specific growth rate of the microorganism, and K  is the half-velocity constant.
However, when applying the Monod model to microbial competition, it leads to a 
conclusion of competitive exclusion, i.e. multiple microorganisms cannot coexist 
stably on limited number of nutrient supplies. The competitive exclusion prediction 
contradicts directly to common observation that microorganisms always coexist in 
real-world environment and pure cultures are almost always the managed result from 
microbiologists.
To overcome this paradox of competitive exclusion, previous researchers have 
introduced various external factors into the Monod growth equation, such as 
time-varying inputs (Fredrickson et al. 1981), diversity of resources (Freter et al. 
(1983a, 1983b, 1983c, 1983d); Winkinson (2002a, 2002b, 2002c); Munoz-Tamayo et 
al. (2010, 2011); Lawson et al. (2011)), time-delay factors (Freedman et al. 1989), 
spatial heterogeneity (Fredrickson et al. (1981); Winkinson (2002a, 2002b, 2002c), 
random motility (Ballyk et al. (1998, 1999, 2001); Winkinson (2002a, 2002b, 
2002c); Jones et al. (2002)), and wall attachment etc (Freter et al. (1983a, 1983b, 
1983c, 1983d); Ballyk el al. (1999, 2001); Stemmons et al. (2000); Jones et al. (2000,
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2002); Winkinson (2002a, 2002b, 2002c); Munoz-Tamayo et al. (2010, 2011)). 
These external factors typically appear as additional terms of different forms in the 
growth equation. But for all these modifications, competitive exclusion can still 
happen, and steady-state coexistence is often only a rare possibility of these models. 
Hence, it will be investigated independently in this research to seek a uniform model 
that intrinsically allows coexistence in microbial competition.
The rest of this Chapter is organized as follows. In Section 7.2, a mathematical 
model for batch fermentation is developed, and the corresponding simulation results 
are validated against the batch fermentation experiments described in Chapter 4. In 
Section 7.3, the batch fermentation model is extended to a chemostat fermentation 
model that can cope with an arbitrary number of connected chemostats, and the 
corresponding simulation results are validated against the continuous fermentation 
experiments described in Chapter 5. In Section 7.4, a theoretical analysis on 
steady-state coexistence of microorganisms is presented to show how the new growth 
model can overcome the paradox of competitive exclusion predicted by previous 
theories. Finally, concluding remarks are made in Section 7.5.
7.2 Modelling of batch fermentation
A series of batch fermentation experiments were carried out in the first part of this 
research, for which the method and results are presented in Chapter 4. As listed in 
Table 7.1, four single-strain probiotics (CUL08, CUL61, CUL60 and CUL21) and 
two multiple-strain probiotics (LAB4 and LAB4B) were investigated. These 
probiotics strains are commercial products from Cultech / Obsidian Ltd, the industry 
partner of the project. For each of these fermentation studies, two different culture 
media were tested, including the commercially available culture medium MRS and 
the artificial gut medium MMGM. The initial pH condition was set at two different 
values, pH 5.5 to mimic the acid condition of the ascending colon and pH 6.5 to 
mimic the neutral environment at the descending colon. Both controlled pH and 
uncontrolled pH environments were examined.
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Table 7.1 List of batch fermentation experiments conducted in this research
Cultech Organism Medium Uncontrolled pH Controlled pH
Lactobacillus paracasei MRS 6.5 or 5.5 -
(CUL08) MMGM1 6.5 or 5.5 6.5 or 5.5
Lactobacillus salivarius MRS 6.5 or 5.5 -
(CUL61) MMGM1 6.5 or 5.5 6.5 or 5.5
Lactobacillus acidophilus MRS 6.5 or 5.5 -
(CUL60) MMGM1 6.5 or 5.5 6.5 or 5.5
Lactobacillus acidophilus MRS 6.5 or 5.5 -
(CUL21) MMGM1 6.5 or 5.5 6.5 or 5.5
LAB4 2 MMGM1 6.5 or 5.5 -
LAB4B 3 MMGM1 6.5 or 5.5 -
1MMGM: modified Macfarlane’s gut medium
2 LAB4: L. acidophilus (CUL60), L. acidophilus (CUL21), B. Lactis (CUL34) and B. 
bifidum (CUL20).
3LAB4B : L. salivarius (CUL61), L. paracasei (CUL08), B. Lactis (CUL34) and B. bifidum 
(CUL20).
7.2.1 Single-strain batch fermentation
The single-strain batch fermentation is first considered. Let Px denote the mass 
concentration of the probiotic strain and p 2 denote the mass concentration of the
substrate. In this work, the following ordinary differential equations are proposed to 
describe the change of mass concentrations for probiotic and substrate over time:
d P\ (72)
dt C + P2 "h &P\
^Ll  = -D  , (7.3)
dt C + f 2 +
where B is the maximum specific growth rate, C the velocity-delay constant, £ 
the interaction coefficient, and D the yield rate. In the above growth model, the
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coefficient B corresponds to the maximum specific growth rate fJ ,^  in the
Monod model (7.1), and it represents the maximum possible value for the specific 
growth rate when there is a plentiful supply of nutrient. The velocity-delay 
coefficient C corresponds to the half-velocity constant in the Monod model (7.1), 
and it represents the delay effect when the substrate concentration is changed. The 
coefficient £ is a new assumption that does not exist in the Monod model or any 
previous models, and it represents the bulk interaction effect caused by the growth 
and presence of microorganisms. For example, metabolite products may gradually 
change the acid condition, and subsequently affects the following growth of 
microorganisms. The coefficient D represents the conversion rate between the 
substrate and the microorganism. Overall, the growth efficiency, i.e. how fast the 
microbe can grow on the given nutrient, is described by the parameters B and C ; 
the growth productivity, i.e. how much biomass can be grown from the limited 
nutrient, is described by the parameter D .
The motivation to introduce the new growth model in Eqns. (7.2-7.3) is twofold. 
First, the Monod model only provides a rough approximation to the in vitro test data, 
and in some cases the history-matching simply cannot be achieved. Secondly, the 
Monod model and its various modifications with external factors do not allow 
steady-state coexistence of microorganisms, while coexistence is intrinsically 
supported by the new model. The second point will be discussed in more detail in 
Section 7.4. It should be noted that, instead of being contradictory to the classic 
Monod model, the new model is an improvement by taking into account the various 
internal factors caused by bacteria interaction. Indeed, if s  = 0, the new model 
degenerates into the Monod model.
In all simulations, the unit for mass concentrations and is g/ml. According
to the setup of the in vitro batch fermentation experiments, the initial mass 
concentration of the MRS medium was set as 0.053 g/ml and the mass concentration 
of the MMGM medium was set as 0.043 g/ml. Based on Cultech's technical 
specification of their probiotic strains, the number density of microorganisms was
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estimated as 1 g = 1011 cfu . The above settings have been retained the same in all in 
vitro experiments performed in this research.
Using Eqns. (1.2-73) to approximate, in the least-squares sense, the growth history 
measured from the in vitro experiments, the optimal parameters B , C , D and e 
in the growth model can be determined. That is to find the parameter values in the 
growth model that best fit the real growth history measured from the in vitro batch 
fermentations. Then, using these calibrated parameters, the simulation is performed 
again to show the best-fit growth curve from the computational model. It should be 
noted that the growth model in Eqns. (7.2-7.3) only simulates the log phase and the 
stationary phase on the growth curve, while the lag phase and the death phase are not 
considered.
The simulation results corresponding to the single-strain batch fermentation 
experiments are given in Figures 7.1-7.4. It can be seen that very good agreement is 
achieved for all in vitro batch fermentation experiments. The history matching 
confirms the effectiveness of the proposed growth model in Eqns. (7.2-7.3). 
Corresponding to the simulations shown in Figures 7.1-7.4, the growth-model 
parameters are listed in Tables 12-1.5 respectively.
For the maximum specific growth rate B , it can be observed from Figures 7.1-7.4 
that, with both MRS and MMGM media and in both controlled and uncontrolled pH 
conditions, the B value at the initial pH 5.5 is always lower than the corresponding 
value at the initial pH 6.5. This is in line with our expectation as the growth rate of 
most microorganisms is suppressed in acid environments. However, the sensitivity 
with respect to the pH change is different for different microbe species. Among the 
four tested probiotic species (CUL08, CUL61, CUL60 and CUL21), the CUL61 
probiotic is most sensitive to pH change, and the other three probiotic species are 
more robust in terms of the growth rate. Between the two culture media, the MRS 
delivers a higher growth rate in general, which may be related its higher initial 
concentration at 0.053 g/ml in comparison to MMGM's concentration at 0.043 g/ml.
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The conditions of controlled pH or uncontrolled pH do not have a significant and 
uniform impact on the growth rates.
For the velocity-delay constant C , no simple relations can be observed with respect 
to the change of initial pH, the change of culture media, or the change between 
controlled and uncontrolled pH conditions.
For the yield rate D , it can be observed in Figures 7.1-7.4 that the D value is 
always lower in controlled pH conditions. This indicates that the conversion rate 
from substrate to biomass is higher when the pH condition is controlled at a stable 
level. However, the conversion rate is not sensitive to the initial pH value and no 
clear correlation can be observed. Between the two culture media, the conversion 
rate for the MRS is higher than the MMGM.
For the interaction coefficient s , it can be observed in Figures 7.1-7.4 that the s  
value with the initial pH 5.5 is generally lower than the corresponding case with the 
initial pH 6.5. This is because the main metabolite products from these probiotics are 
lactate and acetate, which can gradually make the culture media more acid and in 
turn reduce the growth rate of microorganisms. When the initial condition is neutral, 
this acidizing suppression effect is more significant, compared with the acid initial 
condition. To some extent, this suppression effect can be reduced by controlling the 
pH at a stable level, which can also be observed in these figures. Clearly, the acid 
condition is not the only interaction route between microorganisms. The interaction 
modelled by the coefficient s  is also affected by the choice of culture media, either 
MRS or MMGM.
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Figure 7.1 Computational modelling of Lactobacillus paracasei CUL08 in batch 
fermentations
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Figure 7.2 Computational modelling o f Lactobacillus salivarius CUL61 in batch 
fermentations
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Figure 7.3 Computational modelling of Lactobacillus acidophilus CUL60 in batch 
fermentations
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Figure 7.4 Computational modelling of Lactobacillus acidophilus CUL21 in batch 
fermentations
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Table 7.2 Growth model for Lactobacillus paracasei CUL08 in batch fermentations
MMGM MMGM MMGM MMGM MRS MRS
pH5.5 pH6.5 pH5.5 pH6.5 pH5.5 pH6.5
Uncontrolled Uncontrolled Controlled Controlled Uncontrolled Uncontrolled
B 0.4 0.6 0.4 0.5 0.4 0.5
C 0.06 0.045 0.01 0.04 0.01 0.02
D 100 100 35 52 12 13.6
£ 0 380 0 0 0 15
B : 1/hour; C : g/ml; D : dimensionless; £ :  dimensionless
Table 7.3 Growth model for Lactobacillus salivarius CUL61 in batch fermentations
MMGM MMGM MMGM MMGM MRS MRS
pH5.5 pH6.5 pH5.5 pH6.5 pH5.5 pH6.5
Uncontrolled Uncontrolled Controlled Controlled Uncontrolled Uncontrolled
B 0.25 0.8 0.45 0.8 1.0 1.2
C 0.0005 0.008 0.01 0.01 0.01 0.01
D 18 10 7.6 5 2.6 2.1
£ 6 15 0 0 0 3
B : 1/hour; C  : g/ml; D : dimensionless; s : dimensionless
Table 7.4 Growth model for Lactobacillus acidophilus CUL60 in batch fermentations
MMGM
pH5.5
Uncontrolled
MMGM
pH6.5
Uncontrolled
MMGM
pH5.5
Controlled
MMGM
pH6.5
Controlled
MRS
pH5.5
Uncontrolled
MRS
pH6.5
Uncontrolled
B 0.5 0.65 0.5 0.5 0.8 1.0
C 0.015 0.013 0.02 0.02 0.005 0.005
D 157 127 35 57 10 8
£ 0 25 10 20 55 85
B : 1/hour; C  : g/ml; D : dimensionless; £ :  dimensionless
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Table 7.5 Growth model for Lactobacillus acidophilus CUL21 in batch fermentations
MMGM MMGM MMGM MMGM MRS MRS
pH5.5 pH6.5 pH5.5 pH6.5 pH5.5 pH6.5
Uncontrolled Uncontrolled Controlled Controlled Uncontrolled Uncontrolled
B 0.25 0.5 0.7 0.7 1.5 2.2
C 0.01 0.01 0.045 0.01 0.025 0.01
D 120 65 24 47 8 8
£ 100 100 10 100 70 100
B : 1/hour; C : g/ml; D : dimensionless; £: dimensionless 
7.2.2 Multiple-strain batch fermentation
Extending the growth model in Eqns. (7.2-7.3) to batch culture of multiple 
microorganisms is straightforward. Specifically, the governing ODE system becomes
dt c , +p f!+ Y j£lJp J
7=1
= ----- DiB<P>&. , (7.5)
W C, +
7=1
where /?,, i = 1, • • •, N  -1 , represents the mass concentration of microbe i , Bt the 
associated maximum specific growth rate, C, the associated velocity-delay 
constant, Z> the associated yield rate, fiN the mass concentration of substrate, and 
etj the interaction coefficient from the microbe j  onto the microbe i . The growth 
efficiency is described by Bt and Ct . Larger Bt value and smaller C( value 
correspond to faster microbe growth. The growth productivity is described by Dt . 
Smaller Di values correspond to higher conversion rates from nutrient to biomass. 
The unit for the mass concentrations /?,, i = 1,• • •,N  are g/ml, the unit for growth
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rates Bt is 1/hour and the unit for velocity-delay constants C; is g/ml, while the 
yield rates Di and the interaction coefficients £(j are dimensionless.
In vitro batch fermentation experiments of multiple microorganisms were carried out 
using probiotic mixtures LAB4 and LAB4B, both of which contain B. Lactis 
(CUL34) and B. bifidum (CUL20). B. Lactis and B. bifidum are very sensitive to 
environmental conditions, and they did not grow well during the batch culture 
experiments. These unsuccessful experiments could not offer sufficient data for 
validation of the multiple-strain batch fermentation model in Eqns. (7.4-7.5). 
However, the multiple-strain batch fermentation model will be examined and 
validated in Section 7.3 together with the chemostat fermentation model.
7.3 Modelling of chemostat fermentation
A series of continuous culture experiments were also performed using a chemostat 
setting, as listed in Table 7.6. These experiments were designed to mimic the gut 
fermentation environment. Therefore, the MMGM has been adopted as the sole 
culture medium in all these chemostat-based fermentations. The experiments include 
2 single-stage continuous fermentations and 2 two-stage continuous fermentations. 
Each of these experiments was run and continuously monitored for 10 days. In the 
rest of this section, the new growth model proposed in Eqns. (7.2-7.5) will first be 
extended and validated on the single-stage fermentation experiments, followed by 
further extended and validation on the two-stage fermentation experiments.
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Table 7.6 List of chemostat fermentations conducted in this research
Continuous model1 Microorganisms Vessel 1 pH Vessel 2 pH
Single-stage Mixture of gut microbes2, LAB43 5.5 N/A
Single-stage Mixture of gut microbes2, LAB4B4 5.5 N/A
Two-stage Mixture of gut microbes2, LAB43 5.5 6.5
Two-stage Mixture of gut microbes2, LAB4B4 5.5 6.5
1 Culture medium: MMGM; Working volume: 250 ml; Flow rate: 10.4 ml/h; Running time: 
240 hrs
2 Mixture of gut microbes: E. coli (QC1), E. cloacae (QC4), E.faecalis (QC9)
3 LAB4: L. acidophilus (CUL60), L. acidophilus (CUL21), B. Lactis (CUL34) and B. 
bifidum (CUL20)
4 LAB4B: L. salivarius (CUL61), L. paracasei (CUL08), B. Lactis (CUL34) and B. bifidum 
(CUL20)
7.3.1 Single-stage chemostat fermentation
The single-stage chemostat fermentation was conducted using a single vessel with a 
working volume of 250 ml. Initially, the vessel was filled with 250 ml MMGM 
medium at concentration 0.043 g/ml, and with the flow rate set at 0, three 
microorganisms (E. coli (QC1), E. cloacae (QC4), E. faecalis (QC9)) that are 
typically found in the human gut were cultured for 24 hours. Then, after inoculating 
a mixture of probiotic strains (either LAB4 or LAB4B) to the culture media, the flow 
rate was switched to 10.417 ml/h to add into the vessel a constant inflow of the same 
MMGM medium. The chemostat fermentation was run continuously for another 9 
days. During the 240 hours fermentation period, the culture medium was regularly 
sampled to record the growth of microorganisms.
LAB4 comprises L. acidophilus (CUL60), L. acidophilus (CUL21), B. Lactis 
(CUL34) and B. bifidum (CUL20), while LAB4B comprises L. salivarius (CUL61), 
L. paracasei (CUL08), B. Lactis (CUL34) and B. bifidum (CUL20). The aim of these 
in vitro studies was to investigate how these two probiotic mixtures react in a 
gut-like environment. Hence, the pH was controlled at 5.5 to mimic the acid 
environment of the ascending colon.
177
Chapter 7 Computer Simulation of In Vitro Fermentation Experiments
To simulate the single-stage chemostat fermentation with a constant inflow and 
outflow, the multiple-strain batch fermentation model defined in Eqns. (7.4-7.5) is 
extended as follows:
where <7 = 10.417 ml/h denotes the constant flow rate operated in the chemostat,
V = 250 ml the working volume of the chemostat, =0.043 g/ml the mass
concentration of substrate at the inflow. Other symbols in the above equations share 
the same definitions as in Eqns. (7.4-7.5).
Single-stage chemostat fermentation o f  LAB4
The single-stage chemostat fermentation using LAB4 is first investigated here. The 
in vitro fermentation contains two steps: batch culture of the gut microbes (for 24 
hours) and chemostat culture of gut microbes and probiotics LAB4 (for 9 days). The 
first step is simulated using the multiple-strain batch fermentation model defined in 
Eqns. (7.4-7.5). Specifically, the parameters Bt , C; , Di and €y in Eqns.
(7.4-7.5) are determined by approximating the batch fermentation data, and then the 
simulation is performed again using the optimized parameter values to show how the 
simulation results fit to the experimental data. Figure 7.5 shows the simulation 
results, and the corresponding growth model is given in Table 7.7. The second step 
chemostat fermentation is simulated using the single-stage chemostat fermentation 
model defined in Eqns. (7.6-7.7). Again, the optimal parameter values are 
determined through history matching. The simulation results are shown in Figure 7.6, 
and the corresponding growth model is given in Table 7.8. A good agreement
(7.6)
(7.7)
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between the computer simulation and the in vitro experiment can be observed in 
Figure 7.5(a). As shown in Figure 7.5(b), the MMGM ran out quite quickly. This is 
expected because in Figure 7.5(a), all three microbes stopped growing after 6 hours. 
Good approximation between computer simulation and in vitro experiment is also 
observed in Figure 7.6, where three gut microorganisms (QC1, QC4, QC9) and two 
probiotics (CUL60&21, CUL34&20) grow together on MMGM. The simulation is 
performed for a longer period than the in vitro experiment, which confirms that the 
probiotic strains can remain alive in the chemostat environment. Comparing the 
growth models in Table 7.7 and Table 7.8, it can be seen that the activities o f 
microbes are very complicated, and the same microorganism can behave very 
differently when the environmental condition or the population structure changes.
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Figure 7.5 Computational modelling of the initial batch culture during the single-stage 
chemostat fermentation of LAB4.
Table 7.7 The growth model corresponding to Figure 7.5
B C D (£/,)
QC1 0.7708 0.0096 1.0326 0.0000 0.0000 0.0000
QC4 0.6000 0.0023 18.0465 0.0004 0.0009 0.0000
QC9 0.1976 0.0009 1.0154 0.0001 0.0002 0.0000
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Figure 7.6 Computational modelling of the chemostat culture during the single-stage 
chemostat fermentation of LAB4.
Table 7.8 The growth model corresponding to Figure 7.6
B C D (£//)
QC1 2.5093 0.0144 49.8519 365.6324 999.9892 0.0024 0.3233 0.0376
QC4 2.0063 0.0750 1.0110 971.5688 243.4935 0.5441 12.5855 170.2440
QC9 1.9850 0.0102 1.0313 131.6302 1.6167 0.7436 62.0416 0.0019
CUL60&21 3.7201 0.0148 14.1635 11.1077 6.5539 0.0000 3.0880 241.9406
CUL34&20 4.9790 0.0001 1.0757 0.1130 0.8822 307.4753 0.0020 341.3134
Single-stage chemostat fermentation o f LAB4B
The single-stage chemostat fermentation using LAB4B is similarly investigated. 
Figure 7.7 shows the simulation result for the first step batch fermentation, which 
only contains gut microbes QC1, QC4 and QC9. The growth model is given in Table 
7.9. For the second step chemostat fermentation, the simulation results are plotted in 
Figure 7.8, and the corresponding growth model is given in Table 7.10. Again, 
Figures 7.7(a) and 7.8(a) show a good agreement between the simulation results and 
the in vitro experiments. The prolonged simulation confirms that the probiotic strains 
LAB4B can also stay alive in the chemostat environment. Note that bacteria death is
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not considered in the proposed growth model, and therefore a difference is observed 
for QC9 growth curves in Figure 7.7(a).
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Figure 7.7 Computational modelling of the initial batch culture during the single-stage 
chemostat fermentation of LAB4B.
Table 7.9 The growth model corresponding to Figure 7.7
B C D
QC1 1.1585 0.0142 1.5129 93.7294 42.7131 5.2019
QC4 0.6253 0.0000 1.0001 112.5818 0.0091 0.9896
QC9 0.0000 2.0000 29.9384 999.9910 999.9913 999.9892
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Figure 7.8 Computational modelling of the chemostat culture during the single-stage 
chemostat fermentation of LAB4B.
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Table 7.10 The growth model corresponding to Figure 7.8
B C D (*<,)
QC1 2.6981 0.2818 1.1545 769.5034 154.9972 15.5373 134.9945 0.0243
QC4 0.4010 1.7245 1.8824 826.0380 832.5866 5.4989 630.6081 533.2154
QC9 4.2628 0.0059 48.6567 0.0109 88.5103 999.9675 81.2933 997.0603
CUL60&21 4.7092 0.0107 9.2137 0.3956 0.0308 49.0666 350.9284 0.0046
CUL34&20 4.5027 0.0518 21.3773 15.4833 60.8776 708.4021 240.3648 277.6824
7.3.2 Two-stage chemostat fermentation
The two-stage chemostat fermentation was performed using two connected vessels, 
each having a working volume of 250 ml. Initially, both vessels were filled with 250 
ml MMGM of concentration 0.043 g/ml, and were inoculated with three gut 
microorganisms (E. coli (QC1), E. cloacae (QC4), E. faecalis (QC9)). The first 
vessel was controlled at pH 5.5 to mimic the ascending colon while the second vessel 
was controlled at pH 6.5 to mimic the descending colon. With the flow rate set to 0, 
the gut microorganisms were first cultured for 24 hours in both vessels. Then, LAB4 
(or LAB4B) probiotic strains were inoculated into both vessels and at the same time, 
the flow rate was switched to 10.417 ml/h to deliver a constant inflow of MMGM of 
the same concentration. The continuous fermentation in the connected vessels was 
run continuously for another 9 days. During the whole 240 hours fermentation 
period, the culture medium was regularly sampled and tested.
To simulate the two-stage chemostat fermentation described above and other more 
general experiments, a uniform mathematical model that can cope with chemostat 
fermentation with arbitrary number of connected vessels is developed. Figure 7.9 
shows a general chemostat system with M  connected vessels operated at a constant 
flow rate q . Each vessel m e {  1, ■ • •, M} can have a different working volume Vm,
and can also contain a different collection of microbial species. For the m -th vessel, 
different microorganisms in the vessel are distinguished by the local index
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n = 1, • • •, N m - 1, the substrate is denoted by n = N m, and their corresponding global 
indices are r  = K m + n , where K m = V N
m  ’  w  , = i  J
•  •  • A/
vessel 1
local ID =
global ID /c, = 0 
in Eqn
r — K, + n
m
n = \ t - - , N n
m-1
* -  = Iy-i
r = K... + n
M
M-1
y=i
r  =  A:a/ + n
Figure 7.9 Schematic illustration of chemostat fermentation with M  connected vessels
Based on the single-stage chemostat fermentation model in Eqns. (7.6-7.7), the 
governing equation for the general chemostat model in Figure 7.9 can be established 
in each vessel m as:
dfir
dt
BrPK .N_P,
A L - 1
A' +A/„ +
+ y { P l ~ P r )  for -1 (7.8)
y=i
dp, N m - \K,„+N„
dt = - Z
M=1 Cr+ fiKm+Nm+Nf s rJ s
j=i
+ -^r(PNm ~P Km+Nm) (7.9)
where s = + j , denotes the mass concentration o f the n -th microbe in the
vessel m , the maximum specific growth rate o f the n -th microbe, Cr the 
velocity-delay constant o f the n -th microbe, Dr the yield rate o f the n -th 
microbe, Srs the interaction coefficient from the j  -th microbe to the n -th microbe
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within the vessel m , (3K +N the mass concentration o f the substrate in the vessel 
m , p i  the mass concentration o f the microbe in the previous vessel (i.e. the vessel 
m - 1) that is o f the same type as the current vessel's n -th microbe, p*N = p K +iVm 
for m *  1 and p*N =0.043 g/ml for m - 1.
Two-stage chemostat fermentation o f LAB4
The two-stage chemostat fermentation o f LAB4 is first considered. For the initial 
batch fermentation o f the gut microorganisms (QC1, QC4 and QC9), the 
multiple-strain batch fermentation model defined in Eqns. (7.4-7.5) is used, and the 
optimal values for parameters Bi , C, , Z> and e are determined by
approximating the growth data from the batch fermentation experiment. The 
simulation results for vessel 1 are plotted in Figure 7.10, and the corresponding 
growth model is given in Table 7.11. The simulation results for vessel 2 are plotted 
in Figure 7.11, and the corresponding growth model is given in Table 7.12. Both 
growth curves in Figure 7.10(a) and Figure 7.11(a) show a good agreement between 
the simulation and the experimental data. Figure 7.10(b) and Figure 7.11(b) show 
respectively the changes o f substrates in vessel 1 and vessel 2, which will feed into 
the simulation for the second-step chemostat fermentation.
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Figure 7.10 Computational modelling o f the initial batch culture during the two-stage 
chemostat fermentation o f LAB4, vessel 1.
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Table 7.11 The growth model corresponding to Figure 7.10
B C D (*(,)
QC1 0.9612 0.0074 1.3751 5.8992 124.9120 0.0053
QC4 0.6344 0.0006 1.9862 59.4466 7.6396 0.0001
QC9 0.1467 0.0652 1.3137 64.6401 5.8659 58.1393
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Figure 7 .11 Computational modelling of the initial batch culture during the two-stage 
chemostat fermentation of LAB4, vessel 2.
Table 7.12 The growth model corresponding to Figure 7.11
B C D (£//)
QC1 0.8072 0.0055 1.7751 61.1230 13.4653 0.1179
QC4 0.7193 0.0000 5.4996 75.4874 1.9233 1.8412
QC9 0.0000 2.0000 4.6674 999.8134 999.8452 999.9997
The second-step chemostat fermentation is simulated using the model defined in 
Eqns. (7.8-7.9), whose optimal parameters are determined through history matching 
with the in vitro chemostat fermentation data. The results for vessel 1 are plotted in 
Figure 7.12, and the corresponding growth model is given in Table 7.13. The results 
for vessel 2 are plotted in Figure 7.13, and the corresponding growth model is given 
in Table 7.14. It can be seen from Figure 7.12(a) and Figure 7.13(a) that good 
agreement for the growth histories is achieved for both vessel 1 and vessel 2. The
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simulation is performed for 360 hours, which confirms that LAB4 probiotic strains 
can remain stable in the simulated gut environment for a longer period. Comparing 
the growth models in Table 7.13 and Table 7.14, it can be observed that the 
maximum specific growth rates Bt generally dropped from vessel 1 to vessel 2, the
velocity-delay constants C, increased, and the yield rates Dt increased as well.
All o f these indicate that the microbial growth in vessel 1 is more active and more 
productive than vessel 2, despite its higher pH value.
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Figure 7.12 Computational modelling of the chemostat culture during the two-stage 
chemostat fermentation of LAB4, vessel 1.
Table 7.13 The growth model corresponding to Figure 7.12
B C D K )
QC1 2.2266 0.0000 1.0001 0.1134 266.8761 311.7281 0.0806 40.2105
QC4 3.3634 0.0000 3.3311 0.6152 998.7156 364.3487 17.0817 25.6989
QC9 4.7218 0.0001 15.5450 2.7920 6.1136 191.7519 201.6215 20.5157
CUL60&21 3.0654 0.0004 1.4597 5.1234 0.5552 4.8979 145.1772 225.8366
CUL34&20 2.6617 0.0001 1.1073 0.9760 57.0839 29.4460 0.0086 441.9062
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Figure 7.13 Computational modelling of the chemostat culture during the two-stage 
chemostat fermentation of LAB4, vessel 2.
Table 7.14 The growth model corresponding to Figure 7.13
B C D (*/,-)
QC1 0.0026 1.2983 2.7645 440.3544 525.9277 370.3374 391.7867 360.5794
QC4 0.0100 1.8877 3.5455 918.8279 924.4341 968.3675 406.3729 973.5825
QC9 0.1556 1.3705 46.5474 774.1974 723.4212 602.7597 429.8577 783.7700
CUL60&21 2.0465 0.2071 31.8893 2.8713 116.5025 25.1375 56.6308 0.0078
CUL34&20 3.4988 0.0143 1.1128 44.1394 0.0025 213.7069 0.0026 0.1763
Two-stage chemostat fermentation o f LAB4B
The two-stage chemostat fermentation o f LAB4B is similarly investigated. The 
initial batch fermentation for QC1, QC4 and QC9 are approximated using the 
multiple-strain batch fermentation model defined in Eqns. (7.4-7.5). The simulation 
results for vessel 1 are plotted in Figure 7.14, and the corresponding growth model is 
given in Table 7.15. The simulation results for vessel 2 are plotted in Figure 7.15, 
and the corresponding growth model is given in Table 7.16. The QC9 curves in 
Figure 7.14(a) and Figure 7.15(a) show a difference between the simulation and the 
in vitro data. This is because the current model only considers the growth o f bacteria,
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and the death is not modelled. However, this does not affect the simulation for 
chemostat fermentation where microbe death is negligible.
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Figure 7.14 Computational modelling of the initial batch culture during the two-stage 
chemostat fermentation of LAB4B, vessel 1.
Table 7.15 The growth model corresponding to Figure 7.14
B C D (*</)
QC1 1.2265 0.0170 3.3648 55.6959 0.0001 5.1047
QC4 0.7530 0.0021 1.6911 34.9202 0.0000 1.0455
QC9 0.0000 2.0000 29.9384 999.9910 999.9913 999.9892
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Figure 7.15 Computational modelling of the initial batch culture during the two-stage 
chemostat fermentation of LAB4B, vessel 2.
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Table 7.16 The growth model corresponding to Figure 7.15
B c D (*//)
QC1 3.1606 0.1136 1.0013 156.1207 0.0003 6.4608
QC4 2.5749 0.1125 2.7299 141.5258 0.0027 70.6244
QC9 0.0000 2.0000 7.8227 1000.0000 999.9954 999.8780
For the second-step chemostat fermentation, the simulation results are plotted in 
Figure 7.16 for vessel 1 and Figure 7.17 for vessel 2. For both vessels and all five 
microorganisms, good agreement is achieved between the simulation and the in vitro 
experiment. The simulation confirms that LAB4B probiotic strains can stay alive for 
a longer period, with CUL61&08 performing better than CUL34&20. Comparing the 
two growth models in Table 7.17 and Table 7.18, it can be seen that the growth 
efficiency (described by Bi and Ci ) for QC1 improved from vessel 1 to vessel 2,
the growth efficiency for QC4 dropped, and the growth efficiencies for QC9, 
CUL61&08 and CUL34&20 remained stable. However, described by the parameter 
Dt , the productivity of QC1, QC4 and CUL34&20 dropped from vessel 1 to vessel
2, the productivity of QC9 improved, and the productivity of CUL61&08 remained 
stable. Overall, for LAB4B, the difference in terms of growth activity between vessel 
1 and vessel 2 is not as significant as LAB4. This may indicate that LAB4B is more 
tolerant to nutrient concentration but more sensitive to the pH condition, while LAB4 
is more tolerant to pH condition but more sensitive to nutrient concentration.
Chapter 7 Computer Simulation o f In Vitro Fermentation Experiments
Figure 7.16 Computational modelling of the chemostat culture during the two-stage 
chemostat fermentation of LAB4B, vessel 1.
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Table 7.17 The growth model corresponding to Figure 7.16
B C D K )
QC1 0.2144 0.0000 1.0001 365.3467 955.2005 0.0004 0.0230 0.0028
QC4 0.2579 0.0001 16.3991 999.9998 906.7089 0.0001 0.0118 55.8880
QC9 4.9987 0.0002 35.9326 0.0531 5.9478 561.5483 18.0402 999.8233
CUL61&08 1.2289 0.0078 6.8060 3.2450 0.1877 850.3422 11.4753 0.0163
CUL34&20 2.4495 0.0002 1.0564 27.4268 34.1825 0.9013 45.8434 18.4661
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Figure 7.17 Computational modelling of the chemostat culture during the two-stage 
chemostat fermentation of LAB4B, vessel 2.
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Table 7.18 The growth model corresponding to Figure 7.17
B C D (*„)
QC1 4.8166 0.0000 10.5178 8.0387 933.1889 0.5070 0.6065 0.0025
QC4 0.0024 1.9810 49.9990 858.6434 802.3901 995.6263 994.8830 991.2607
QC9 4.9997 0.0026 2.0451 27.7543 0.0136 31.2625 0.7044 185.9525
CUL61&08 0.8107 0.0000 5.0374 0.0384 0.0000 963.5968 17.5485 0.0001
CUL34&20 4.9492 0.0212 8.9034 1.7567 0.0001 981.2848 302.5761 10.6220
7.3.3 Prediction of a three-stage chemostat fermentation
To demonstrate how the computational model can help to scale up the study from the 
component-level to the system-level, a three-stage chemostat fermentation is 
simulated using the general chemostat fermentation model defined in Eqns. (7.8-7.9). 
The first two vessels are set at the same condition as the two-stage chemostat 
fermentation of LAB4B described in Section 7.3.2, and the last vessel is set at the 
same condition as the second vessel. Thus, vessel 1, vessel 2 and vessel 3 are set 
respectively at pH 5.5, pH6.5 and pH6.5, and sequentially they mimic the ascending 
colon, the transverse colon and the descending colon. The simulation results are 
plotted in Figure 18, Figure 19 and Figure 20 respectively. From the growth history, 
it can be seen that the global patterns of all five microorganisms are similar in the 
three vessels, and differences are mainly observed for the period when the microbial 
populations are changing rapidly. The biomass concentrations of all five microbes 
increase from vessel 1 to vessel 3. As shown in the substrate plots, the fermentation 
activity becomes more stable from vessel 1 to vessel 3. The conclusions made on 
simulation results should be treated with care, because their reliability largely 
depends on the reliability of the validation data set. However, they do provide a 
useful reference when planning new in vivo or in vitro tests.
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Figure 7.18 Computational modelling of a three-stage chemostat fermentation of LAB4B, 
vessel 1.
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Figure 7.19 Computational modelling of a three-stage chemostat fermentation of LAB4B, 
vessel 2.
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Figure 7.20 Computational modelling of a three-stage chemostat fermentation of LAB4B, 
vessel 3.
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7.4 A theoretical analysis on steady-state coexistence of 
microorganisms
This section provides a theoretical analysis to show how the new growth model 
proposed in Eqns. (12-1.9) can overcome the paradox of competitive exclusion 
predicted by previous microbial competition theories. Without loss of generality, a 
single-stage chemostat with one substrate and two microorganisms is considered 
here.
Following the classic microbial competition theory (Hansen et al. 1980), the 
governing equation for the system is
(7.io)
dt C,+/?3 V
dJh = B1PiP1 _q_p  ( 7 n )
dt C2+/?3 V
dPi _ D2B2P3P2 | / qin q  \ T7 12)
dt Cl+ fr  c 2+fr
where and fi2 denote the mass concentrations of the two microbes 1 and 2 
respectively, J33 the mass concentration of the limiting substrate.
When a steady state is reached, the time derivatives in Eqns. (7.10-7.12) vanish and
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_ DAPA  _ + 11 _  P  ) = 0 . (7.15)
c , + a  Q + A
The solutions to Eqns. (7.13-7.14) are
(7.16)
(7.17)
The above solutions cannot hold simultaneously unless the growth rates o f the two 
microbial species intersect with each other, as shown in Figure 7.21 where the 
growth rates o f microbe 1 and microbe 2 intersect at the green point. But even in this 
case, the coexistence is not stable. If the substrate concentrate is slightly larger than 
the intersection concentration marked by the green point, microbe 1 (marked in red) 
will eliminate microbe 2 (marked in blue) from the chemostat. If the substrate 
concentration is slightly smaller than the interaction concentration, microbe 2 will 
eliminate microbe 1 from the chemostat. Hence, according to the classic Monod 
growth model, stable coexistence cannot happen, which is in direct contradiction to 
common knowledge o f real-world microbial communities.
*► Pi
Figure 7.21 Illustration o f the growth rate
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All previous research works in mathematical / computational modelling of gut 
microbiota have been based on the classic Monod model. The prediction of 
competitive exclusion is fundamentally wrong, knowing that the gut microbiota for 
healthy adults is very stable with hundreds of microbial species living together 
happily in the GI tract. There have been some modifications, such as infinite 
diversity of nutrients, wall attachment and random motility etc. But these external 
factors do not resolve the intrinsic character of competitive exclusion in the Monod 
model, and in essence coexistence is still a rare possibility in these modified models.
Based on the proposed growth model, the governing equation of the chemostat with 
one substrate and two microorganisms is
d Pi = ________
dt Cx +/?3 + £UPX +£uP2 V
(7.18)
H k  M li l  (7.19)
dt C2 + Pi + f21 P\ 2^2 Pi V
d Pl _  D\B\PzP\   ^ l^ lP lP l
dt C) +/?3 +£n/?1 + £12/^ 2 C2 + Pi + ^ 2\P\ 2^2Pi V
At the steady state, the above equations simplify to
+ f ( A " - A ) -  (7-20)
— £  = o, (7.21)
C] + Pi + 1 Pi &\lPl V
- 2-  =  0 , (7.22)
^2 Pi ^2\P\ 2^2Pi V
 D\B\PiP\_______________D2 ^ 2  Pi Pi______1 ^ ( Bin p \  = 0 (7 23)
C, + /?3 + eup x + s nP2 C2+ fi3 + s2XPx + £22P2 V
The solutions to Eqns. (7.21-7.22) are
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fAl
,-1
'12
\ S 21 ’22 J
VBxp 2-q C x- q p 2
VB2P3-q C 2-q P 2
(7.24)
Substituting Eqn. (7.24) into Eqn. (7.23), the solution of P\ can be readily obtained.
With appropriate growth parameters Bt, C ., Dj and etJ, the above steady-state
solution always exists, and the coexistence solution is also stable. Hence, the new 
growth model intrinsically supports steady-state coexistence. It should be noted that, 
the Monod model is a special case of the new model with ev = 0 . Under the new
model, microbial coexistence is a common phenomenon, while the exclusion 
becomes a relatively rare possibility.
7.5 Conclusion
In this Chapter, a new microbial growth model is proposed. The new model is a 
natural extension of the classic Monod model, by taking into account the various 
interactions between microorganisms. However, unlike the Monod model that leads 
to the paradox of competitive exclusion, the new model intrinsically supports 
steady-state coexistence of microorganisms. Based on the new growth model, a 
versatile simulation platform for batch and chemostat fermentations is developed. 
The simulation platform is extensively validated against the in vitro experiments 
described in Chapter 4 and Chapter 5. The benefits from mathematical / 
computational modelling are multi-dimensional. In particular it has been 
demonstrated how the computer simulation can help to better interpret experimental 
results and how the computer simulation can predict at the system level the gut 
microbiota based on the knowledge gained at the component level.
The new microbial growth model and the computational platform for in vitro 
fermentation experiments presented in this Chapter lays the foundation to develop a 
full mathematical / computational model for the human gut and the gut microbial 
ecosystem.
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Chapter 8 An Integrated Model of the 
Human Gut and Gut Microbial 
Ecosystem
Abstract
This Chapter presents a comprehensive mathematical model for the human gut and 
the gut microbial ecosystem. The new model correctly recognizes the fluid flow in 
the gut as Stokes flow, takes into account the deformation of the gut and its dynamic 
interaction with the gut media flow, and captures the anaerobic fermentation 
performed by various colonic microorganisms. The model is derived from reliable 
knowledge of the human gut and gut microbiota, principles in physics (mass and 
momentum conservations), rigorous mathematical formulations, and appropriate 
approximations. To the best of our knowledge, this is the first mathematical model 
that represents the anatomy, physiology and metabolism of the human gut and gut 
microbial ecosystem as one uniform system. This comprehsive mathematical model 
provides a solid and versatile foundation for futher numerical studies of the human 
gut and gut microbiota.
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8.1 Introduction
8.1.1 Aim and motivation
After the development of the mathematical model and computational platform for in 
vitro fermentation, the objective of this part of the project was to build a relatively 
comprehensive mathematical model for the human gut and the gut microbial 
ecosystem. It is believed that a better system-level understanding of the human gut 
and its relation to human health and disease is mostly likely to be achieved by 
studying the anatomy, physiology and metabolism simultaneously in an integrated 
system, rather than treating them separately as isolated functional modules.
In principle, in vivo studies are the ideal approach to investigate the human gut as a 
whole system. But due to technical and ethical restrictions, it is often hard, if not 
impossible, to monitor closely in-situ microbial activities and interactions with the 
host. Hence, animal trials have been widely pursued. However, care must be taken to 
interpret the results from animal trials, because animal guts (rat, pig and chicken etc.) 
are known to have very different anatomy, physiology and metabolism compared to 
the human gut.
In vitro experiments provide an alternative platform to study the human gut under 
controlled environments. The main limitation for in vitro experiments comes from 
their limited complexity. Up to now, all in vitro gut simulators have used rigid 
vessels to simulate the soft and deformable GI tract, which completely ignores the 
physical interaction between the gut and gut media. Most in vitro gut simulators are 
based on chemostat cultures which largely ignores the heterogeneous pattern of gut 
medial flow and the absorption function in the gut. Finally, but more importantly, it 
is estimated that at least 80% bacterial species in the gut cannot be cultured with 
known culture media.
The potential of mathematical modelling in the study of the human gut and gut 
microbial ecosystem has long been recognized. In particular, compared with in vivo
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and in vitro approaches, it is expected that mathematical modelling will be a better 
tool for system-level (in contrast to component-level) study of the human gut and gut 
microbiota. However, progress in this research direction has been very limited. A 
critical review on mathematical / computational modelling of the human gut is given 
in Chapter 2. In Section 8.1.2, some limitations and defects identified in previous 
mathematical models are discussed in more detail, so that the development of the 
new model can be better oriented.
8.1.2 Limitations and defects of previous mathematical / computational gut 
models
Like any other human tissue, the gut wall is soft and deformable to allow large food 
particles to pass through the GI tract more easily and to provide temporary storage 
space between excretions. However, all previous mathematical / computational gut 
models have modelled the gut as a rigid vessel. Most models (Freter 1983d; Coleman 
et al. 1996; Stemmons et al. 2000; Ballyk et al. 2001; Jong et al. 2007; 
Munoz-Tamayo et al. 2010, 2011; Lawson et al. 2011) treated the gut as a chemostat 
(i.e. a rigid container with small inlet and outlet as shown in Figure 8.1(a)). In this 
case, the velocity of gut media flow is practically zero and a perfect mixing state has 
to be assumed, which completely ignores the heterogeneous flow pattern in the GI 
tract. As the chemostat is rigid with a constant volume, it cannot simulate periodic 
excretion, diarrhoea or constipation, which are perhaps the most common clinical 
conditions related to the gut. Several models (Kung et al. (1992); Ballyk et al. (1998, 
1999, 2001); Jones et al. (2000, 2002); Wilkinson (2002a, 2002b, 2002c)) have 
treated the gut as a plug flow reactor (i.e. a rigid tube as shown in Figure 8.1(b)). In 
this case, the velocity of gut media flow is a constant, which again does not allow 
any spatial variation along the GI tract and cannot capture such common clinical 
conditions as diarrhoea and constipation.
Another fundamental aspect of the human gut that has been largely missed out by 
previous mathematical / computational models is what drives the gut media flow and 
how it is varied. In the chemostat model (Figure 8.1(a)), small inlet and outlet are
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connected to the container, inside which the flow velocity is assumed as zero and gut 
media are assumed to be perfectly mixed at all time. In the plug flow model (Figure 
8.1(b)), a small constant flow rate is assumed for the whole tube and at all time. 
Neither o f these two models simulates the real gut media flow, which varies 
depending on time and spatial location in the GI tract. To make gut media move 
along the GI tract, a few researchers ((Kung et al. (1992); Ballyk et al. (1998, 1999, 
2001); Jones et al. (2002); Wilkinson (2002a, 2002b, 2002c)) have invented a 
diffusion effect. That is, the movement o f gut media is driven by the concentration 
gradient. However, due to the high viscosity o f gut media, the diffusion effect is 
negligible in practice.
Chemostat gut
Plug flow gut
(a) Chemostat model (b) Plug flow model
Figure 8.1 Gut models in the literature, where Q denotes the constant flow rate.
Gut media is a mixture of food particles, biomass, water and gas. It is clinically well 
known that the composition and physical property o f gut media varies significantly 
along the GI tract. As gut media moves through the proximal colon, the transverse 
colon and the distal colon, the concentration o f water gradually reduces, the 
concentration of short chain fatty acid first increases and then decreases, and the 
concentration of biomass increases. The composition difference leads to varying 
physical properties of gut media along the GI tract, such as changing density and 
viscosity. Disturbance to the normal heterogeneity o f  gut media causes clinical 
conditions such as diarrhoea and constipation. However, up to now, the multiphase 
nature o f gut media has never been recognized in any previous mathematical / 
computational model.
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Finally, it is well known that hundreds o f microbial species inhabit the gut o f healthy 
adults and form a stable gut microbial ecosystem. It is this stable and diverse gut 
microbiota community that perform key metabolic functions, protect the host from 
pathogen invasion, and stimulate and modulate the immune system. However, all 
previous mathematical / computational gut models have described the microbe 
growth using the classic Monod model, which leads to competitive exclusion. Based 
on these fermentation models, only one bacterial species can remain alive at a steady 
state, which is obviously not true for the real gut microbial ecosystem.
8.1.3 The structure of a comprehensive mathematical for the human gut and gut 
microbiota
The new mathematical model for human gut and gut microbial ecosystem is aimed at 
overcoming all aforementioned limitations and defects. It is expected that the new 
model will serve as a solid and flexible foundation for future numerical studies of 
human gut and gut microbiota. The development o f the new gut model can be 
addressed through four distinct but inter-related functional modules, as shown in 
Figure 8.2.
Bulk flow n the gut
Stokes flow o f gut mdia
M ultiphase gut media
i
Anaerobic fermentation and microbial competition
Figure 8.2 The structure o f a comprehensive mathematical model for the human gut and gut 
microbial ecosystem
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The first module aims to appropriately model the interaction between the gut and gut 
media such that the bulk flow in the gut can be correctly captured. The second 
module recognizes the low Reynolds number o f  the gut media flow, and based on 
this the governing equations can be significantly simplified. The third module 
generalizes the bulk flow model to distinguish between the multiple components and 
phases in gut media, which is essential to capture various clinical conditions and to 
correctly represent the gut environment where various microbial metabolic activities 
take place. The last module deals with the anaerobic metabolic activities o f bacteria, 
within the gut flow environment specified through the first three modules. Details o f 
these four modules are addressed in Sections 8.2-8.5, respectively.
8.2 B u lk  flow in the  gu t
8.2.1 Anatomy of gut and the new gut model
Lumen
muscle Mucosa
Gland (e.g. salivary, liver)
\
Muscularis mucosa
Subm 
Circular
Longitudinal
Mesentery
Brunner's Glands
Crypt of
Ijeberkuhn gland
Serosa
Tubular gland 
Villi
Peritoneum
Figure 8.3 The general structure o f  the intestinal wall (source from W ikipedia)
The human colon has a cylindrical shape, and is approximately 150 cm in length and 
6 cm in diameter. It contains three connected sections: the proximal colon (around 20 
cm in length), the transverse colon (around 50 cm in length) and the distal colon 
(around 80 cm in length). As shown in Figure 8.3, the colon is supported by a 
circular muscle and longitudinal muscles, which allow the colon to deform, contract 
and expand.
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To correctly reflect the anatomy o f the colon and its deformable nature, it is proposed 
to represent the colon by an elastic tube. As the length o f the colon is significantly 
larger than its diameter (25 times longer), it is reasonable to adopt a one-dimensional 
model to reduce the complexity o f mathematical modelling. The new gut model is 
shown in Figure 8.4, where x denotes the location along the GI tract, t time, 
w (x,/) the bulk velocity o f gut media flow and^f(x ,/) the cross section area. That
is, the gut is represented as a one-dimensional rotationally-symmetric elastic tube. 
Gut media flow through the lumen and depending on its pressure, the gut wall 
contracts or expands, leading to changes o f the cross section area. The flow in the 
lumen must obey the conservation laws, and the interaction between the wall and the 
flow must satisfy the equilibrium relation. All o f these form the basic governing 
equations o f gut media flow, which are addressed separately in Section 8.2.2, Section
8.2.3 and Section 8.2.4.
The elastic wall o f colon
Figure 8.4 The gut model, where x  denotes the location along the GI tract, t time, 
u ( x , t )  the velocity o f gut media flow, A (x , t )  the cross section area.
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8.2.2 Mass conservation of the gut media flow
Without loss of generality, a segment of colon with a length / (between x = 0 and 
x = l)  is considered, as shown in Figure 8.4. At time t, the mass conservation for 
the gut media flow in this segment of colon can be expressed as
■^- + /?(/,^)^4(/,/)w(/,r)-p(0,^)^4(0,^)w(0,^) = 0, (8.1)
dt
where M  denote the total mass of gut media remaining in this segment of colon at 
time t and p (x ,t)  is the bulk density of the gut media. The above equation can be 
written in the integral form as
p (x ,t)  A (x ,t)dx  + Jo^ [ p (x ,f ) ^ (x ,f ) w  (*,£)]*&: = 0, (8.2a)
|  — [ p (x ,t)A (x it)^dx + J —  [p(x,f)^(x,f)w(jc,f)]c&; = 0, (8.2b)
J j — [p(x,^)yf(x,f)]  + — [p(x ,/ )^(x ,r )w(x ,f ) ] lc& = 0. (8.2c)
1 I
As the length / is arbitrary, Eqn. (8.2c) is equivalent to
± ( PA )+± ( PA u ) - 0 .  (8.3)
The above partial differential equation represents the mass conservation for the bulk 
flow in the gut. It is fundamentally different from previous chemostat and plug flow 
models, where no deformation of the gut is allowed.
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8.2.3 Momentum conservation of the gut media flow
Considering the same bulk flow in the gut as in Section 8.2.2, the momentum 
conservation at time t can be expressed as
d r 1 2 1— pAudx  + pAu~\ -  p A u
d t Jo u=/ jc=0
= F. (8.4)
where F  represents the total external force exerted on the gut media flow. Eqn. 
(8.4) can be rewritten in the integral form as
|  — ( p A u ) d x  + J —  ( p A u 2 ^dx = F  .
,0 dt °dx
The total external force can be represented as follows:
F = pA L,o -  H«, + Ida P ,do)dx + j j d x
(8.5)
(8.6)
where the first two terms represent the pressure forces at each end o f the colon 
segment, the third term represents the accumulated pressure along the colon segment, 
and the last term represents the total friction force exerted by the colon wall onto the 
gut media flow.
The gut wall Q.
X
Figure 8.5 Illustration o f the pressure from the gut wall to the gut media flow
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As shown in Figure 8.5, the accumulated pressure along the gut segment can be 
calculated as
f  |*
)a P,dto = )aP sn M C l = p — . (8.7)
The dynamic friction between the gut wall and the gut media flow is assumed to be 
proportional to the flow velocity u and the dynamic viscosity n  of gut media, 
such that
/  = kjuu, (8.8)
where k is a constant depending on the velocity profile along the cross section of
gut. Eqn. (8.8) is a common treatment in engineering applications for the friction
force between the fluid and the wall.
Substituting Eqn. (8.7) and Eqn. (8.8) into Eqn. (8.6) yields
F  = £  -  d- 7^- \ dx + £  p — cbc + £  kfxudx, (8.9a)
F  = ^ ^ - A ^ -  + kfiu dx. (8.9b)
Eqn. (8.9b) is the total external force exerted onto the gut media flow, which includes 
both pressure and friction contributions. Substituting Eqn. (8.9b) into Eqn. (8.5) 
yields
^ — {pAu}dx + ^ — [pAu2^dx = ^ { - A  —  + kiJU d x . (8.10)
As the length / is arbitrary, the above integral equation is equivalent to
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-^-(pAu) + -^-(pAu2) = - A ^ -  + kpu .
dx
dp
dx
(8 .11)
Eqn. (8.11) represents the momentum conservation of the bulk flow of gut media. 
The interaction between the gut wall and the gut media flow
8.2.4 The interaction between the gut wall and the gut media flow
There are three unknowns in the mass conservation equation (8.3) and momentum 
conservation equation (8.11), namely the velocity u , the cross section area A and 
the pressure p . To solve the system, an extra equation must be supplied. The 
dynamic interaction between the gut wall and the gut media flow provides this 
necessary relation to close the equation system.
Figure 8.6 Timoshenko's shell model for the gut wall
As gut media move very slowly in the colon, the interaction between the gut wall and 
the gut media flow can be considered as quasi-static such that the gut wall is in the 
equilibrium state. Timoshenko's thin shell theory (Timoshenko et al. 1959) is 
employed here to analyze the gut wall under equilibrium. Consider the cylindrical 
gut wall shown in Figure 8.6, the governing equations of equilibrium are
a2 i —v a2 'i
V^ 2 2 d9 1 ;
+■ ■ + v-du„
4,2( l - v 2)
2 d$d(p d% Eh
1 + v d Ug 
2 dEjdq)
+
1 — v d2 d2 
+  ■
2 d ?  dq?
(8.12a)
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v — -  + —
dus d
d% d(p
where Rq is the rest radius of the cylindrical gut, h the thickness of the gut wall,
normal displacements, respectively; and , qv , and qn are the distributed loads 
along the longitudinal, tangential and normal directions, respectively.
As the gut deformation is predominantly in the normal direction, the deformation in 
the longitudinal and tangential directions are ignored here. Thus, all derivatives with 
respect to £ and (p vanish in Eqns. (8.12a-c), and Eqn. (8.12c) becomes
In Eqn. (8.13), the displacement along the normal direction can be expressed as
where R denotes the radius of the colon after deformation, Rq the radius of the 
colon at rest, A the cross section area of the colon after deformation, Aq the cross 
section area of the colon at rest.
In Eqn. (8.13), the distributed load along the normal direction can be expressed as
XE Young's modulus of the gut wall, v Poisson's ratio of the gut wall, = — ,
h d da2 = -----j-, V2 = — —H u ,, u and un are the longitudinal, tangential and
\2Rl ’ dip2 d£
(8.13)
(8.14)
<ln=P-Po- (8.15)
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where p  denotes the pressure from the gut media flow to the wall and p Q the 
atmospheric pressure.
Substitution of Eqn. (8.14) and Eqn. (8.15) into Eqn. (8.13) yields
Through a simple algebraic relation, Eqn. (8.16) links the pressure p  to the area A 
and closes the equations system. Hence, the mass conservation equation (8.3), the 
momentum conservation equation (8.11) and the wall-flow interaction equation
(8.16) together form the general governing equations for the bulk flow of gut media, 
which determine the bulk velocity of the gut media flow u , the pressure of the gut 
media flow p  and the cross section area of the gut A .
8.3 Stokes flow of gut media
For UK adults, the transit time of gut media in the colon is about 55 hours. It is also 
known that for adults, the average length of colon is about 1.5 m, and the average 
diameter is about 0.06 m. The density of gut media is similar to water, at 10 kg/m . 
The gut media are known to be a very sticky fluid, but it is hard to find in the 
literature the exact viscosity of gut media for humans. However, for reference, the 
dynamic viscosity of blood is 3.5 x 10-3 Pa • s , while the dynamic viscosity of honey 
is 6 Pa-s. Using the blood viscosity, the Reynolds number of the gut media flow 
can be estimated as
(8.16)
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Using the honey viscosity, the Reynolds number of the gut media flow can be 
estimated as
. 103x ----- —------x0.06
Re = ^  = -------55x60x60---------= 7.6xl0“5. (8.18)
p  6
The actual Reynolds number for flow in the gut is expected to be closer to the honey 
estimation. In any case, it can be safely concluded that the Reynolds number of the 
gut media flow is significantly less than one, i.e. Re «: 1. In fluid mechanics, fluid 
flows with very low Reynolds numbers are called Stokes flow, for which the inertia 
force terms in the momentum equation can be ignored, compared to the viscous force 
term (Happel et al. 1981). Hence, the momentum equation (8.11) simplifies to
-A ^ -+ k f ju  = 0. (8.19)
dx
Taking into account the low Reynolds number nature of the gut media flow, the 
associated governing equations can be summarized as follows
~ ( p A )  + -^ (p A u )  = 0 , (8.20)
dp _ kpu  
dx A
(8.21)
P = Po+ A . A  ■ (8.22)
4>(1-v  )
Eqn. (8.20) describes the mass conservation of the bulk flow in the gut, Eqn. (8.21) 
represents the momentum conservation, and Eqn. (8.22) determines the interaction 
between the gut wall and the gut media flow. These three simple equations govern 
the hydrodynamics of the bulk flow in the colon, and to the best of our knowledge 
they have never been reported in the literature. The fundamental difference between
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our model and all previous models are twofold. First, the gut flow in the proposed 
model is driven by the pressure gradient, in contrast to a constant velocity (zero or 
non-zero) or being driven by the concentration gradient as in previous models. 
Secondly, the colon deformation is properly modelled in the new model, while all 
previous models have assumed the gut to be rigid and cannot even capture the most 
common physiological function or clinical conditions of the gut.-
8.4 Multiphase gut media
In Section 8.2 and Section 8.3, the movement of gut media has been treated as a bulk 
flow, moving at an average velocity. However, in reality, gut media is a mixture of 
various food particles, metabolic products, bacterial species, water and several 
different gases. To correctly model the growth and metabolic activities of various 
microbial species in the gut, it is essential to distinguish between the individual 
components in the flow model. Hence, the concept of volume fraction is introduced 
for this purpose, and the governing equations for the bulk flow (Eqns. (8.20-8.22)) 
need to be extended to cope with the multiphase flow.
The volume fraction of a component or phase i is defined as the volume of the
component / phase divided by the total volume of all components / phases prior to 
mixing. Following the theory of multiphase flow (Yeoh et al. (2010); Brennen 
(2009); Crowe et al. (2012)), the bulk-flow governing equations (8.20-8.22) can be 
reconstructed for each individual component / phase in a multiphase flow system as
(8.23)
dpL = kftftL
dx A
(8.24)
(8.25)
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where i denotes the / -th component / phase, a i is the volume fraction of 
component z, pt the rest density of component z, ut the velocity of component 
z, p t the partial pressure of component z, p t the viscosity of component z, k 
the resistant coefficient, A the cross section area of gut, p Q the atmospheric 
pressure, E Young's modulus of the gut wall, v Poisson's ratio of the gut wall, h 
the thickness of the gut wall, and 4> the cross section area of the gut when it is at 
rest.
It should be noted that the volume fractions at are also unknown functions of the 
location x and time t . As the temperature change is not considered here, the rest 
density pt is a constant for each component or phase. For the multiphase flow of
gut media, Eqn. (8.23) represents the mass conservation with respect to the 7-th 
component, Eqn. (8.24) represents the momentum conservation with respect to the 
7-th component, and Eqn. (8.25) represents the pressure-area relation determined by 
the interaction between the gut flow and the gut wall. The partial pressure of all 
components pt has been assumed to share the same value, as indicated in Eqn.
(8.25). The distribution of partial pressure among components / phases defines the 
constitutive relation of a multiphase flow, and the assumption that all components 
share the same pressure value is the most commonly adopted treatment in 
engineering applications. Such treatment is accurate for mixtures of immiscible 
components / phases, and is also a reasonable approximation for various other 
practical fluids. To close the equation system, the following identity of volume 
fractions is also needed:
I > ,  = U  (8.26)
1=1
where N  denotes the total number of components / phases in the gut media flow. 
Eqns. (8.23-8.26) describe the movement of different food particles, bacterial 
species, metabolic products, water and gases in the colon. For a gut media flow with
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N  components or phases, Eqns. (8.23-8.26) provide 3N+1 independent 
equations, and the independent unknowns include N  volume fractions a ., N
velocities ut , N  pressures p t , and the cross section area of gut A . As different
components / phases have different physical properties, they do not necessarily move 
at the same velocity, which sequentially causes a mixing effect and spatial 
heterogeneity in the colon.
8.5 Microbial fermentation in the gut
There are hundreds of microbial species living in the colon, and they breakdown 
dietary carbohydrate and protein not digested or absorbed in the small intestine into 
short chain fatty acids, which in turn provide energy for the host. This process is 
called fermentation, and it can be organized into a series of fermentation pathways, 
through which food chyme (undigested carbohydrate and protein from the ileum) is 
converted into metabolic products (e.g. short chain fatty acids) and biomass. For the 
multiphase flow of gut media, these fermentation pathways practically form various 
transformations between different components or phases, which can be captured as 
source or sink terms in the mass conservation equation (8.23). As the gut media flow 
is modelled as Stokes flow and the inertia forces are ignored in the momentum 
equation, the mass transformation caused by microbial fermentation does not affect 
the momentum equation (8.24). Also, the pressure-area relation in Eqn. (8.25) 
remains unchanged.
Another important feature of the colon that needs to be considered is the mucus 
layer, as shown in Figure 8.3 and Figure 8.7. In the human colon, microorganisms 
mix with food particles in the lumen and they also attach to the mucus layer. As gut 
media continuously flow through the lumen space, the mucus layer provides a more 
stable shelter site for bacteria to live in. The flow motion in the mucus layer is 
negligible, but the metabolic activities occurring on the mucus layer cannot be 
ignored. Indeed, it is generally believed that the mucus layer plays a key role for 
maintaining a stable population of gut microbiota.
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Mucosa
Submucosa
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Subserosa 
Serosa
Peritoneum
Figure 8.7 Anatomy of the colon. The lumen and the mucus layer are highlighted in red.
8.5.1 An outline of fermentation pathways
A fermentation pathway is a route through which a specific bacteria species 
metabolizes certain substrate (e.g. carbohydrate) to produce certain fermentation 
products (e.g. short chain fatty acids) and during this process, the population o f the 
specific bacteria species grows.
The composition o f substrates and fermentation products are relatively well known 
for the human gut environment. The main substrates in the human colon are dietary 
carbohydrate and dietary protein not digested in the upper gut. The main 
fermentation products are short chain fatty acids (acetate, propionate, butyrate etc.), 
hydrogen and carbon dioxide etc. However, much less is known about the population 
structure o f gut microorganisms and their metabolic functions. For a long time, the 
biological and medical communities have been searching for a "core" microbiome 
for humans at the level of microbial species shared by everyone. But recent 
culture-independent surveys based on metagenomic sequencing indicate such a core 
does not exist at the level o f  species, and instead what appear to be shared are 
microbial functions (Turnbaugh et al. (2009a); Qin et al. (2010); McDonald et al. 
(2013)).
Lumen
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Table 8.1: Bacteria, their substrates and fermentation products in the human large intestine
Bacteria Substrate Fermentationproducts
Acetate-Succinate group (e.g. 
Bacteroides) Carbohydrate and protein A, P,S
Butyrate producer 1 (e.g. 
Clostrdial cluster XlVa+b 
(Roseburis/Eubacterium rectal 
group))
Carbohydrate and acetate B, L-Lactate, F, H2, C02
Butyrate producer 2 (e.g. 
Clostridial cluster IV 
(Faecalibacterium prausnitzii))
Carbohydrate and acetate B, D-Lactate, F
Butyrate producer 3 (e.g. 
Clostridial cluster XlVa+b 
(Eubacterium hallii))
Carbohydrate, acetate and lactate B, F, A, H2, C02
Propionate producer (e.g. 
Clostridial cluster IX 
(Propionibacteria))
Carbohydrate, lactate, Succinate P, A, C02
Lactate producer 1 (e.g. 
Bifidobacteria) Carbohydrate L-Lactate, A
Lactate producer 2 (e.g. 
Lactobacilli) Carbohydrate L
Fiber degraders (e.g. Clostridial 
clusters IV(Ruminococci)) Carbohydrate A
Non-butyrate starch degraders 
(e.g. Clostridial cluster IV 
(Ruminococcus bromiil 
Ruminococcus flavefaciens))
Carbohydrate a ,h2, co2,
Methanogenic bacteria (MB)
(e.g. Methanobrevibacter/ 
Methanosphaera)
H2 and C02
CH4
Acetogens (e.g. 
Peptostreptococci) h 2, c o 2 Acetate
Sulfate-reducing bacteria (SR) 
(e.g. Desulfovibrio) H2 and sulfate H2S
A= acetate; P = propionate; B = butyrate; L= lactate; F = formate; S = succinate
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Based on information collected from a number of references (Louis et al. (2007); 
Macfarlane et al. (1986a, 1986b, 2003); Nicholson et al. (2012); Mussatto et al. 
(2007); Dethlefsen et al. (2006); Cummings et al. (1997); Gibson et al. (1993, 1990); 
Bemalier et al. (1999)), the human gut microorganisms are divided into 12 functional 
groups (Table 8.1), and each functional group is associated with certain substrates 
and fermentation products. Table 8.1 is not expected to be complete or without 
defects, but it serves as a viable strarting point to set up the mathematical model for 
microbial fermentation. It is highlighted that future updates to Table 8.1 will not 
affect the structure of the mathematical model to be presented here. Indeed, for 
newly identified fermentation pathways, the model only needs to be extended with 
new entries and its structure remains without change.
Let N  denote the total number of components or phases in the gut media, which 
include different substrates, fermentation products and microbial species. Let an 
i = 1,2, • • •, N  denote the volume fraction for each component or phase in the lumen, 
and let a n i = N  +1, TV + 2, • • •, 2N  denote the volume fraction for component or
phase attached to the mucus layer. The indices i and N + i represent the same 
type of component, one for the lumen and the other for the mucus layer. Therefore, 
the rest densities of component i and component N  + i are the same, i.e.
p, = p N+i for / = 1,2, • • •, AL (8.27)
From the viewpoint of mass transformation, a fermentation pathway can be seen as 
the specific substrate converting into specific fermentation products and biomass. For 
the purpose of mathematical modelling, the fermentation pathways and their relations 
to different components or phases of gut media can be illustrated by the mass 
conversion matrix below
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where the entries in the first row indicate the indices of different components found 
in the lumen ( /=  1,2,•••,#) and on the mucus layer (/ = JV + 1,N  + 2 ," - ,2 N ), the 
entries in the first column indicate the fermentation pathways occurring in the lumen
( / { ’f i  and on the mucus layer [f\M J i  N lf is the total
number of fermentation pathways occurring in the lumen, NF is the total number 
of fermentation pathways occurring on the mucus layer, the matrix entry 
represents the mass yield of the component i during the y-th fermentation 
pathway in the lumen, and the matrix entry represents the mass yield of the 
component i during the y-th fermentation pathway on the mucus layer. The unit 
of the mass yields and is kg/(m -s) , representing the mass yield 
undertaken in a unit time and within a unit length of the colon.
To explain how the entries and in the mass conversion matrix (8.28) are 
determined, the y-th fermentation pathway in the lumen is considered here as an 
example. Let T denote the specific functional group of bacteria that participates in 
this fermentation pathway, S  denote the corresponding substrate, and ^ , i2, • • •, ip j 
denote the associated fermentation products. Following the new microbial growth
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model proposed in Chapter 7, the growth rate of the functional microbe T can be 
expressed as
rL _ DjTBjT(p sa s )(pTaT) /o onx
Jj,r ~ 2n ’
Cj T +  P s OCs  +  ^ , £ j tTk ( P l c a k )
k =1
where p ; denotes the rest density of the component i , at the volume fraction of 
the component i , DL] T = 1 the mass yield coefficient of the microbe T during the 
j  -th fermentation pathway in the lumen, BLj T the maximum specific growth rate of 
the microbe T during the j  -th fermentation pathway in the lumen, C Lj T the 
velocity-delay coefficient of the microbe T during the j  -th fermentation pathway 
in the- lumen, £^n  the interaction coefficient between the microbe T and the 
component k during the j  -th fermentation pathway in the lumen.
Corresponding to the growth of microbe T , the mass change of the substrate S  can 
be expressed as
f L  _  D j , sB j , T  ( P s a s ) ( p T a T )
J j , S  ~  I N  > t O . j U j
C j J  "*■ P s a S +  ^  £ j,Tk  ( P k a k  )
k=  1
where D ljS is the mass yield coefficient for the substrate S  during the j  -th
fermentation pathway in the lumen. Similarly, the mass changing rate of the 
fermentation products ixJ 2f , i p can be expressed as
f L D l B ' ; r ( p s ^ ) { p Ta T)  ( g 3 1 )
C j , T  P s a S  ^  £ j,Tk  ( P k a k )
k=l
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where DLjik denotes the mass yield coefficient for the component ik during the 
y-th fermentation pathway in the lumen.
As the mass conservation law must be satisfied during each fermentation pathway, 
the sum of the mass yield coefficients must be zero, i.e.
Pj
= °- (8-32)
k=1
For all other components that do not participate in this fermentation pathway, the 
mass yield coefficients are zero, i.e.
f j j =°
In reality, most fermentation pathways only involve a small number of components, 
including the specific substrate, fermentation products and biomass. As a result, most 
entries in the matrix (8.28) vanish, and the mass conversion matrix is highly sparse. 
The metabolic processes must satisfy the mass conservation law, therefore the 
following identities hold for the mass yields f tLj  and f* j :
2N
£ / £ =  0 for y = 1,2, ■ • ■, , (8.34a)
/=1
2 N
£ / "  =0 fory' = l ,2,---,Np . (8.34b)
M
jII
i & | s , y, /j, ? * *' 5 ipj |  j 
i & |  Sy T, Z], , * ■ •, z'jo | .
(8.33a)
(8.33b)
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8.5.2 Mass conservation in the lumen
Based on Eqn. (8.23) and taking into account the component transformation through 
fermentation pathways in Eqn. (8.28), the mass conservation equation for the gut 
media flow in the lumen can be constructed for each component i = 1,2, • • •, N  as
j t (a lPlA) + j ( a lPlA u )  = F ^  G,' + H ,. (8.35)
In Eqn. (8.35), the first source term F]L on the right-hand-side represents the mass 
contribution through various fermentation pathways to component i = \,2,---,N  in 
the lumen, and it can be expressed as
Np
F'L = 'L f jLA a ) + 'Z f j 'A a )> <8-36>
y=i 7=1
where a  = {ax,a 2, • • •,a 2N)T is the volume fraction vector for all components in the 
lumen and on the mucus layer.
The second source term Gf in Eqn. (8.35) represents the absorption effect of 
component i in the lumen, and can be expressed as
G ^ = -gia iPi, (8.37)
where g t , i = represents the absorption rate of component i in the
lumen. Note that the death of bacteria is ignored here. But if necessary, it can be 
similarly modelled as the absorption term.
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The last source term Hi in Eqn. (8.35) represents the transport of component i
and component N + i between the mucus layer and the lumen, and it can be 
expressed as
where ht e (0,1) represents that transport rate for component i from the lumen to 
the mucus layer, and hN+l e (0,1) represents the transport rate for component N + i
from the mucus layer to the lumen. This component-exchange model assumes that 
the transport of component i from the lumen to the mucus layer is proportional to 
its volume fraction in the lumen and also proportional to the free sites available on 
the mucus layer. The transport of component N + i from the mucus layer to the 
lumen is assumed to be proportional to its volume fraction on the mucus layer, while 
there is no space limit from the lumen side.
Besides the mass conservation equation (8.35), the volume fractions a t , 
i = 1,2, • • •, N  in the lumen must also satisfy the identity
This identity does not hold for the mucus layer, because the volume fraction of free
N
sites on the mucus layer is denoted by 1 -  ^  a N+j.
j=i
8.5.3 Mass conservation on the mucus layer
(8.38)
V J=l
N
(8.39)
;=i
The governing equation for mass conservation on the mucus layer can be similarly 
constructed. The only difference is that on the mucus layer, the velocity of each
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component is negligible and set to zero. Therefore, the mass conservation for each 
component / = N  +1, N  + 2, • • •, 2N  on the mucus layer can be expressed as
where AM represents the constant cross section area of the mucus layer.
In Eqn. (8.40), the first term on the right-hand-side represents the mass contribution 
through various fermentation pathways to the component / = N  +1, N  + 2, • • •, 2N  on 
the mucus layer, and can be expressed
The above equation has the same format as Eqn. (8.36), but it should be noted that 
the component index / takes values from different ranges and deal with different 
components in the matrix (8.28). Eqn. (8.36) applies to the lumen with / = 1,2,• • •, N , 
while Eqn. (8.41) applies to the mucus layer with / = N  +1, N  + 2, • • •, 2N .
The second term in the right-hand-side of Eqn. (8.40) represents the absorption effect 
of the component i = N  +1, N  + 2, • • •, 2N  on the mucus layer, and can be expressed 
as
(8.40)
(8.41)
(8.42)
where g; is the absorption rate of component i . Eqn. (8.42) and Eqn. (8.37) share
the same form, but they represent different groups of components. Again, the death 
of bacteria is ignored here.
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The last source term Ht in Eqn. (8.40) is the same as in Eqn. (8.38), representing 
the component exchange between the lumen and the mucus layer.
8.6 Summary and discussion
ecosystem has been established in this Chapter. The new model integrates the 
conservation laws for the gut media flow, the deformation of the gut wall, and the 
microbial fermentation into one system, for which the governing equations are 
summarized below:
Eqn. (8.43) and Eqn. (8.44) represent the mass conservation in the lumen; Eqn.
(8.45) represents the mass conservation on the mucus layer; Eqn. (8.46) represents 
the momentum conservation in the lumen; and Eqn. (8.47) represents the interaction 
between the gut medial flow and the gut wall. The microbial fermentation is 
modelled by the source terms F(L and FtM in Eqn. (8.43) and Eqn. (8.45). The
absorption effect of the colon is modelled by the sink terms Gf and G f  in Eqn.
A comprehensive mathematical model for the human gut and the gut microbial
N
(8.44)
/=!
(8.46)
(8.45)
4 , ( l - v 2)
(8.47)
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(8.43) and Eqn. (8.45). The Hi term in Eqn. (8.43) and Eqn. (8.45) represents the 
component exchange between the lumen and the mucus layer.
The derivation of these equations is based on reliable knowledge of the human gut 
and gut microorganisms, physical laws, rigorous mathematical formulations and 
appropriate approximations. To the best of our knowledge, the proposed 
mathematical model for the human gut and gut microbial ecosystem is the first model 
of its nature.
It will be interesting to develop appropriate numerical algorithms to solve these 
equations, and to investigate the human gut and the gut microbial ecosystem through 
computer simulations. However, this task is beyond the scope of the current research 
project. One of the main challenges for the future numerical study is to determine the 
model parameters. The new model contains only a small number of physical 
parameters, including viscosity and density of gut media, Young's modules and 
Poisson's ratio of the gut wall, and the cross section area etc. These physical 
parameters are relatively easy to find in the literature or estimate based on 
experience. The real challenge arises from the fermentation pathways represented by 
the mass conversion matrix (8.28), whose entries are defined by the microbial growth 
model in Eqns. (8.29-8.31). Estimation of the parameters in the microbial growth 
model requires large sets of reliable data on microbial metabolic activities in the gut.
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Chapter 9 Conclusion and Future 
Work
9.1 Conclusion
This research investigated the microbial ecosystem in the human gut. A novel and 
unique research strategy has been adopted, which combines the strengths of in vitro 
experiments, in vivo trials and mathematical modelling. The main body of work can 
be summarized into three distinct and interrelated parts.
9.1.1 In vitro experiments
Following a unique design of an anaerobic workstation, a continuous fermentation 
platform has been built from scratch, which provides a flexible and reliable gut-like 
environment for various in vitro experiments related to gut microbiota. A series of 
batch fermentation experiments have been carried out to investigate the growth 
behaviour of a specific set of probiotic strains in different media and under different 
pH conditions. In addition, a series of continuous fermentation experiments have 
been performed using both single-stage chemostat setting and two-stage chemostat 
setting, to study the competition between gut microorganisms and these probiotic 
strains in a simulated gut environment. The results obtained from these in vitro 
experiments have improved the understanding of the metabolic activity of these 
probiotic strains in the human gut. These first-hand data also served as a reliable 
reference for validation of the new mathematical model proposed in this research.
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9.1.2 In vivo studies
Using the next generation DNA sequencing technology (454-pyrosequencing), 50 
faecal samples from 9 healthy infants were analyzed. These 9 infants were part of a 
large clinical trial, which involved both healthy and atopic infants with probiotic 
administration during the last week of pregnancy and the first six months after birth. 
The 454-pyrosequencing analysis revealed the complete gut microbiota profiles of 
these infants at different stages. The results show the specific probiotic strains used 
in the in vivo trials did have a positive effect on the development of infant gut 
microbiota. However, due to the lack of accurate diet information, the data generated 
from the in vivo study are unsuitable for use in mathematical modelling.
9.1.3 Mathematical modelling
The classic Monod model was extended to resolve the paradox of competitive 
exclusion. The new bacteria growth model has been extensively validated using the 
data obtained from the in vitro experiments carried out in this research. Good 
agreement between the simulation results and the in vitro data has been achieved in 
all cases. Using the new growth model, a versatile simulation framework has been 
developed, which is capable of simulating and predicting microbial competition in 
various in vitro fermentation experiments. Finally, a comprehensive mathematical 
model was proposed for the human gut and gut microbial ecosystem. This new 
theoretical model contains four integrated features recognizing, respectively, the 
deformation of the gut, the nature of low Reynolds number flow in the GI tract, the 
multiphase nature of gut media and microbial fermentation activities. To our best 
knowledge, this new gut model is the first mathematical model that correctly takes 
into account the anatomy of the gut, the flow of gut media and microbial metabolism.
9.2 Future work
This research represents the first step of Swansea's research group in the 
multidisciplinary field of gut microbiology and engineering modelling. An ambitious
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target was set to join together the complementary strengths of in vitro experiment, in 
vivo study and mathematical modelling. Starting from scratch, a series of promising 
research outcomes have been achieved in all three research themes. Still, many 
aspects of this research can be seen as exploratory and feasibility studies, which have 
shed light on promising future research. Listed below is an incomplete list of further 
research that can be identified from this work.
• The continuous fermentation platform designed in this research can be 
viewed as a prototype gut simulator. It would be interesting to continue along 
this line and improve the current platform into a full artificial gut simulator. 
Indeed, external funding has been secured to further develop this platform for 
quick testing of probiotic products.
• Limited by funding, the 454-pyrosequencing analysis only studied healthy 
infants with administration of probiotic strains. It would be interesting to see 
how the specific probiotic strains have worked on atopic infants.
• The mathematical gut model proposed in this work has a number of 
advantages over previous theories and models. It would be very exciting to 
see how the new model performs in numerical simulation of gut microbiota 
and its interaction with the host.
• Validation against in vitro fermentation experiments has been extensively 
used in this research. DNA sequencing analysis based on in vivo studies 
generates large cohorts of data with complete profiles of gut microbiota. At 
least in principle, these data sets can also help the development of 
mathematical / computational models, although quantification of the diet 
input is required.
• Great variability of gut microbiota exists between individuals. This may 
indicate a promising future for host-specific simulation of gut microbial 
ecosystem.
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